

Property values tagged with IC are from the SIC/VINITI data file provided by InfoChem.

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN-STINGIES/stnotes27.pdf>

\Rightarrow a sta que 1.5

= 0.0 sta que 125
 L11 STP 2050 OR 2050 OF 2043 OR 2043 OF 2052 OR 2052 OR 2051 O
 E 2043 OF 2054 OF 1918 OF 2016 OF 2016 OF 1844 OR 2117 OF 2012
 L13 STP

[illegible]

VER 31-NHC, 16/22/25/30

$$12 = \text{OH}^+ \text{H}_2\text{C}^+ / 14$$
$$77.6 \quad 35 = AK/OY$$
$$\text{VAF: } 34=\text{CH}_2, 30, 34$$
$$V_{AF} = 35 = (OH/2)H_2$$
$$\text{r.r.f.} = 136 = (1 - 2) \text{ CH.}$$

NAME ATTRIBUTES:

REF ID: A73541

UNSEC IS FC AT 20

NOTED IS FC AT 25

UNPEC IS PC AT 5

CONNECT IS M1 FOR AT

CONNECT IS M1 FC AT 7

CONNECT IS M1 F2 AT

CONNECT IS M1 FC AT 27

PLANNED TO BE 1:1 F C AT

CONNECT TO M1 FC AT -

CONNECT IS 11 RC AT 33

DEFAULT MLEVEL IS 400

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 38

2847 ANSWERS

140.0 PROCESSED 2:0703 ITERATIONS
SEARCH TIME: 04.00.24

= e d sta que 118
 L11 SCR 2039 OR 2050 CR 2049 OR 2048 OR 2053 OR 2052 OR 2051 O
 F 2043 OF 2054 OF 1916 OF 2016 OR 2026 OR 1844 OF 2127 CR 2012
 L13 STF

[illegible]

```

VAR G1=NHL/18/22/15/30
VAR G2=OH/NHC/14
VAR G3=AK/CY
VAR G4=CH2/32/34
VAR G5=OH/NHC
DEF G6=(1-1) CH2
MORE ATTRIBUTES:

```

```

NAME ATTRIBUTES:
NSPEC      IS FC      AT 14
NSPEC      IS FC      AT 21
NSPEC      IS FC      AT 25
NSPEC      IS FC      AT 30
CONNECT    IS M1      FC AT 4
CONNECT    IS M1      FC AT 7
CONNECT    IS M1      FC AT 8
CONNECT    IS M1      FC AT 18
CONNECT    IS M1      FC AT 22
CONNECT    IS M1      FC AT 25
CONNECT    IS M1      FC AT 30
DEFAULT    MLEVEL IS ATOM
DEFAULT    ENLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF RINGS IS 38

STEREO ATTRIBUTES: NONE
1647 SEA FILE=REGISTRY CSS FUL L23 NOT L21
STF

```

      21      39      29
      O      O      O
N      G3      N      CHO
@14  14      @30  51
      N      C      G3      N      C      N      G3
      @18  19  20      @22  24      @25  26  27  29
      O
      41
      53
      Me
      11      12      17
      O      O      O
      C      N      C      C      N      C      C      G2
      1      3      4      6      7      9      15
      G5      G4 42      G5
      55      47
      42  O      O
      43
      NH2
      44

```

VAR G1=NH2/18/23/25/30

VAR G2=OH/NH2/14

VAR G3=AK/CY

REF G4=(1-2) CH2

VAR G5=48/50

VAR G6=OH/SH/NH2

NODE ATTRIBUTES:

NSPEC 1S FC AT 12

NSPEC 1S FC AT 21

NSPEC 1S FC AT 25

NSPEC 1S FC AT 30

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OF EMBEDDED

NUMBER OF NODES IS 42

STEREO ATTRIBUTES: NONE

L13 16 SEA FILE=REGISTRY SUB=L25 CSS FUL L26

100.0% PROCESSED 55 ITERATIONS

SEARCH TIME: 00.00.20

16 ANSWERS

=> d his

(FILE 'HOME' ENTERED AT 09:53:31 ON 16 OCT 2002)
SFT COST OFF

FILE 'REGISTRY' ENTERED AT 09:53:48 ON 16 OCT 2002

```

L1      STR
L2      22 S L1 CSS
L3      SCR 2043 CR 2117
L4      7 S L1 NOT L3 CSS
L5      STR L1
L6      6 S L3 CSS

```

L7 STR L5
 L8 SCF 1949 OR 1947 OR 1950 OR 2019 OR 2048 OR 2053 OR 2052 OR 205
 L9 3 S L7 NOT L9 CSS
 L10 SCF 1949 OR 1946 OR 1929
 L11 2 S L7 NOT L8 OR L10 CSS SAM
 L12 SCF 1949
 L13 9 S L7 NOT L12 OR L10 OR L12 CSS SAM
 L14 SCF 1949
 L15 6 S L7 NOT L12 OR L10 OR L12 OR L14 CSS SAM
 L16 7 S L1 NOT L1
 L17 SCF 1949 OR 1940 OR 1949 OR 1948 OR 2053 OR 2052 OR 2051 OR 204
 L18 7 S L7 NOT L17 CSS
 L19 SCF 1949 OR 1940 OR 1949 OR 1948 OR 2053 OR 2052 OR 2051 OR 204
 L20 4 S L7 NOT L19 CSS
 L21 SCF 1949 OR 1940 OR 1949 OR 1948 OR 2053 OR 2052 OR 2051 OR 204
 L22 7 S L7 NOT L21 CSS
 L23 STR L7
 L24 16 S L23 NOT L21 CSS
 L25 2847 S L23 NOT L21 CSS FUL
 L26 SAV L23 GABIN74A/A
 L27 STR L23
 L28 0 S L23 NOT SAM SUB=L25
 L29 16 S L23 NOT FUL SUB=L25
 L30 SAV L23 GABIN74A/A
 L31 16 S L23 NOT SQL/FA
 L32 2831 S L23 NOT L23
 L33 2674 S L23 NOT SQL/FA

FILE 'HCAPLUS' ENTERED AT 10:30:07 ON 16 OCT 2002

L32 5 S L32
 L33 E SERIALS M/AD
 L34 17 S E4, E5
 L35 E M/AD S/AD
 L36 199 S E4, E5, E11-E15
 L37 E SHEET S/AD
 L38 13 S E6-E8
 L39 54249 S (COMPENT OR DU (PONT OR NEMOUR?)/PA, CS
 L40 1 S L32 AND L32-L36
 L41 SEL FU

FILE 'REGISTRY' ENTERED AT 10:32:47 ON 16 OCT 2002

L38 11 S E1-E11
 L39 17 S L38 AND L38
 L40 11 S L38 NOT L38
 L41 16 S L38 NOT L38/CI
 L42 7 S L41 NOT SQL/FA
 L43 2 S L38, L42
 L44 5 S L38 NOT L41
 L45 SAV L43 GABIN74B/A

FILE 'HCAPLUS' ENTERED AT 10:35:08 ON 16 OCT 2002

L45 0 S L45
 L46 1 S L45 AND L38-L39
 L47 0 S L45, L46

FILE 'USEFUL', 'USEFUL' ENTERED AT 10:35:26 ON 16 OCT 2002

L48 0 S L48


FILE 'REGISTRY' ENTERED AT 10:36:01 ON 16 OCT 2002

=> d ide can not be

L43 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2002 ACS

RN 452280-60-3 REGISTRY
 CN L-Prolinamide, N-acetyl-L-seryl-L-asparaginyl-4-hydroxy-, (4R)- (9CI) (CA
 INDEX NAME)
 FS STEREOSEARCH
 MF C14 H23 N5 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 157:195579

L43 ANSWER 2 OF 22 REGISTRY COPYRIGHT 2002 ACS
 EN 452280-59-0 REGISTRY
 CN L-Prolinamide, (4R)-1-acetyl-4-hydroxy-L-prolyl-L-asparaginyl-4-hydroxy-,
 (4R)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C16 H25 N5 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 3 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-58-9 REGISTRY
CN L-Serinamide, (4R)-1-acetyl-4-hydroxy-L-prolyl-L-asparaginyl- (9CI) (CA
INDEX NAME)
FS STEREOSEARCH
MF C14 H13 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 4 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-57-9 REGISTRY
CN D-Serinamide, N-acetyl-L-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 5 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-56-7 REGISTRY
CN D-Serinamide, N-acetyl-L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 6 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-55-8 REGISTRY
CN L-Serinamide, N-acetyl-L-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 7 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-54-5 REGISTRY
CN L-Serinamide, N-acetyl-L-seryl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H20 N4 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 8 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-53-4 REGISTRY
CN D-Serinamide, N-acetyl-D-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 9 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-52-3 REGISTRY
CN D-Serinamide, N-acetyl-D-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H11 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 10 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-51-2 REGISTRY
CN L-Serinamide, N-acetyl-L-seryl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C13 H22 N4 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 11 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-50-1 REGISTRY
CN L-Serinamide, N-acetyl-L-serylglycyl- (9CI) (CA INDEX NAME)
FS STEPEOSEARCH
MF C10 H18 N4 O6
SP CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 12 OF 22 REGISTRY COPYRIGHT 2002 ACS
RN 452280-49-8 REGISTRY
CN L-Serinamide, N-acetyl-D-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C12 H21 N5 O7
SP CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 13 OF 22 REGISTRY COPYRIGHT 2002 ACS
 RN 452830-43-7 REGISTRY
 CN L-Serinamide, N-acetyl-D-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)
 FS STEFEOSEARCH
 MF C12 H21 N5 O7
 SR CA
 LC STM Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 14 OF 22 REGISTRY COPYRIGHT 2002 ACS
 RN 452280-47-6 REGISTRY
 CN L-Serinamide, N-acetyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C11 H20 N4 O6
 SR CA
 LC STM Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 15 OF 22 REGISTRY COPYRIGHT 2002 ACS
 RN 452280-43-2 REGISTRY
 CN L-Serinamide, N-acetyl-L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C12 H21 N5 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 16 OF 22 REGISTRY COPYRIGHT 2002 ACS
 RN 452280-43-1 REGISTRY
 CN L-Serine, L-seryl-L-glutaminyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C11 H20 N4 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 17 OF 22 REGISTRY COPYRIGHT 2002 ACS
 RN 452285-41-0 REGISTRY
 CN L-Serine, L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)
 FS STEFEOSEARCH
 MF C10 H13 N4 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:195579

L43 ANSWER 18 OF 22 REGISTRY COPYRIGHT 2002 ACS
 RN 291270-25-0 REGISTRY
 CN D-Serinamide, N-acetyl-D-threonyl-D-asparaginyl-N-methyl- (9CI) (CA INDEX NAME)
 FS STEFEOSEARCH
 MF C14 H25 N5 O7
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:128995

L43 ANSWER 19 OF 22 REGISTRY COPYRIGHT 2002 ACS
 RN 130024-99-6 REGISTRY
 CN L-Threonine, N-(N,L-L-threonyl-L-asparaginyl)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C12 H22 N4 O7
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 113:189278

L43 ANSWER 20 OF 22 REGISTRY COPYRIGHT 2002 ACS
 RN 125746-15-8 REGISTRY
 CN L-Threonine, N-(N,L-L-seryl-L-asparaginyl)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C11 H20 N4 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 112:137251

L43 ANSWER 21 OF 22 REGISTRY COPYRIGHT 2002 ACS
 RN 99026-68-3 REGISTRY

CN L-Serine, N-(N2-L-cysteinyl-L-asparaginy)- (9CI) (CA INDEX NAME)
 FS STEPEOSEARCH
 MF C10 H18 N4 O6 S
 SR CA
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 103:196391

L43 ANSWER 22 OF 22 REGISTRY COPYRIGHT 2002 ACS
 RN 71190-91-5 REGISTRY
 CN L-Cysteine, N-(N2-L-cysteinyl-L-asparaginy)- (9CI) (CA INDEX NAME)
 FS STEPEOSEARCH
 MF C10 H18 N4 O6 S2
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 91:85694

=> file ncaplus
 FILE 'HCAPLUS' ENTERED AT 10:37:06 ON 16 OCT 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STM. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Oct 2002 VOL 137 ISS 16
FILE LAST UPDATED: 16 Oct 2002 (16011015/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SBI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus WFL field in this file.

=> d all history tot 147

L47 ANSWER 1 OF 1 BOCALUS COPYRIGHT 2002 ACS
AN 2002:69113 BOCALUS
DN 117:19:579
TI Angiogenesis-inhibitory tripeptides, compositions, and their methods of use

IN Scialdone, Mark A.; Mousa, Shaker A.; Shuey, Steven W.

PA E.I. DuPont de Nemours and Company, USA

SO PCT Int. Appl., 43 PP.

CODEN: PEXED2

ET Patent

LA English

IC ICM C07B019-79

ICS C07B005-02; A61P035-04

CC 1-8 (Pharmacology)

Section cross-reference(s): 61

FAN.ONT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002/040512	A1	20020829	WO 2002-US5211	20020215

W: CA, CN, JP
FW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRAI US 2001-0055378 1 2001-0116
US 2001-0010479 1 2001-0914

OS MAPPAT 1-7:195579

AB The invention discloses methods and compns. for inhibiting endothelial cell tube formation, the initial step of tumor angiogenesis. More specifically, the invention discloses tripeptides that show inhibition of angiogenesis-mediated processes. The most preferred amino acid sequences are LHS and SIS.

ST tripeptide angiogenesis inhibitor; tumor angiogenesis inhibitor tripeptide

IT Animal cell line

HTVEC; tripeptide angiogenesis inhibitors, compns., and use)

IT Disease, animal

Wistar-Kyoto-Rand disease; tripeptide angiogenesis inhibitors, compns., and use)

SAME

- IT Edema
(anti-edema agents; tripeptide angiogenesis inhibitors, compns., and use)
- IT Antiarteriosclerotics
(antiatherosclerotics; tripeptide angiogenesis inhibitors, compns., and use)
- IT Antibodies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor; tripeptide angiogenesis inhibitors, compns., and use)
- IT Bartonella
(bartonellosis; tripeptide angiogenesis inhibitors, compns., and use)
- IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biodegradable; tripeptide angiogenesis inhibitors, compns., and use)
- IT Eye
(choroid; tripeptide angiogenesis inhibitors, compns., and use)
- IT Inflammation
(cornea; tripeptide angiogenesis inhibitors, compns., and use)
- IT Ligands
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated, with nucleic acids; tripeptide angiogenesis inhibitors, compns., and use)
- IT Nucleic acids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, with ligands; tripeptide angiogenesis inhibitors, compns., and use)
- IT Blood vessel
(endothelium; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
(immunotoxins; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
(injections, i.p.; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
(intracerebral; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
(intracranial; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
(intrauterine; tripeptide angiogenesis inhibitors, compns., and use)
- IT Lasers
(laser therapy; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
(liposomes; tripeptide angiogenesis inhibitors, compns., and use)
- IT Neoplasm
(metastasis, inhibitors; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
(nasal; tripeptide angiogenesis inhibitors, compns., and use)
- IT Prostate gland
(neoplasm, TSC-Pr, inhibitors; tripeptide angiogenesis inhibitors, compns., and use)
- IT Angiogenesis
(neovascularization, eye; tripeptide angiogenesis inhibitors, compns., and use)
- IT Angiogenesis
(neovascularization, retinal; tripeptide angiogenesis inhibitors, compns., and use)
- IT Angiogenesis
Eye, disease
(neovascularization; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems

- (ophthalmic; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
 - (oral; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
 - (osmotic pumps, mini-pump; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
 - (parenterals; tripeptide angiogenesis inhibitors, compns., and use)
- IT Skin, disease
 - (pemphigoid; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
 - (rectal; tripeptide angiogenesis inhibitors, compns., and use)
- IT Eye, disease
 - (retina, neovascularization; tripeptide angiogenesis inhibitors, compns., and use)
- IT Eye
 - (retina; tripeptide angiogenesis inhibitors, compns., and use)
- IT Neoplasm
 - (solid, inhibitors; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug targeting
 - (targeting compds.; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
 - (topical; tripeptide angiogenesis inhibitors, compns., and use)
- IT Eye, disease
 - (trachoma; tripeptide angiogenesis inhibitors, compns., and use)
- IT Drug delivery systems
 - (transdermal; tripeptide angiogenesis inhibitors, compns., and use)
- IT Adenoviridae
 - Angiogenesis
 - Angiogenesis inhibitors
 - Anti-inflammatory agents
 - Antiarthritics
 - Antibiotics
 - Antirheumatic agents
 - Antitumor agents
 - Antiviral agents
 - Atherosclerosis
 - Chemotherapy
 - Drug delivery systems
 - Genetic vectors
 - Human
 - Inflammation
 - Osteoarthritis
 - Radiosensitizers, biological
 - Radiotherapy
 - Retroviral vectors
 - Retroviridae
 - Rheumatoid arthritis
 - Surgery
 - Therapy
 - Virus vectors
 - (tripeptide angiogenesis inhibitors, compns., and use)
- IT Cytokines
 - Tripeptides
 - EL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (tripeptide angiogenesis inhibitors, compns., and use)
- IT RNA
 - Nucleic acids
 - RNA
 - EL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tripeptide angiogenesis inhibitors, compns., and use)
 IT Drug delivery systems
 (vaginal; tripeptide angiogenesis inhibitors, compns., and use)
 IT 452280-41-0P 452280-42-1P 452280-43-2P
 452280-44-3P 452280-45-4P 452280-46-5P 452280-47-6P
 452280-48-7P 452280-49-8P 452280-50-1P
 452280-51-2P 452280-52-3P 452280-53-4P
 452280-54-5P 452280-55-6P 452280-56-7P
 452280-57-8P 452280-58-9P 452280-59-0P
 452280-60-3P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 IT (tripeptide angiogenesis inhibitors, compns., and use)
 25104-18-1, Polylysine 39006-06-5, Polylysine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (tripeptide angiogenesis inhibitors, compns., and use)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Eisai Co Ltd; WO 951861 A 1999 HCAPLUS

(2) Fok, K; WO 951638 A 1999 HCAPLUS

(3) Kleinerman, E; CANCER IMMUNOLOGY IMMUNOTHERAPY 1992, V34(4), P211 MEDLINE

(4) Maeshima, Y; JOURNAL OF BIOLOGICAL CHEMISTRY 2000, V275(28), P21340 HCAPLUS

IT 452280-41-0P 452280-42-1P 452280-43-2P
 452280-47-6P 452280-48-7P 452280-49-8P
 452280-50-1P 452280-51-2P 452280-52-3P
 452280-53-4P 452280-54-5P 452280-55-6P
 452280-56-7P 452280-57-8P 452280-58-9P
 452280-59-0P 452280-60-3P


FL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)

(tripeptide angiogenesis inhibitors, compns., and use)

FN 452280-41-0 HCAPLUS

CN L-Serine, L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



FN 452280-42-1 HCAPLUS


CN L-Serine, L-seryl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-43-2 HCAPLUS
 CN L-Serinamide, N-acetyl-L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-47-6 HCAPLUS
 CN L-Serinamide, N-acetyl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-48-7 HCAPLUS
 CN L-Serinamide, N-acetyl-D-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-49-8 HCAPLUS
 CN L-Serinamide, N-acetyl-D-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-50-1 HCAPLUS
 CN L-Serinamide, N-acetyl-L-serylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-51-2 HCAPLUS
 CN L-Serinamide, N-acetyl-L-seryl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-52-3 HCAPLUS
 CN D-Serinamide, N-acetyl-D-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-53-4 HCAPLUS
 CN D-Serinamide, N-acetyl-D-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-54-5 HCAPLUS
 CN L-Serinamide, N-acetyl-L-seryl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-55-6 HCAPLUS
 CN L-Serinamide, N-acetyl-L-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-56-7 HCAPLUS
 CN D-Serinamide, N-acetyl-L-seryl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-57-3 HCAPLUS
 CN D-Serinamide, N-acetyl-L-seryl-D-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-58-9 HCAPLUS
 CN L-Serinamide, (4R)-1-acetyl-4-hydroxy-L-prolyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 452280-59-0 HCAPLUS
 CN L-Prolinamide, (4R)-1-acetyl-4-hydroxy-L-prolyl-L-asparaginyl-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452280-60-3 HCAPLUS
 CN L-Frolinamide, N-acetyl-L-seryl-L-asparaginyl-4-hydroxy-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L47 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2001 ACS

AN 2001:78530 HCAPLUS

DN 136:138995

TI Evaluation of designed ligands by a multiple screening method: application to glycogen phosphorylase inhibitors constructed with a variety of approaches

AU So, Sung-Sau; Kargus, Martin

CS Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, 02138, USA

SO Journal of Computer-Aided Molecular Design (2001), 15(7), 613-647

CODEN: JCABEQ; ISSN: 0920-654X

PB Kluwer Academic Publishers

ET Journal

LA English

CC 1-12 (Pharmacology)

AB Glycogen phosphorylase (GP) is an important enzyme that regulates blood glucose level and a key therapeutic target for the treatment of type II diabetes. In this study, a no. of potential GP inhibitors are designed with a variety of computational approaches. They include the applications of MOSES, LUDI and CMFA to identify addnl. fragments that can be attached to existing lead mols.; the use of 2D and 3D similarity-based QSAR models (HQSAE and SMKNN) and of the LUDI program to identify novel mols. that may bind to the glucose binding site. The designed ligands are evaluated by a multiple screening method, which is a combination of com. and inhouse ligand-receptor binding affinity prediction programs used in a previous study. Each method is used at an appropriate point in the screening, as detd. by both the accuracy of the calcs. and the computational cost. A comparison of the strengths and weaknesses of the ligand design approaches is made.

ST High throughput drug screening glycogen phosphorylase inhibitor mol modeling

IT Algorithms

(MOSES; evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)

IT QSAR (structure-activity relationship)

(comparative mol. field anal.; evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)

IT High throughput screening

(drug, LUDI; evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)

IT Combinatorial library

Computer program
 Confirmation potential
 Drug design
 Drug screening
 Hydrophilicity
 Hydrophobicity
 Molecular modeling
 Molecular structure
 Potential energy

Evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches

- IT Drug screening
 (high throughput, LUDI; evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)
- IT 9035-74-9, Glycogen phosphorylase
 FL: 230 (Biological study, unclassified); 5376 (Biological study)
 (binding affinity; evaluation of designed ligands by a multiple screening method and application to glycogen phosphorylase inhibitors constructed with a variety of approaches)
- IT 65-88-1 76-74-4 90-80-2 9-85-8 111-09-3, Hexanedinitrile
 110-13-8 294-58-1 461-72-3, 1,4-imidazolidinedione 544-13-4
 542-02-9 591-07-1 621-43-1 9-3-17-5 1875-34-3 1150-13-8
 1629-18-1 3918-67-5 3478-14-1 4413-25-1 4811-67-2 5401-13-8
 5463-81-8, 4,5-Phenanthrenedimethoxyacetic acid 5699-40-1 5977-14-1
 6261-73-1 6526-17-4 6216-84-7 7423-84-1 6913-41-4 7143-77-3
 7305-71-7 11284-61-8 11334-51-8 13601-34-0 15386-43-6 17390-29-7
 21225-76-9 25144-64-8 28013-11-1 36134-53-2 38111-43-9
 37938-77-6 40993-89-4 50813-84-4 55791-84-3 58363-70-6
 58484-06-3 58605-73-8 58648-72-5 59214-01-6 59695-30-3
 67191-53-1 71497-64-2 73231-78-8 92847-88-1 98112-30-3
 18370-13-8 11305-80-1 11363-44-1 113973-53-4 130633-66-1
 131295-44-4 136236-41-6 15384-11-6 160131-33-6 171357-33-4
 175809-11-3 185890-20-7 201870-13-4 201870-13-5 301-70-10-8
 391870-17-0 391870-18-1 391870-19-2 391870-19-3 391870-21-8
 391870-21-7 391870-22-8 391870-24-0 391870-25-0 391870-25-1
 391870-26-1 391870-27-2 391870-28-3 391870-29-4 391870-30-1
 391870-31-8 391870-32-9 391870-33-0 391870-34-1 391870-35-2
 391870-36-3 391870-37-4 391870-38-5 391870-39-6 391870-40-7
 391870-41-0 391870-42-1 391870-43-2 391870-44-3 391870-45-4
 391870-46-1 391870-47-6 391870-48-7 391870-49-8 391870-50-9
 391870-51-1 391870-52-3 391870-53-4 391870-54-5 391870-55-6
 391870-56-7 391870-57-8 391870-58-9 391870-59-0 391870-60-1
 391870-61-4 391870-62-5 391870-63-6 391870-64-7 391870-65-8
 391870-66-9 391870-67-0 391870-68-1 391870-69-2 391870-70-3
 391870-71-6 391870-72-7 391870-73-8 391870-74-9 391870-75-0
 391870-76-1 391870-77-2 391870-78-3 391870-79-4 391870-80-5
 391870-81-6 391870-82-7 391870-83-8 391870-84-9 391870-85-0
 391870-86-1 391870-87-2 391870-88-3 391870-89-4 391870-90-5
 391870-91-6 391870-92-7 391870-93-8 391870-94-9 391870-95-0
 391870-96-1 391870-97-2 391870-98-3 391870-99-4 391871-00-5
 391871-01-6 391871-02-7 391871-03-8 391871-04-9 391871-05-0
 391871-06-1 391871-07-2 391871-08-3 391871-09-4 391871-10-5
 391871-11-6 391871-12-7 391871-13-8 391871-14-9 391871-15-0
 391871-16-1 391871-17-2 391871-18-3 391871-19-4 391871-20-5
 391871-21-6 391871-22-7 391871-23-8 391871-24-9 391871-25-0
 391871-26-1 391871-27-2 391871-28-3 391871-29-4 391871-30-5
 391871-31-6 391871-32-7 391871-33-8 391871-34-9 391871-35-0
 391871-36-1 391871-37-2 391871-38-3 391871-39-4 391871-40-5
 391871-41-6 391871-42-7 391871-43-8 391871-44-9 391871-45-0
 391871-46-1 391871-47-2 391871-48-3 391871-49-4 391871-50-5
 391871-51-6 391871-52-7 391871-53-8 391871-54-9 391871-55-0

391871-56-0 391871-57-1 391871-58-2 391871-59-3 391871-61-7
391871-63-4 391871-64-5 391871-65-6 391871-66-7 391871-67-3
391871-68-4 391871-69-5 391871-70-6 391871-71-7 391871-72-0
391871-73-1 391871-74-2 391871-75-3 391871-76-4 391871-77-5
391871-78-6 391871-79-7 391871-80-8 391871-81-9 391871-82-2
391871-83-3

RE: BSU (Biological study, unclassified); PRE (Properties); THU
(Therapeutic use); RI (Biological study); USES (Uses)
(evaluation of designed ligands by a multiple screening method and
application to glycosyl phosphatase inhibitors constructed with a
variety of approaches)

IT 391871-84-4 391871-85-5 391871-86-6 391871-87-7 391871-88-8
391871-89-9 391871-90-0 391871-91-1 391871-92-2 391871-93-3
391871-94-4 391871-95-5 391871-96-6 391871-97-7 391871-98-8
391872-00-7 391872-01-8 391872-02-9 391895-15-3 391895-16-4

PL: BSU (Biological study, unclassified); PRE (Properties); THU
(Therapeutic use); RI (Biological study); USES (Uses)
(evaluation of designed ligands by a multiple screening method and
application to glycosyl phosphatase inhibitors constructed with a
variety of approaches)

RE: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Agrafiotis, B; J Chem Inf Comput Sci 1999, V37, P341 HCAPLUS
- (2) Ajay; J Med Chem 1998, V41, P314 MELLINE
- (3) Andrea, T; J Med Chem 1991, V34, P224 HCAPLUS
- (4) Agvist, J; Prot Eng 1994, V7, P385 MELLINE
- (5) Bohm, H; J Comput Aid Mol Des 1990, V6, P599 MELLINE
- (6) Bohm, H; J Comput Aid Mol Des 1990, V6, P61 MELLINE
- (7) Bohm, H; J Comput Aid Mol Des 1994, V8, P443 MELLINE
- (8) Bohm, H; J Comput Aid Mol Des 1994, V8, P623 MELLINE
- (9) Brown, F; J Med Chem 1997, V40, P1304 HCAPLUS
- (10) Caffisch, A; J Comput Aid Mol Des 1990, V6, P371 HCAPLUS
- (11) Caffisch, A; J Comput Aid Mol Des 1990, V6, P161 HCAPLUS
- (12) Caffisch, A; J Med Chem 1990, V33, P1141 HCAPLUS
- (13) Caffisch, A; Perspect Drug Discov Des 1995, V3, P51 HCAPLUS
- (14) Caffisch, A; Proc Natl Acad Sci USA 1990, V87, P1746 HCAPLUS
- (15) Charifson, P; J Med Chem 1990, V42, P1006 HCAPLUS
- (16) Cramer, F; J Am Chem Soc 1998, V110, P1009 HCAPLUS
- (17) Damunkoehler, F; J Comput Aid Mol Des 1998, V3, P3 HCAPLUS
- (18) DeWitte, R; J Am Chem Soc 1990, V112, P1113 HCAPLUS
- (19) DeWitte, R; J Am Chem Soc 1997, V119, P4006 HCAPLUS
- (20) de Groot, M; J Med Chem 1990, V42, P1813 HCAPLUS
- (21) de Groot, M; J Med Chem 1990, V42, P4001 HCAPLUS
- (22) Eisen, M; Prot Struct Funct Genet 1994, V19, P199 HCAPLUS
- (23) Elber, R; J Am Chem Soc 1990, V112, P1101 HCAPLUS
- (24) Evensen, E; MOSS Version 2.1
- (25) Evensen, E; OLIGO Version 3.1
- (26) Fisanick, W; J Chem Inf Comput Sci 1994, V34, P110
- (27) Garber, F; J Comput Aid Mol Des 1990, V6, P331 HCAPLUS
- (28) Gillet, V; J Chem Inf Comput Sci 1994, V34, P207 HCAPLUS
- (29) Gillet, V; J Comput Aid Mol Des 1990, V6, P127 HCAPLUS
- (30) Good, A; Reviews in Computational Chemistry 1994, P67 HCAPLUS
- (31) Grigorev, M; J Chem Inf Comput Sci 1997, V37, P114 HCAPLUS
- (32) Grootenhuys, J; J Comput Aid Mol Des 1996, V10, P1 HCAPLUS
- (33) Gschwenda, B; Prot Struct Funct Genet 1997, V22, P159 HCAPLUS
- (34) Hahn, M; J Med Chem 1995, V38, P1331 HCAPLUS
- (35) Hahn, M; J Med Chem 1995, V38, P1331 HCAPLUS
- (36) Joseph-McCarthy, J; Prot Struct Funct Genet 1997, V22, P32 HCAPLUS
- (37) Kaminski, J; J Med Chem 1997, V40, P1111 HCAPLUS
- (38) Kuntz, I; Science 1993, V261, P1078 HCAPLUS
- (39) Langlois, M; Eur J Pharmacol 1993, V214, P7 HCAPLUS
- (40) Leclerc, F; Ther Chem Acc 1998, V101, P131 HCAPLUS
- (41) Lewis, L; Toxicology 1990, V133, P1 HCAPLUS

- (42) Lipinski, C; Adv Drug Delivery Rev 1997, V23, P3 HCAPLUS
 (43) Mareaux, N; Prot Struct Funct Genet 1999, V37, P48 HCAPLUS
 (44) Miranker, A; Prot Struct Funct Genet 1991, V11, P29 HCAPLUS
 (45) Miranker, A; Prot Struct Funct Genet 1995, V23, P472 HCAPLUS
 (46) Molecular Simulations Inc; Cerius2 Version 3.0
 (47) Molecular Simulations Inc; INSIGHT Version 95.0
 (48) Moon, J; Prot Struct Funct Genet 1991, V11, P314 HCAPLUS
 (49) Muegge, I; J Med Chem 1999, V41, P791 HCAPLUS
 (50) Neria, E; J Chem Phys 1996, V105, P1902 HCAPLUS
 (51) Palm, K; J Med Chem 1998, V41, P5382 HCAPLUS
 (52) Richard, A; Mutat Res 1998, V400, P197 HCAPLUS
 (53) Rotstein, S; J Comput Aid Mol Des 1999, V7, P23 HCAPLUS
 (54) Sadowski, J; Chem Rev 1993, V73, P2567
 (55) Sadowski, J; J Med Chem 1995
 (56) Schaefer, M; J Phys Chem 1996, V100, P1578 HCAPLUS
 (57) Shoichet, B; Science 1993, V259, P1447 HCAPLUS
 (58) Simulations Plus Inc; GastroPlus Version 11.3
 (59) So, S; J Comput, Aid Mol Des 1999, V13, P43 HCAPLUS
 (60) So, S; J Med Chem 1992, V35, P3281 HCAPLUS
 (61) So, S; J Med Chem 1996, V39, P1511 HCAPLUS
 (62) So, S; J Med Chem 1996, V39, P5246 HCAPLUS
 (63) So, S; J Med Chem 1997, V40, P4347 HCAPLUS
 (64) So, S; J Med Chem 1997, V40, P4360 HCAPLUS
 (65) Stultz, C; Prot Struct Funct Genet 2000, V40, P258 HCAPLUS
 (66) Tripos Inc; HQSAR Version 1.0
 (67) van Gunsteren, W; Q Rev of Biophy 1994, V27, P435 MEDLINE
 (68) Verlinde, C; Structure 1994, V2, P577 HCAPLUS
 (69) Watson, K; Acta Cryst 1995, V51, P413 HCAPLUS
 (70) Watson, K; Biochemistry 1994, V33, P5745 HCAPLUS
 (71) Wessel, M; J Chem Inf Comput Sci 1998, V38, P726 HCAPLUS

IT 391870-25-0

FL: BSU (Biological study, unclassified); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (evaluation of designed ligands by a multiple screening method and
 application to glycogen phosphorylase inhibitors constructed with a
 variety of approaches)

EN 391870-25-0 HCAPLUS

CI: D-Serinamide, N-acetyl-D-threonyl-D-asparaginyl-N-methyl- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



147 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2002 ACS

AN 1990:599178 HCAPLUS

IN 113:189273


TI A B cell-, T cell-linked epitope located on the adhesin of Mycoplasma pneumoniae

AU Jacobs, E.; Rieck, R.; Palehite, L.

CS Inst. Med. Microbiol. Hyg., Univ. Freiburg, Freiburg, D-7800, Germany
 SO Infection and Immunity (1990), 58(8), 2464-9
 CODEN: INFIER; ISSN: 0019-9567
 DT Journal
 LA English
 CC 15-2 (Immunology)
 AB The identification of specific T cell and B cell epitopes of the P1 protein, which functions as an adhesin and as a major antigen of *M. pneumoniae*, has become of central interest for the design of synthetic vaccines. Here is reported the isolation from guinea pigs infected intranasally with *M. pneumoniae* of hilar and bronchial T lymphocytes which proliferated after in vitro stimulation with sonicated *M. pneumoniae* whole-cell antigen and with the isolated P1 protein. For more detailed information on T cell epitopes, a 51-amino-acid region (histidine 321 to glycine 371; numbered from the N-terminal end) of the P1 protein was analysed for a T cell epitope. An octapeptide, S-G-S-R-S-F-I-P (starting at amino acid 845), stimulated in vitro lymphocytes of bronchial washings and of hilar lymph nodes. This T cell-stimulating amino acid sequence was located at the C-terminal end of a B cell epitope with the sequence T-N-T (starting at amino acid 842).

ST Mycoplasma adhesin T B lymphocyte epitope
 IT Mycoplasma pneumoniae
 (P1 adhesin protein of, B- and T-lymphocyte-linked epitopes on, mapping of)
 IT Lymphocyte
 (B-, Mycoplasma pneumoniae P1 adhesin protein epitopes specific for, mapping of)
 IT Lymphocyte
 (T-, Mycoplasma pneumoniae P1 adhesin protein epitopes specific for, mapping of)
 IT Agglutinins and Lectins
 RL: BIOL (Biological study)
 (adhesins, P1, B- and T-lymphocyte-linked epitopes of, of Mycoplasma pneumoniae, mapping of)
 IT 130024-99-6
 FL: BIOL (Biological study)
 (as Mycoplasma pneumoniae adhesin B-lymphocyte-specific epitope)
 IT 130024-99-6
 FL: BIOL (Biological study)
 (as Mycoplasma pneumoniae adhesin T-lymphocyte-specific epitope)
 IT 130024-99-6
 FL: BIOL (Biological study)
 (as Mycoplasma pneumoniae adhesin B-lymphocyte-specific epitope)
 RN 130024-99-6 HCAPLUS
 CN L-Threonine, N-(12-L-threonyl-L-asparaginy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AN 1930:137251 HCAPLUS
 DN 113:137251
 TI Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
 AU Kast, W. Martin; Offringa, Fienk; Peters, Peter J.; Voordouw, Aris C.; Melsen, Rob H.; Van der Eb, Alex J.; Melief, Cornelis J. M.
 CS Div. Immunol., Natl. Cancer Inst., Amsterdam, 1066 X, Neth.
 SO Cell (Cambridge, Mass.) (1989), 59(4), 603-14
 CCBEN: CEMLB9; ISSN: 0092-8674
 DT Journal
 LA English
 CC 15-10 (Immunohistochemistry)
 AB Cytotoxic T lymphocyte (CTL) clones against adenovirus type 5 (Ad5) early region 1 (E1)-transformed cells were generated in C57BL/6 (B6) mice. A defined peptide encoded by Ad5 E1A is the target structure for H-2Db-restricted CTLs. Upon i.v. injection into B6 nude mice bearing Ad5 E1-induced tumors, these CTLs, if combined with recombinant interleukin-2, destroy s.c. tumor masses up to 10 cm³. The in vivo action of CTLs is highly specific, and long-term memory persists in treated nude mice months after tumor regression. An important role for CTLs directed against a viral nuclear oncogene product in tumor eradication is thus shown.
 ST adenovirus E1A gene tumor cytotoxic lymphocyte; T lymphocyte adenovirus E1A gene tumor; virus adeno E1A gene tumor lymphocyte
 IT Neoplasm, toxic chemical and physical damage
 (adenovirus-induced, cytotoxic T-lymphocytes specific for gene E1A protein toxicity for, H-2Dk-restricted)
 IT Antigens
 FL: BIOL (Biological study)
 (H-2Db, gene E1A protein-specific cytotoxic T-lymphocyte inhibition of adenovirus-induced tumor restricted by)
 IT Lymphocyte
 (T-, cytotoxic, E1A gene protein-specific, adenovirus-induced tumor inhibition by interleukin 2 and, H-2Db-restricted)
 IT Virus, animal
 (adenovirus 5, gene E1A protein of, cytotoxic T-lymphocytes specific for, virus-induced tumor inhibition by interleukin 2 and, H-2Db-restricted)
 IT Phosphoproteins
 FL: BIOL (Biological study)
 (gene E1A, peptides of, of adenovirus 5, cytotoxic T-lymphocyte fine specificity for)
 IT Lymphokines and Cytokines
 FL: BIOL (Biological study)
 (interleukin 2, adenovirus-induced tumor inhibition by gene E1A protein-specific cytotoxic T-lymphocytes and)
 IT Gene and Genetic element, microbial
 FL: BIOL (Biological study)
 (E1A, of adenovirus, cytotoxic T-lymphocytes specific for product of, tumor inhibition by interleukin 2 and)
 IT 5513-86-0 13438-04-0 46886-22-0 71524-42-0 76524-20-4
 120728-88-3 125746-13-6 125746-14-7 125746-15-8
 125746-16-9 125746-17-0 125746-18-1 125746-19-2 125746-20-5
 125746-21-0 125746-22-7 125746-23-8 125746-24-9 125746-25-0
 125746-26-1 125746-27-2 125746-28-3 125746-29-4 125746-30-7
 125746-31-8 125746-32-9 125746-33-0 125746-34-1 125746-35-2
 125746-36-3 125746-37-4 125746-38-5 125746-39-6 125746-40-9
 125746-41-0 125746-42-1 125746-43-2 125746-44-3 125746-45-4
 125746-46-5 125746-47-6 125746-48-7 125746-49-8 125746-50-1
 125746-51-2 125746-52-3 125746-53-4 125746-54-5 125746-55-6
 125746-56-7 125746-57-8 125746-58-9 125746-59-0 125746-60-3
 125746-61-4 125746-62-5 125746-63-6 125746-64-7 125746-65-8
 125746-66-9 125746-67-0 125746-68-1 125746-69-2 125746-70-5
 125746-71-6 125746-72-7 125746-73-8 125746-74-9 125746-75-0

125767-84-2 125767-85-3 125767-86-4 125767-87-5 125767-88-6
 125767-89-7 125767-90-0 125767-91-1 125767-92-2 125767-93-3
 125767-94-4 125767-95-5 125767-96-6 125771-12-2 125785-35-5
 125843-94-7

RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)

(cytotoxic T-lymphocyte fine specificity for, of adenovirus 5 E1A
 protein)

IT 125746-15-8

RL: BAC (Biological activity or effector, except adverse); BIOL
 (Biological study)

(cytotoxic T-lymphocyte fine specificity for, of adenovirus 5 E1A
 protein)

FN 125746-15-8 HCAFLUS

CH L-Threonine, N-(N1-L-seryl-L-asparaginyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L47 ANSWER 5 OF 6 HCAFLUS COPYRIGHT 2002 ACS

AN 1985:96391 HCAFLUS

IN 198:196391

TI Synthesis and biological activity of proposed structures for the
 atriopeptin family of natriuretic hormones

AU Balasubramanian, T. M.; Needleman, P.; Currie, M. S.; Geller, D. M.; Cole,
 B. F.; Marshall, G. E.; Fok, K. F.; Eubanks, S. E.; Zuper, M.; Adams, S.
 P.

CS Sch. Med., Washington Univ., St. Louis, MO, 63110, USA

SO Pept., Proc. Eur. Pept. Symp., 18th (1984), 509-12. Editor(s):
 Ragnarsson, Ulf. Publisher: Almquist & Wiksell, Stockholm, Swed.

COSEN: 53PWAN

BT Conference

LA English

CC 34-3 (Amino Acids, Peptides, and Proteins)

Section cross-reference(s): 2

AB H-Ser-Ser-Cys-Ile-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-
 Cys-Asn-Ser-X-H (X = null, Phe-Arg, Phe-Arg-Tyr) (atrioceptins I, II, and
 III, resp.) were isolated from atrial exts. and also synthesized by solid-
 and liq.-phase methods. Analogs of atriopeptin I in which Asp-9 and Phe-4
 are replaced by Ala were also prepd. and found to have reduced (100- and
 200-fold, resp.) natriuretic activity.

ST atriopeptin isolation synthesis; Merrifield synthesis atriopeptin;
 natriuretic hormone atriopeptin

IT Peptides, preparation

PL: SPN (Synthetic preparation); PREP (Preparation)
 atrioceptins and analogs, prepn. and activities of)

IT Molecular structure-biological activity relationship
 (natriuretic-diuretic, of atriopeptin analogs)

IT Merrifield synthesis
 (of atriopeptins)

IT 00026-71-8L, protected derivs.

RL: ECT (Reactant)
(deprotection of)

IT 89179-53-7P 89179-54-8P 97793-28-7P
RL: ECT (Reactant); PREP (Preparation)
(isolation and synthesis of)


IT 99016-71-9P 99016-72-9P
RL: EAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and biol. activity of)

IT 23571-41-4P, protected derivs. 99026-66-1DP, protected derivs.
99026-67-2DP, protected derivs. 99026-68-3DP, protected derivs.
99016-69-4P, protected derivs. 99026-70-7DP, protected derivs.
RL: ECT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and peptide coupling of)

IT 99026-68-3DP, protected derivs.
RL: ECT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and peptide coupling of)

RN 99016-68-3 HCAPIUS
CN L-Serine, N-[(L-L-cysteinyl-L-asparaginyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



I47 ANSWER 6 OF 6 HCAPIUS COPYRIGHT 2002 ACS
AN 1979:435694 HCAPIUS
EN 91:35694
TI An a priori calculation of the three-dimensional structure of apamin. I.
Fragment Cys1-Pro6
AU Popov, E. M.; Mel'nikov, P. N.
CS M. M. Shemyakin Inst. Bioorg. Chem., Moscow, USSR
SO Bioorg. Khim. (1979), 1(6), 328-47
CODEN: BIKH07
DT Journal
LA Russian
CC 6-3 (General Biochemistry)
AB The conformational possibilities of the apamin N-terminal fragment Cys-Asn-Cys-Lys-Ala-Pro (Cys1-Pro6) were calcd. A multistage anal. involved preliminary calcons. for the overlapping di-, tri-, and tetrapeptide portions of the Cys1-Pro6 hexapeptide. Low-energy nonpeptide conformations were used for computing the dipeptide structures. Anal. of the Cys1-Pro6 fragment produced several stable structures which are promising for studies of longer apamin fragments.
ST apamin conformation calcn
IT chains, chemical
(conformation of, of apamin, a priori calcn. of)
IT Conformation and Conformers
of amino acids of apamin, polypeptide conformation calcn. in relation to)
IT 14345-16-1
RL: BIOL (Biological study)
(conformation of N-terminal hexapeptide of, a priori calcn. of)

IT 17043-71-3 63097-15-0 71190-87-9 71190-88-0 71190-89-1
 71190-90-4 71190-91-5 71190-92-6 71190-93-7
 RL: PRP (Properties)
 (conformation of, a priori calcul. of, apamin in relation to)
 IT 71190-91-5
 RL: PRP (Properties)
 (conformation of, a priori calcul. of, apamin in relation to)
 RN 71190-91-5 HCAPLUS
 CN L-Cysteine, N-(N-L-cysteinyl-L-asparaginyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his 149-

(FILE 'REGISTRY' ENTERED AT 10:36:01 ON 16 OCT 2002)

FILE 'HCAPLUS' ENTERED AT 10:37:06 ON 16 OCT 2002

L49 5144 S L31
 L50 5055 S L43 AND (PL=20010216 OR PRD<=20010216 OR AD<=20010216)
 L51 51 S L50 AND ANGIOGENE
 E ANGIOGENESIS/CT
 E E3+ALL
 L52 7139 S E4+NT
 E E10+ALL
 L53 2605 S E4+NT
 E E7+ALL
 L54 1515 S E3,E4,E2+NT
 E E9+ALL
 L55 1755 S E6,E5+NT
 E ANGIOGENESIS/CT
 E E3+ALL
 E E12+ALL
 L56 127085 S E5,E4+NT
 E ANGIOGENESIS/CT
 E E7+ALL
 L57 2605 S E4+NT
 L58 43 S L50 AND L53-L55,L57
 L59 138 S L50 AND L50
 L60 2279 S L56 (L) ANGIOGENE
 L61 38951 S L56 (L) ENDOTHEL?
 L62 37 S L59 AND L60,L61
 L63 122 S L51,L55,L60
 L64 121 S L63 NOT L43
 L65 68 S L64 AND P/NT
 L66 41 S L65 AND US/PC
 L67 414 S L61 (L) (FAC OR THU)/RL
 L68 45 S L67 AND L64
 L69 22 S L68 AND L66
 SEL HIT EN

FILE 'REGISTRY' ENTERED AT 10:45:54 ON 16 OCT 2002

L70 20 S E1-E26
L71 25 S L70 NOT NUSCOWES

FILE 'HCAIPLUS' ENTERED AT 10:51:54 ON 16 OCT 2002

L72 914 S L71
L73 11 S L72 AND L69

=> d all hitser tot L73

L73 ANSWER 1 OF 41 HCAIPLUS COPYRIGHT 2002 ACS

AN 2002:518594 HCAIPLUS

DN 137:89441

TI Compounds and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides

IN Blaschuk, Orest W.; Gour, Barbara J.; Farockhi, Riaz

PA McGill University, Can.

SO U.S., 61 pg., Cont.-in-part of U.S. Ser. No. 249,074.

CODEN: USXKAM

DT Patent

LA English

IC ICM A61B038-00

ICS C07K005-00; C07K001-00

NCL 530317000

CC 1-6 (Pharmacology)

FAN.CMT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FI	US 6417323	B1	19990709	US 1999-353717	19990720 ---
	US 6231071	A	19980229	US 1997-495534	19970711 ---
	US 6169071	B1	19970109	US 1997-096679	19971223 ---
	US 6346513	B1	19990212	US 1999-148074	19990210 ---
	US 6465427	B1	19991119	US 1999-453870	19991210 ---
PRAI	US 1996-216121	P	19960713	---	---
	US 1997-893534	A1	19970711	---	---
	US 1997-996679	A1	19971223	---	---
	US 1999-148074	A1	19990210	---	---
	US 1999-192717	A1	19990720	---	---
AB	Agents that inhibit the development of cancer and tumor growth are provided. Such agents comprise a classical cadherin cell adhesion recognition (CAR) sequence HAV within a cyclic peptide ring, and may be used to prevent or treat cancer. The cyclic peptide N-Ac-CHAVC-NH2 disrupted melanoma cell adhesion and inhibited angiogenesis .				
ST	cancer treatment cadherin cyclic peptide (CAR) sequence; cell adhesion recognition cyclic peptide cadherin antitumor; angiogenesis inhibition cyclic peptide cadherin; melanoma cell adhesion disruption cyclic peptide				
IT	Cadherins FI: B3U (Biological study, unclassified); B1C1 (Biological study) (E-; compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)				
IT	Cadherins FI: B3U (Biological study, unclassified); B1C1 (Biological study) (N-; compds. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)				
IT	Angiogenesis inhibitors Antitumor agents Apoptosis Carcinoma Cell adhesion Drug delivery systems Human				

- Leukemia
Mammalia
Melanoma
Neoplasm
Ovary, neoplasm
(comps. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)
- IT Cadherins
FL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(comps. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)
- IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclic, cell adhesion modulating; comps. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)
- IT Mammary gland
(neoplasm; comps. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)
- IT Blood
(stability of cyclic peptide in; comps. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)
- IT 60961-76-4 99896-85-2 132151-24-7
143113-41-1 157535-09-6 175177-02-3
175177-14-7 175177-70-5 204644-26-3 231281-15-0 231282-43-2
231282-44-3 231282-45-4 231282-46-5 231282-47-6
FL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cell adhesion recognition sequence; comps. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)
- IT 209971-59-8 214064-49-8 219971-63-2 229971-61-3 239971-62-4
239971-63-5 239971-64-6 239971-65-7 239971-67-9 239971-68-0
239971-68-1 239971-69-4 239971-70-5 239971-71-6 239971-72-7
317320-04-4 317320-12-3 317320-13-5 317320-14-4 331224-65-3
331224-66-4 331224-67-5
FL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cell adhesion modulating cyclic peptide; comps. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)
- IT 239971-59-9
FL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comps. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)
- IT 239971-81-7 239971-82-9 239971-84-9 239971-85-1 239971-86-2
239971-88-4 239971-91-9 331229-47-1
FL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comps. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)
- IT 442111-54-3 442111-55-5 442111-56-6 442111-58-7 442111-59-8
442111-60-1 442111-61-2 442111-62-3 442111-63-4 442111-64-5
442111-65-6 442111-66-7
FL: PRP (Properties)
(unclaimed protein sequence; comps. and methods for cancer therapy using cadherin cell adhesion recognition cyclic peptides)
- IT 33208-80-4 33208-81-2 33208-82-4 33208-83-6 33208-84-8
33208-85-0 33208-86-2 33208-87-4 33208-88-6 33208-89-8
33208-90-0 33208-91-2 33208-92-4 33208-93-6 33208-94-8
33208-95-0 33208-96-2 33208-97-4 33208-98-6 33208-99-8
FL: PRP (Properties)
(unclaimed sequence; comps. and methods for cancer therapy using

cadherin cell adhesion recognition cyclic peptides)

RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Alexander; Journal of Cellular Physiology 1993, V116, P610 HCAPLUS
- (2) Ali; J Med Chem 1994, V37(1), P100
- (3) Anon; EI 406428 E1 1991 HCAPLUS
- (4) Anon; WO 9104745 1991 HCAPLUS
- (5) Anon; WO 9204781 1992 HCAPLUS
- (6) Anon; WO 9411001 1994 HCAPLUS
- (7) Anon; WO 9549781 1995 HCAPLUS
- (8) Anon; WO 9707300 1997 HCAPLUS
- (9) Anon; WO 9804430 1998 HCAPLUS
- (10) Anon; WO 9845519 1998 HCAPLUS
- (11) Beesley; Biochemical Society Transactions 1995, V23, P59 HCAPLUS
- (12) Blakemore; Nature 1977, V266, P68 MEDLINE
- (13) Blakemore; Nature 1977, V266, P68 MEDLINE
- (14) Blaschuk; Proc Natl Acad Sci USA 1979, V76(1), P514
- (15) Blaschuk; US 6061071 A 1998 HCAPLUS
- (16) Blaschuk; US 6106071 E1 1991 HCAPLUS
- (17) Blaschuk; US 6207600 E1 1991 HCAPLUS
- (18) Blaschuk; Developmental Biology 1993, V156, P564 HCAPLUS
- (19) Blaschuk; The Canadian Journal of Zoology 1994, V72(4), P291 MEDLINE
- (20) Blaschuk; The Canadian Journal of Zoology 1994, V72(4), P291 MEDLINE
- (21) Bottenstein; Proc Natl Acad Sci USA 1979, V76(1), P514 HCAPLUS
- (22) Broome; Neuroscience 1996, V74(1), P775 HCAPLUS
- (23) Brookes; Brain Research 1979, V185, P195 MEDLINE
- (24) Bronson; US 5591402 A 1997 HCAPLUS
- (25) Brook; GLIA 1994, V3, P40 MEDLINE
- (26) Byers; Development Biology 1991, V150, P411 HCAPLUS
- (27) Cardarelli; The Journal of Biological Chemistry 1992, V267(23), P23159
- (28) Carlstedt; Brain Research Bulletin 1989, V21, P9 MEDLINE
- (29) Cepek; Proc Natl Acad Sci USA 1996, V93, P6567 HCAPLUS
- (30) Chuan; Developmental Brain Research 1991, V60, P113 MEDLINE
- (31) Craig; Biopolymers (Peptide Science) 1991, V37, P157
- (32) Doherty; Current Opinion in Neurobiology 1994, V4, P49 HCAPLUS
- (33) Doherty; Molecular and Cellular Neuroscience 1996, V8(Article No 0049), P99
- (34) Doherty; Neuron 1991, V6, P447 HCAPLUS
- (35) Duncan; Journal of Neurocytology 1988, V17, P351 MEDLINE
- (36) Fok-Seang; Brain Research 1995, V689, P307 HCAPLUS
- (37) Fok-Seang; Developmental Biology 1993, V171, P1 HCAPLUS
- (38) Franz; Curr Probl Dermatol 1979, V2, P33 HCAPLUS
- (39) Franz; The Journal of Investigative Dermatology 1975, V64(3), P190 HCAPLUS
- (40) Georger; US 5519828 A 1996 HCAPLUS
- (41) Ghainikar; GLIA 1994, V11, P307 MEDLINE
- (42) Gumbiner; The Journal of Cell Biology 1989, V107, P1575 HCAPLUS
- (43) Iruela-Arispe; Molecular Biology of the Cell 1995, V6, P417 HCAPLUS
- (44) Laird; The Journal of Cell Biology 1995, V130(5), P1193 HCAPLUS
- (45) Lee; Journal of Immunology 1994, V153, P1653 HCAPLUS
- (46) Letourneau; Journal of Neurobiology 1991, V22(7), P797 HCAPLUS
- (47) Lidor; US 5352067 A 1994 HCAPLUS
- (48) Liscini; Science 1997, V277, P443 MEDLINE
- (49) Lutz; Journal of Biomolecular Structure & Dynamics 1995, V13(3), P447 HCAPLUS
- (50) Matsuzaki; The Journal of Cell Biology 1990, V110, P1239 HCAPLUS
- (51) McCarthy; J Cell Biology 1990, V105, P490 HCAPLUS
- (52) Mege; Proc Natl Acad Sci USA 1996, V93, P1174 HCAPLUS
- (53) Moran; Pharmaceutical Forum Issue 1996, V76, P4
- (54) Munro; Cell Adhesion and Invasion in Cancer, Chapter 3 1996, P17 HCAPLUS
- (55) Munro; Cellular Immunology 1996, V169(Article No 0123), P309
- (56) Nace; Cell 1994, V76, P147 HCAPLUS
- (57) Orr; Genetic Engineering News 1994, P15
- (58) Overduin; Science 1995, V267, P380 HCAPLUS

- (59) Panscht; US 5585351 A 1996 HCAPLUS
 (60) Redies; Development Biology 1996, V180, P413 HCAPLUS
 (61) Saffell; Neuron 1997, P231 HCAPLUS
 (62) Samanen; J Med Chem 1991, V34(10), P3114 HCAPLUS
 (63) Schasteen; US 5231082 A 1993 HCAPLUS
 (64) Shapiro; Nature 1995, V374, P327 HCAPLUS
 (65) Suzuki; US 5646250 A 1997 HCAPLUS
 (66) Tsutsui; J Biochem 1996, V119, P1034 HCAPLUS
 (67) Wickelgren; PS 1996, V12, P-6
 (68) Willems; FEBS Letters 1998, V363, P239 HCAPLUS
 (69) Williams; Eur J Biochem 1988, V122, P297 HCAPLUS
 (70) Williams; Neuron 1994, V13, P533 HCAPLUS
 (71) Yang; US 5665590 A 1997 HCAPLUS

IT 60961-76-4 99896-85-2 132151-24-7

143113-41-1 157535-09-6 175177-02-3

RL: PAC (Pharmacological activity); PRP (Properties); THU
 (Therapeutic use); BIGL (Biological study); USES (Uses)

(as cell adhesion recognition sequence; compds. and methods for cancer
 therapy using cadherin cell adhesion recognition cyclic peptides)

EN 60961-76-4 HCAPLUS

CH L-Tyrosine, L-.alpha.-glutamyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



EN 99896-85-2 HCAPLUS

CH L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



EN 132151-24-7 HCAPLUS


CH L-Glutamine, L-.alpha.-glutamyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 143113-41-1 HCAPLUS
 CN L-Valine, L-histidyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 157535-09-6 HCAPLUS
 CN L-Lysine, L-asparaginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175177-02-3 HCAPLUS
 CN L-Lysine, L-.alpha.-aspartyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



DT Patent
LA English
ICI ARI
CC 8-9 (Enzymation Biochemistry)
Section cross-reference 11:1

FAN.CNT 1

PATENT NO.		PI	DATE	APPLICATION NO.		DATE
PI	WO 2001098240	A2	20010616	WO 2001-US4231	20010209	4--
	WO 2001098240	A3	20010911			

[illegible]

AC 1001034979	A5	20010320	AC 1001-34979	20010109	---
UG 1002040013	A1	20020404	GS 1001-751141	20010109	---

PRAI	US	2000-191641F	F	20000119	---
	WG	2001-US4271	W	20010119	---

WO 2001-054201 W 20010119 ---
AB Provided are methods and compns. for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.

ST target the photosensitizer to choroidal neovascularization
photodynamic therapy eye choroidal neovascularization
antiangiogenic agent; apoptosis modulator eye choroidal
neovascularization photodynamic therapy

IT Proteins, specific or class
 FL: BPS (Biological process); BSN (Biological study, unclassified); BICL
 (Biological study); BRC (Process)
 (Bak; photodynamic therapy of ocular conditions characterized by
 presence of unwanted choroidal neovascularization; apoptosis)

IT Proteins, specific or class
 FL: BFP (Biological process); BBU (Biological study, unclassified); BIOL
 (Biological study); PRU (Process)
 (Pax; treatment of ocular conditions with photodynamic therapy and
 acortosis-modulating agents)

IT Proteins, specific or class
 PL: BFR (Biological process); BST (Biological study, unclassified); BIOL
 (Biological study); BFR (Biosynthesis)
 (Bol-xL; treatment of earlier conditions with photodynamic therapy and
 apoptosis-modulating agents)

IT Proteins, specific or class
HL: BPP (Biological process ; BSM (Biological study, unclassified); BIOL
(Biological study); BP (Biological process)
(Biological study); BP (Biological process)
(Biological study); treatment of ocular conditions with photodynamic therapy and
apoptosis-modulating agents;

IT Eye

- (choroid; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT Eye, disease
(inflammation; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT Eye, disease
(macula, degeneration, age-related; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT Vision
(nyctopia, pathol.; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT **Angiogenesis**
(neovascularization; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT Histoplasma capsulatum
(ocular infection with; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT **Angiogenesis inhibitors**
Drug targeting
Laser radiation
Photodynamic therapy
Photosensitizers (pharmaceutical)
(photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT Antibodies
Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT Azo dyes
(photosensitizers; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT Amino acids, biological studies
Porphyrins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(photosensitizers; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT Apoptosis
(treatment of ocular conditions with photodynamic therapy and apoptosis-modulating agents)
- IT Integrins
RL: EPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(α .v.beta.3, **antiangiogenic** agents binding to; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT Integrins
RL: EPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(α .v.beta.5, **antiangiogenic** agents binding to; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT 329000-75-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)
- IT 84000-03-6, Angiotensin
RL: EAC (Biological activity or effector, except adverse); EPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(photodynamic therapy of ocular conditions characterized by presence of unwanted choroidal neovascularity)

- IT 99896-85-2D, peptides contg. 184240-26-1D, peptides contg.
187823-07-3, Eribostatin 187830-93-1, pigment epithelium derived factor
RL: THU (Therapeutic use); BSL (Biological study); USES (Uses)
(photodynamic therapy of ocular conditions characterized by presence of
unwanted choroidal neovasculation)
- IT 104592-50-7, caspase 3
RL: BPP (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(photodynamic therapy of ocular conditions characterized by presence of
unwanted choroidal neovasculation: caspase activation)
- IT 246352-04-1, Lutetium texaglysin
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); THU (Therapeutic use);
BIOL (Biological study); PROC (Process); USES (Uses)
(photosensitizer; photodynamic therapy of ocular conditions
characterized by presence of unwanted choroidal neovasculation)
- IT 92-83-1D, Xanthene, derivs. 101-86-0D, Porphyrin, benz derivs.
109-97-7D, Pyrrole, derivs. 574-88-6D, Phthalocyanine, derivs.
2683-84-5D, Chlorin, derivs. 14458-29-1D, Hematoporphyrin, derivs.
RL: THU (Therapeutic use); BSL (Biological study); USES (Uses)
(photosensitizers; photodynamic therapy of ocular conditions
characterized by presence of unwanted choroidal neovasculation)
- IT 99896-85-2D, peptides contg.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(photodynamic therapy of ocular conditions characterized by presence of
unwanted choroidal neovasculation)
- RN 99896-85-2 HCAPLUS
CN L-Aspartic acid, L-arginylalanyl- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2012 ACS
AN 0001:519535 HCAPLUS
EN 136:111977
TI Diagnostic/therapeutic agents having phospholipid-based microbubbles
coupled to one or more vectors
IN Klaveness, Jo; Fongved, Pal; Hogset, Anders; Tolleshaug, Helge; Naevestad,
Anne; Bellebust, Halldis; Hoff, Lars; Cuthbertson, Alan; Lovhaug, Dagfinn;
Albakken, Magne
PA Mycomed Imaging As, Norway
SO U.S., 89 pp., Cont.-in-part of U.S. Ser. No. 958,993.
CODEN: CCEXAM
IT Patent
LA English
IC ICM A61B009-00
ICS A61B009-050; A61K001-007; A61K 49-04; A61F019-14
NCL 424009529
PC 63-0 (Pharmaceuticals)
Section cross-references : 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6061537	B1	2/10/717	US 1997-960054	19971029 <--
CN 1234742	A	13/9/1110	CN 1997-199047	19971028 <--

	US 6331289	B1	20 11 11	US 1997-359206	19971028 <--
	FR 2000012829	A	20 08 29	FR 1999-743634	19990427 <--
	US 2001101119	A1	20 01 11	US 2001-765614	20010122 <--
PRAI	GB 1996-10366	A	19 01 19 <--		
	GB 1996-10367	A	19 01 19 <--		
	GB 1996-10368	A	19 01 19 <--		
	GB 1997-898	A	19 01 19 <--		
	GB 1997-899	A	19 01 19 <--		
	GB 1997-11842	A	19 01 19 <--		
	GB 1997-11846	A	19 01 19 <--		
	US 1997-49166P	F	19 01 19 <--		
	US 1997-49165P	F	19 01 19 <--		
	US 1997-49168P	F	19 01 19 <--		
	US 1997-558993	A2	19 07 13 <--		
	GB 1996-11369	A	19 01 19 <--		
	GB 1997-3195	A	19 01 19 <--		
	GB 1997-11837	A	19 07 06 <--		
	GB 1997-11839	A	19 07 06 <--		
	US 1997-49268P	F	19 07 07 <--		
	US 1997-49266P	F	19 07 07 <--		
	US 1997-900054	A1	19 01 19 <--		
AB	Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprise gas-filled microbubbles stabilized by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector. The gas is air, nitrogen, oxygen, carbon dioxide, hydrogen, an inert gas, a sulfur fluoride, selenium hexafluoride, a low mol. wt. hydrocarbon, a ketone, an ester, a halogenated low mol. wt. hydrocarbon or their mixts. The film-forming surfactant material is one or more phospholipids selected from the group consisting of phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and cardiolipins. A therapeutic agent is an antineoplastic agent, blood product, intl. response modifier, antifungal agent, hormone or hormone analog, vitamin, enzyme, antiallergic agent, tissue factor inhibitor, platelet inhibitor, coagulation protein target inhibitor, fibrin formation inhibitor, fibrinolysis promoter, antiangiogenic , circulatory drug, metabolic potentiator, antitubercular, antiviral, vasodilator, antibiotic, anti-inflammatory, antiprotoccol, antirheumatic, narcotic, opiate, cardiac glycoside, neuromuscular blocker, sedative, local anesthetic, general anesthetic or genetic material. For example, an endothelial cell adhesion of phosphatidylserine-encapsulated perfluorobutane microbubbles coated with polylysine was higher than adhesion of uncoated microbubbles. Also, a thrombus was detected by ultrasound in patients with suspected venous thrombosis using i.v. phosphatidylserine-encapsulated microbubbles. The microbubbles contained inactivated human thrombin-succinyl-PEG 3400-distearoylphosphatidylethanolamine incorporated into the encapsulating membrane.				
ST	phospholipid surfactant peptide microbubble diagnostic therapeutic				
IT	Plasmid vectors				
	(BR323; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)				
IT	Selectins				
	FL: B30 (Biological study, unclassified); B10L (Biological study) (E-, antibodies against; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)				
IT	Cell adhesion molecules				
	FL: B30 (Biological study, unclassified); B10L (Biological study) (ICAM-1 (intercellular adhesion mol. 1), antibodies against; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)				
IT	Imaging Agents				

- (acoustic imaging contrast agents; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Adrenoreceptors
Interleukin 1
RL: BSU (Biological study, unclassified); BIOL (Biological study) (affinity for; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Diagnosis
(agents; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Hormones, animal, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (and analogs; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Transferrin receptors
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antibodies against and FITC-labeled; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT CD34 (antigen)
Carcinoembryonic antigen
Selectins
RL: BSU (Biological study, unclassified); BIOL (Biological study) (antibodies against; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Antibodies
RL: BCT (Reactant); RACT (Reactant or reagent) (biotinylated; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Oligonucleotides
RL: SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (biotinylated; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Glycosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cardiac; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Antibodies
RL: SFN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (conjugates, with polyethoxylated phospholipid deriv.; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Blood vessel
Endothelium, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT DNA
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (fragments, fluorescein-labeled; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Anesthetics

- (general; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Hydrocarbons, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (labeled; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Fibrins
 RL: BIOL (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Drug delivery systems
 (injections, i.v.; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT CD antigens
 Integrins
 RL: BIOL (Biological study, unclassified); BIOL (Biological study)
 (integrin .beta.5, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Perfluoro compounds
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ketones; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Avidins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (labeled; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Anesthetics
 (local; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Hydrocarbons, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (low-mol.-wt.; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Drug delivery systems
 (microbubbles; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Transferrins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (modified; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Ketones, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (perfluoro; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Perfluoro compounds
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (perfluoroalkyl ethers; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Ethers, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(perfluoroalkyl; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

- IT Air
 - Allergy inhibitors
 - Angiogenesis**
 - Angiogenesis inhibitors**
 - Anti-inflammatory agents
 - Antibiotics
 - Anticoagulants
 - Antirheumatic agents
 - Antitumor agents
 - Antiviral agents
 - Atherosclerosis
 - Blood products
 - Cardiovascular agents
 - Drug targeting
 - Encapsulation
 - Fibrinolytics
 - Fungicides
 - Gene therapy
 - Hypnotics and Sedatives
 - Narcotics
 - Neuromuscular blocking agents
 - Platelet aggregation inhibitors
 - Protozoacides
 - Surfactants
 - Thrombosis
 - Thrombus
 - Transformation, genetic
 - Tuberculostatics
 - Vasodilators
 - (prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Lipopeptides
 - RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Cardiolipins
 - Enzymes, biological studies
 - Esters, biological studies
 - Fibronectins
 - Ketones, biological studies
 - Opioids
 - Peptides, biological studies
 - Perfluorocarbons
 - Phosphatidic acids
 - Phosphatidylglycerols
 - Phosphatidylinositols
 - Phosphatidylserines
 - Vitamins
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Drug delivery systems
 - (prodrugs; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Metabolism, animal
 - (promoters; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

- IT Thiols (organic), reactions
 RL: PCT (Reactant); RACT (Reactant or reagent)
 (reaction products with antibodies; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Drug delivery systems
 (suspensions; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Antibodies
 RL: PCT (Reactant); RACT (Reactant or reagent)
 (conjugates; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha.v.beta.3, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha.v.beta.5, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha.2.beta.1, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha.5, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha.6, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha.8.beta.1, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.beta.1, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.beta.3, binding to; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT C7072-45-3, FITC
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (C171 labeled with; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)
- IT C321-07-5, Fluorescein
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (DNA fragments labeled with; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

more vectors)

IT 115740-78-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(crosslinker; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 9602-04-45F, Inositol, reaction products with polyethoxylated phospholipid deriv.
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PPEP (Preparation); USES (Uses)
(inactivated; prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 57-88-5, Cholesterol, reactions 78-81-0, Isopropylamine, reactions 106-89-8, Epichlorohydrin, reactions 108-89-7, 2-Dimethylaminoethylamine 108-90-5, Succinic anhydride, reactions 544-77-4, 1-Iodohexadecane 546-18-9, 5-Beta-Olanolic acid 1142-10-7, 307-84-1, 4537-70-1, Distearoylphosphatidylethanolamine 7144-03-3, Cholesteryl chloroformate 14139-15-0, Methyl 4-hydroxyphenylacetate 5130-13-4, N-Succinimidyl-3-maleimidopropylate 0371-91-2, Captopril 75040-62-2 109292-40-8 125716-21-0 126108-1-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 24131-13-1P 71204-27-2P 73070-24-3P 91544-50-3P 99818-27-1P 115399-07-0P 120074-77-3P 151156-36-4P 16727-11-5P 167267-14-3P 167287-31-8P 167291-75-3P 167292-78-1P 167293-10-9P 167293-82-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PPEP (Preparation); RACT (Reactant or reagent)
(prepn. of diagnostic/therapeutic agents having phospholipid-based gas-filled microbubbles coupled to one or more vectors)

IT 57-88-50F, Cholesterol, conjugates with drugs 9013-10-12P, Streptavidin, reaction products with polyethoxylated phospholipid deriv. 31170-17-8P 137086-73-3P 148901-65-4P 195018-46-8P 197297-14-7P 197297-15-8P 197297-17-0P 197297-18-1P 197297-19-2P 197297-20-3P 197297-21-4P 197297-22-5P 197297-23-6P 197297-24-7P 197297-25-8P 197297-26-9P 197297-27-0P 197297-28-1P 197297-29-2P 197297-30-3P 197297-31-4P 197297-32-5P 197297-33-6P 197297-34-7P 197297-35-8P 197297-36-9P 197297-37-0P 197297-38-1P 197297-39-2P 197297-40-3P 197297-41-4P 197297-42-5P 197297-43-6P 197297-44-7P 197297-45-8P 197297-46-9P 197297-47-0P 197297-48-1P 197297-49-2P 197297-50-3P 197297-51-4P 197297-52-5P 197297-53-6P 197297-54-7P 197297-55-8P 197297-56-9P 197297-57-0P 197297-58-1P 197297-59-2P 197297-60-3P 197297-61-4P 197297-62-5P 197297-63-6P 197297-64-7P 197297-65-8P 197297-66-9P 197297-67-0P 197297-68-1P 197297-69-2P 197297-70-3P 197297-71-4P 197297-72-5P 197297-73-6P 197297-74-7P 197297-75-8P 197297-76-9P 197297-77-0P 197297-78-1P 197297-79-2P 197297-80-3P 197297-81-4P 197297-82-5P 197297-83-6P 197297-84-7P 197297-85-8P 197297-86-9P 197297-87-0P 197297-88-1P 197297-89-2P 197297-90-3P 197297-91-4P 197297-92-5P 197297-93-6P 197297-94-7P 197297-95-8P 197297-96-9P 197297-97-0P 197297-98-1P 197297-99-2P 197297-100-3P 197297-101-4P 197297-102-5P 197297-103-6P 197297-104-7P 197297-105-8P 197297-106-9P 197297-107-0P 197297-108-1P 197297-109-2P 197297-110-3P 197297-111-4P 197297-112-5P 197297-113-6P 197297-114-7P 197297-115-8P 197297-116-9P 197297-117-0P 197297-118-1P 197297-119-2P 197297-120-3P 197297-121-4P 197297-122-5P 197297-123-6P 197297-124-7P 197297-125-8P 197297-126-9P 197297-127-0P 197297-128-1P 197297-129-2P 197297-130-3P 197297-131-4P 197297-132-5P 197297-133-6P 197297-134-7P 197297-135-8P 197297-136-9P 197297-137-0P 197297-138-1P 197297-139-2P 197297-140-3P 197297-141-4P 197297-142-5P 197297-143-6P 197297-144-7P 197297-145-8P 197297-146-9P 197297-147-0P 197297-148-1P 197297-149-2P 197297-150-3P 197297-151-4P 197297-152-5P 197297-153-6P 197297-154-7P 197297-155-8P 197297-156-9P 197297-157-0P 197297-158-1P 197297-159-2P 197297-160-3P 197297-161-4P 197297-162-5P 197297-163-6P 197297-164-7P 197297-165-8P 197297-166-9P 197297-167-0P 197297-168-1P 197297-169-2P 197297-170-3P 197297-171-4P 197297-172-5P 197297-173-6P 197297-174-7P 197297-175-8P 197297-176-9P 197297-177-0P 197297-178-1P 197297-179-2P 197297-180-3P 197297-181-4P 197297-182-5P 197297-183-6P 197297-184-7P 197297-185-8P 197297-186-9P 197297-187-0P 197297-188-1P 197297-189-2P 197297-190-3P 197297-191-4P 197297-192-5P 197297-193-6P 197297-194-7P 197297-195-8P 197297-196-9P 197297-197-0P 197297-198-1P 197297-199-2P 197297-200-3P 197297-201-4P 197297-202-5P 197297-203-6P 197297-204-7P 197297-205-8P 197297-206-9P 197297-207-0P 197297-208-1P 197297-209-2P 197297-210-3P 197297-211-4P 197297-212-5P 197297-213-6P 197297-214-7P 197297-215-8P 197297-216-9P 197297-217-0P 197297-218-1P 197297-219-2P 197297-220-3P 197297-221-4P 197297-222-5P 197297-223-6P 197297-224-7P 197297-225-8P 197297-226-9P 197297-227-0P 197297-228-1P 197297-229-2P 197297-230-3P 197297-231-4P 197297-232-5P 197297-233-6P 197297-234-7P 197297-235-8P 197297-236-9P 197297-237-0P 197297-238-1P 197297-239-2P 197297-240-3P 197297-241-4P 197297-242-5P 197297-243-6P 197297-244-7P 197297-245-8P 197297-246-9P 197297-247-0P 197297-248-1P 197297-249-2P


(prepn. of diagnostic/therapeutic agents having phospholipid-based
gas-filled microbubbles coupled to one or more vectors)

RECENT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Anon; WO 9115044 1991 HCAPLUS
- (2) Anon; WO 9308901 1993 HCAPLUS
- (3) Anon; CA 2141500 1994
- (4) Anon; WO 9407539 1994 HCAPLUS
- (5) Anon; WO 9408873 1994 HCAPLUS
- (6) Anon; WO 9408874 1994 HCAPLUS
- (7) Anon; WO 9501109 1995 HCAPLUS
- (8) Anon; WO 9501110 1995 HCAPLUS
- (9) Anon; WO 9507072 1995 HCAPLUS
- (10) Anon; WO 9515112 1995 HCAPLUS
- (11) Anon; EP 0737235 1996 HCAPLUS
- (12) Anon; US 5664046 1996
- (13) Anon; WO 9609149 1996 HCAPLUS
- (14) Anon; WO 9609277 1996 HCAPLUS
- (15) Anon; WO 9609285 1996 HCAPLUS
- (16) Anon; WO 9609286 1996 HCAPLUS
- (17) Anon; WO 9703895 1997
- (18) Anon; WO 9703474 1997 HCAPLUS
- (19) Anon; WO 9701898 1997 HCAPLUS
- (20) Anon; DE 19636876 1996 HCAPLUS
- (21) Anon; WO 9800171 1998 HCAPLUS
- (22) Anon; WO 9804293 1998 HCAPLUS
- (23) Anon; WO 9810705 1998 HCAPLUS
- (24) Anon; WO 9810886 1998 HCAPLUS
- (25) Anon; WO 9802094 1998 HCAPLUS
- (26) Elmaleh; US 5716594 1998 HCAPLUS
- (27) Friden; US 5614924 1998 HCAPLUS
- (28) Grinstaff; US 5605982 1996
- (29) Grinstaff; US 5656156 1997 HCAPLUS
- (30) Grinstaff; US 5660193 1997 HCAPLUS
- (31) Klibanov; Acta Radiologica 1997, V38(Supp 412), P113
- (32) Lanza; US 5611057 1997 HCAPLUS
- (33) Lanza; US 5606907 1997 HCAPLUS
- (34) Lanza; US 5700010 1998
- (35) Matsueda; US 4927816 1990 HCAPLUS
- (36) McEver; US 5198434 1993 HCAPLUS
- (37) Muzykantsev; J Nuclear Medicine 1994, V35(8), P1353 MEDLINE
- (38) Porter; US 5643727 1998 HCAPLUS
- (39) Schneider; US 5643157 1997
- (40) Tait; US 5632903 1997 HCAPLUS
- (41) Thomas, F; Microparticle Preparations Made From Biodegradable Copolymers 1999
- (42) Torchilin; US 5534241 1996
- (43) Tourner; US 5610360 1998 HCAPLUS
- (44) Unger; US 5656211 1997 HCAPLUS
- (45) Unger; US 5735972 1998 HCAPLUS
- (46) Unger; US 5646517 1998 HCAPLUS
- (47) Wordle; US 5613550 1997 HCAPLUS
- (48) Wordle; US 5613551 1997 HCAPLUS
- (49) Worthington Biochemical Corporation; Worthington Enzyme Manual, enzymes, enzyme reagents, related biochemicals 1972
- IT 99896-85-2D, analogs
PL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of diagnostic/therapeutic agents having phospholipid-based
gas-filled microbubbles coupled to one or more vectors)
- EN 99896-85-2 HCAPLUS
- CA L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

R66



L73 ANSWER 4 OF 21 HCAPLUS © COPYRIGHT 2001 ACS
 AN 2000:756723 HCAPLUS
 DN 133:308225
 TI Adhesion modulatory peptides and methods for use
 IN Ashkar, Samy
 PA Children's Medical Center Corp., USA
 SO PCT Int. Appl., 35 pp.
 CODEN: EIKXD2

DT Patent

LA English

IC ICM C07K007-04

ICS C07K005-08; A61K038-06; A61K038-08

CC 13-7 (Mammalian Biochemistry)

Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000003236	A1	20001026	WO 2000-US10329	20000417 ---
WO 2000003236	A3	20010613		
W:	AE, AG, AL, AM, AT, AU, AV, BA, BE, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DO, EE, EG, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KH, KR, LA, LB, LC, LI, LU, LV, MA, MD, MG, MK, MN, MO, MP, MQ, NA, NE, NG, NI, NO, NZ, PA, PE, PG, PH, PL, PT, PU, SE, SI, SK, SL, SM, SN, SR, SS, SV, SW, SY, TA, TH, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AN, AR, AS, AT, AU, BA, BE, BG, BR, BY, CA, CH, CN, CR, DE, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE, SF, SJ, CF, CS, CI, CM, GA, GN, GW, ML, MF, NE, SN, TD, TG			
EP 1173469	A2	20020123	EP 2000-923447	20000417 ---
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, FO			
BR 2000009804	A	20010416	BR 2000-9804	20000417 ---
US 2002058336	A1	20020516	US 2000-732411	20001207 ---
PRAI US 1999-129709P	P	19990416 ---		
WO 2000-US10329	W	20000417 ---		

AB The invention provides methods for modulating adhesion of endothelial cells, fibroblasts, macrophages, neutrophils, or myofibroblasts to a substrate. The substrate may be polyvinyl, gel, collagen, hyaluronic acid, titanium, or PGA. The invention also provides novel adhesion modulatory peptides, substrates coated with such adhesion modulatory peptides, and devices for modulation of target cell adhesion.

ST cell adhesion modulating peptide; endothelial cell adhesion modulating peptide; fibroblast adhesion modulating peptide; macrophage adhesion modulating peptide; neutrophil adhesion modulating peptide; myofibroblast adhesion modulating peptide

IT Cell adhesion
 Fibroblast
 Macrophage
 Melanoma
 Neutrophil


(adhesion modulatory peptides and methods for use)

IT Peptides, biological studies

FL: BAS (Biological activity or effector, except adverse); BSU Biological

- study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (adhesion modulatory peptides and methods for use)
- IT Fibronectin receptors
 Glycosaminoglycans, biological studies
 RL: BPF (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PFOC (Process)
 (cell surface receptor; adhesion modulatory peptides and methods for use)
- IT **Blood vessel**
 (endothelium; adhesion modulatory peptides and methods for use)
- IT Drug delivery systems
 (gels, substrate for cell adhesion; adhesion modulatory peptides and methods for use)
- IT Fibroblast
 (myofibroblast; adhesion modulatory peptides and methods for use)
- IT Medical goods
 (peptide-coated; adhesion modulatory peptides and methods for use)
- IT Vinyl compounds, biological studies
 RL: BPF (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PFOC (Process)
 (polymers, substrate for cell adhesion; adhesion modulatory peptides and methods for use)
- IT Gels
 (substrate for cell adhesion; adhesion modulatory peptides and methods for use)
- IT Integrins
 RL: BPF (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PFOC (Process)
 (.alpha.v.beta.3, cell surface receptor; adhesion modulatory peptides and methods for use)
- IT Integrins
 RL: BPF (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PFOC (Process)
 (.alpha.4, cell surface receptor; adhesion modulatory peptides and methods for use)
- IT 110590-62-0 111793-75-0 130557-33-2 205741-55-2 302577-35-3
 302577-96-4 302577-27-5 302577-28-6 302577-39-7 302578-30-3
 302578-01-4 302578-02-5 302578-03-6 302578-04-7 302578-05-8
 302578-13-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (adhesion modulatory peptides and methods for use)
- IT 7440-32-6, Titanium, biological studies 9004-61-9, Hyaluronic acid
 26009-03-0, Poly(glycolide) 26202-08-4, Poly(glycolide)
 RL: BPF (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PFOC (Process)
 (substrate for cell adhesion; adhesion modulatory peptides and methods for use)
- IT **302578-05-8**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (adhesion modulatory peptides and methods for use)
- RN 302578-05-8 HCAPLUS
 CN L-Valine, L-teryl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 5 OF 31 HCAPLUS COPYRIGHT 2002 AFS
 AN 2000:53713 HCAPLUS
 DN 132:136963
 TI Compounds and methods for modulating cadherin-mediated functions
 IN Doherty, Patrick; Blaschuk, Ernest W.; Gou, Barbara J.
 PA Adherex Technologies, Inc., Can.
 SO PCT Int. Appl., 144 pp.
 CODEN: PHEMB2

DT Patent

LA English

IC ICM C07K014-705

ICS C07K007-06; C07F007-04; A61K047-48; B31N013-00

CC 15-3 (Immunochemistry)

FAN.CNT 1

PATENT NO.	FIND	DATE	APPLICATION NO.	DATE
WO 2000001917	A2	20000120	WO 1999-CA627	19990712 ---
WO 2000001917	A3	20000120		
W:	AE, AL, AM, AT, AU, AZ, BA, BE, BG, BI, BY, CA, CH, CN, CU, CE, DE, DK, EE, ES, FI, GB, GR, HE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, ME, MN, MW, MX, NC, ND, NG, NL, NO, NZ, PA, PE, PG, PH, PI, PL, PT, PU, SD, SE, SG, SI, SK, SL, TM, TR, TT, UA, US, US, US, VN, YU, ZA, ZW, AM, AZ, BY, BG, KB, MD, RU, TJ, TM			
FW:	GH, GM, HE, LS, MW, SD, SL, SZ, NG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MF, NE, SN, TD, TG			
US 6277824	B1	20010811	US 1998-111977	19980710 ---
AU 9945964	A1	20000301	AU 1998-45964	19990712 ---
EP 1097183	A1	20010809	EP 1998-028063	19990712 ---
F:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, BG			
JP 2002020010	T2	20010709	JP 2000-353146	19990712 ---
PRAI US 1998-111977	A	19990710 ---		
WO 1999-CA627	W	19990712 ---		

AB Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analog or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion mols. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

ST HAV binding motif cadherin cell adhesion

IT Cadherins

FL: BFF (Biological process; BSW (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 [E-; compd. comprising HAV binding motif for modulating

- cadherin-mediated functions)
- IT Polynucleotides
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(HAV binding motif-encoding; compd. comprising HAV binding motif for
modulating cadherin-mediated functions)
- IT Protein motifs
(HAV-binding; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Acetyl group
(N-; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Cadherins
RL: BPF (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(N-; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Cell adhesion molecules
RL: BPF (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(N-CAM; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Cell migration
(Schwann cell; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Transplant and Transplantation
(adhesion enhancement; compd. comprising HAV binding motif for
modulating cadherin-mediated functions)
- IT Gingiva
Skin
(blood sampling; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Thiocethers
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(bond; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Animal cell
(cadherin-expressing; compd. comprising HAV binding motif for
modulating cadherin-mediated functions)
- IT Drug delivery systems
(carriers; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Neoplasm
(cells; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Nervous system
(central, demyelination; compd. comprising HAV binding motif for
modulating cadherin-mediated functions)
- IT Nervous system
(central, drug delivery; compd. comprising HAV binding motif for
modulating cadherin-mediated functions)
- IT Chemistry
(chem. compds., cell adhesion-modulating; compd. comprising HAV binding
motif for modulating cadherin-mediated functions)
- IT Cell adhesion molecules
RL: BPF (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(claudins; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Amide group
Angiogenesis
Bioreactors
Carcinoma

- Cell adhesion
- Disulfide group
- Drug delivery systems
- Drug screening
- Drug targeting
- Drugs
- Epithelium
- Fluorescent substances
- Immunostimulation
- Immunosuppression
- Labels
- Leukemia
- Lymphocyte
- Melanoma
- Membranes, nonbiological
- Microparticles
- Multiple sclerosis
- Oligodendrocyte
- Ovary, neoplasm
- Peptidomimetics
- Protein sequences
- Test kits
- Ultrathin films
- Wound healing
 - (compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Cadherins
 - Fibronectins
 - Integrins
 - Laminins
 - RL: BFR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 - (compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Antigens
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Antibodies
 - RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Plastics, biological studies
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Peptides, biological studies
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (cyclic, HAV-binding; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Glycoproteins, specific or class
 - RL: BFR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 - (desmogleins; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Glycoproteins, specific or class
 - RL: BFR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 - (desmogleins; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Antitumor agents
 - (drug delivery; compd. comprising HAV binding motif for modulating

- cadherin-mediated functions)
- IT **Blood vessel**
(endothelium; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Proteins, specific or class
RL: BPP (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(extracellular matrix-assocd.; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Apoptosis
(induction; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Spinal cord
(injury; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Cell adhesion molecules
RL: BPP (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(functional; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Neoplasm
(metastasis, inhibition; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Schwann cell
(migration; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Bladder
(neoplasm; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Nerve
(neuron; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Cell adhesion molecules
RL: BPP (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(occludin; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Axon
(outgrowth; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT **Blood vessel**
Blood vessel
(permeability, enhancement; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Biological transport
(permeation, vascular, enhancement; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Medical goods
(plastic dishes; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Pregnancy
(prevention; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Glialdendrocyte
(progenitor; compd. comprising HAV binding motif for modulating cadherin-mediated functions)
- IT Blood
(sampling; compd. comprising HAV binding motif for modulating cadherin-mediated functions)

- IT Drug delivery systems
(skin patch; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Transplant and Transplantation
Transplant and Transplantation
(skin; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Synapse
(stability; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Drug delivery systems
(sustained-release; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Medical goods
(sutures; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Drug delivery systems
(transdermal; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Skin
Skin
(transplant; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT Medical goods
(tubes, plastic; compd. comprising HAV binding motif for modulating
cadherin-mediated functions)
- IT 110590-64-1, Yipsi peptide+ 143304-70-4, Kysfnydyse peptide+
231282-35-0, Lyhy peptide+
RL: REF (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(branched peptide contg.; compd. comprising HAV binding motif for
modulating cadherin-mediated functions)
- IT 73-22-3, Tryptophan, biological studies
PL: PSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(cadherin-modulating agent contg. .beta.1.1.delta.1-11; compd.
comprising HAV binding motif for modulating cadherin-mediated
functions)
- IT 53-67-9D, Penicillamine, derivs. 56-84-8, L-Aspartic acid, biological
studies 56-86-0, L-Glutamic acid, biological studies 56-87-1,
L-Lysine, biological studies 70-26-2, L-Ornithine 107-96-0D,
.beta.-Mercaptopropionic acid, derivs. 108-98-5D, Mercaptobenzene,
derivs. 137-07-3D, 2-Mercaptocaniline, derivs. 108330-39-8D,
.beta.,.beta.-Pentamethylene-.beta.-mercaptopropionic acid, derivs.
155052-54-6D, .beta.,.beta.-Tetramethylene cysteine, derivs.
155052-60-9D, .beta.,.beta.-Pentamethylene cysteine, derivs.
155052-61-0D, 2-Mercaptoproline, derivs.
PL: PSU (Biological study, unclassified); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(cadherin-modulating agent contg.; compd. comprising HAV binding motif
for modulating cadherin-mediated functions)
- IT 155052-13-1, Ifilnpisgql peptide+ 155052-14-1, Ifilnpisgql peptide+
155052-15-4, Vlavsketqwl peptide+ 155052-16-5, Vfsinsmsgrm peptide+
155052-17-6, Vtileretqwl peptide+ 155052-18-7, Vftiekesgwl peptide+
155052-19-8, Vnidsmsgrm peptide+ 155052-20-1, Wlkidsvngqi peptide+
155052-21-2, Wlkidpyngqi peptide+ 155052-22-3, Wlamdpdsqyv peptide+
155052-23-4, Wlhinatnqqi peptide+ 155052-24-5, Wleinpdtgai peptide+
155052-25-6, Wlavcpasqqi peptide+ 155052-26-7, Wleinpetgai peptide+
155052-27-8, Wihintsngqi peptide+ 155052-28-9, Nlkidpyngqi peptide+
155052-29-0, Lclspvngqi peptide+ 155052-30-3, Inp_sgg peptide+
155052-31-4, Lclspvngqi peptide+ 155052-32-5, Idpvsgq peptide+ 155052-33-6, Kispvngq
peptide+ 155052-34-7, Pasgq peptide+ 155052-34-7D, cyclic derivs.
155052-35-8, Ivnngq peptide+ 155052-36-9D, cyclic derivs. 155052-36-9,

Pysgr peptide+ 255052-36-9D, cyclic derivs. 255052-37-0, Idpvn
 peptide+ 255052-38-0D, cyclic derivs. 255052-38-1, Inpis peptide+
 255052-38-1D, cyclic derivs. 255052-39-2, Kidpv peptide+ 255052-39-2D,
 cyclic derivs. 255052-40-5 255052-41-6 255052-42-7 255052-43-8
 255052-44-9 255052-45-0 255052-46-1 255052-47-2 255052-48-3
 255052-49-4 255052-50-7 255052-51-8 255052-52-9 255052-53-0D,
 LKldpangqi peptide+, derivs. 255052-54-1D, LKldpangqi peptide+, derivs.
 255052-55-1 255052-56-3 255052-57-4 255052-65-4D, cyclic
 derivs. 255375-17-4 255395-20-6
 FL: PRP (Properties); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)

(compd. comprising HAV binding motif for modulating cadherin-mediated
 functions)
 IT 231261-43-3, Iysy peptide+ 240016-10-1, Ifvidksg peptide+
 250268-79-1, Idks peptide+ 250268-80-5, Idks peptide+ 250268-81-6,
 Viddk peptide+ 250268-82-7, Idks peptide+ 250268-83-3, Viddks
 peptide+ 250268-84-3, Dkskg peptide+ 250268-85-0, Idkskg peptide+
 250268-86-1, Viddkskg peptide+ 250268-87-2, Fvidk peptide+
 250268-88-3, Fvidks peptide+ 250268-89-4, Fvidkskg peptide+
 250268-90-7, Ifvidk peptide+ 250268-91-1, Ifvidks peptide+
 255052-58-5, Idpvnqi peptide+
 FL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)


(preferred CAR sequence; compd. comprising HAV binding motif for
 modulating cadherin-mediated functions)
 IT 222311-36-6, 196-243-occludin (human) 24248-46-6, E-Cadherin (rat
 fragment) 255703-57-2 255703-58-3 255703-59-4 255703-60-7
 255703-61-8 255703-62-9 255703-63-0 255703-64-1 255703-65-2
 255703-66-7 255703-67-4 255703-68-8 255703-69-6 255703-70-9
 255703-71-0 255703-72-1 255718-04-2
 FL: PRP (Properties)

(unclaimed protein sequence; compds. and methods for modulating
 cadherin-mediated functions)
 IT 250268-78-1 255369-44-3 255369-45-0 255369-46-1 255369-47-2
 255369-48-3 255369-49-4 255369-50-7
 FL: PRP (Properties)

(unclaimed sequence; compds. and methods for modulating
 cadherin-mediated functions)
 IT 255052-65-4D, cyclic derivs.
 FL: PRP (Properties); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)
 (compd. comprising HAV binding motif for modulating cadherin-mediated
 functions)

RN 255052-65-4 HCAPLUS
 CN L-Proline, L-Isoleucyl-L-asparaginyl- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:723064 HCAPLUS

DN 132:18774

TI Peptide analogs of the cell adhesion regions of non-classical cadherins for use in the treatment of cancer

IN Blaschuk, Grest W.; Gour, Barbara J.; Byers, Stephen

PA Adherex Technologies, Inc., Can.

SO PCT Int. Appl., 253 pp.

CODEN: EINHIC

DT Patent

LA English

IC ICM C07K014-705

ICS C07K016-28; A61K038-17

CC 1-6 (Pharmacology)

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
				WO 1999-CA363	19990505
PI	WO 9957149	A2	19991111		
	WO 9957149	A3	20000802		
	W:	AE, AL, AM, AT, AU, AZ, BA, BE, BG, BF, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GI, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, ME, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	PW:	GH, GM, KE, LS, MG, SD, SL, SE, SG, SW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6358920	B1	20020319	US 1999-197859	19981106
	US 2002103044	A1	20020905	US 1999-234395	19990120
	CA 1327590	AA	19991111	CA 1999-2327530	19990505
	AU 9938907	A1	19991113	AU 1999-35907	19990505
	EP 1075404	A2	20010114	EP 1999-317706	19990505
	E:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, FI, IE, FI			
	JP 2002513804	T1	20020514	JP 2000-547117	19990505
PRAI	US 1998-73040	A	19990505		
	US 1998-127859	A	19991106		
	US 1999-234395	A	19991120		
	US 1999-234395	A	19991120		
	WO 1999-CA363	W	19990505		
OS	MAFRAT 132:18774				
AB	Peptides that can be used to control cell adhesion, invasion and metastasis that are analogs of the cell adhesion regions (CAR) of				

non-classical cadherins are described. These peptides are at least 50 identical to a nonclassical cadherin CAP sequence or they may be peptidomimetics. Peptidomimetics may also be used, as may antibodies recognizing the CAP sequences. Genes encoding peptides contg. CAP sequence analogs may also be used. Methods for using such modulating agents for modulating nonclassical cadherin-mediated cell adhesion in a variety of contexts are also provided.

- ST cadherin peptide analogs cell adhesion modulation cancer chemotherapy
- IT Receptors
 FL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); BPC (Process); USES (Uses)
 (CDR (cadherin-related neuronal receptor), modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Animal cell line
 (MDA-MB-131, disruption of adhesion of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Leukemia
 Ovary, neoplasm
 (OB cadherin in metastatic cells of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
 RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); BPC (Process); USES (Uses)
 (T-cadherin, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
 FL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); BPC (Process); USES (Uses)
 (cadherin 12, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
 RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); BPC (Process); USES (Uses)
 (cadherin 14, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
 FL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); BPC (Process); USES (Uses)
 (cadherin 16, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
 RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); BPC (Process); USES (Uses)
 (cadherin 9, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
 RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); BPC (Process); USES (Uses)
 (cadherin 6, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
 RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); BPC (Process); USES (Uses)
 (cadherin 7, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of

- cancer)
- IT Cadherins
RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PFOC (Process); USES (Uses) (cadherin 2, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PFOC (Process); USES (Uses) (cadherin 11, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PFOC (Process); USES (Uses) (cadherin 12, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Antitumor agents
(cadherin peptide analogs as; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Glycoproteins, specific or class
RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PFOC (Process); USES (Uses) (desmogleins, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Glycoproteins, specific or class
RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PFOC (Process); USES (Uses) (desmogleins, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Blood vessel
(endothelium, disruption of adhesion of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Proteins, specific or class
RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PFOC (Process); USES (Uses) (extracellular matrix-associ., modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Synthetic gene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (for cadherin 11 peptide analogs; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Bioreactors
Membranes, nonbiological
Microparticles
Ultrathin films
(immobilization cadherin-binding peptides on; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Proteins, specific or class
RL: BPF (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PFOC (Process); USES (Uses) (membrane, integral, claudins, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Neoplasm
(metastasis, non-classical cadherins in, control of; peptide analogs of

- cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Fibronektins
Laminins
RL: BPP (Biological process); ESU (Biological study, unclassified); THU (Therapeutic use); BICL (Biological study); PPOC (Process); USES (Uses)
(modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Mammary glands
angiogenesis; disruption of cell adhesion; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Adhesion, biological
Cell adhesion
(non-classical cadherin-mediated, control of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
RL: BPP (Biological process); ESU (Biological study, unclassified); THU (Therapeutic use); BICL (Biological study); PPOC (Process); USES (Uses)
(non-classical, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Peptidomimetics
(of cadherin CAR peptides; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Immobilization, biochemical
(protein, of cadherin-binding peptides; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Cadherins
RL: BPP (Biological process); ESU (Biological study, unclassified); THU (Therapeutic use); BICL (Biological study); PPOC (Process); USES (Uses)
(protocadherins, modulation of function of; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Medical goods
(sutures, immobilization cadherin-binding peptides on; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT Antibodies
RL: THU (Therapeutic use); BICL (Biological study); USES (Uses)
(to cadherin CAR peptides; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
- IT 5513-86-0 50981-76-4 51043-74-3 76726-70-0 45407-25-0
102302-15-0 15551-90-8 155514-20-0 130135-23-7 130191-24-7
148777-43-0 157135-09-8 154114-81-0 171334-05-0 171334-05-0
175177-02-0 175177-12-5 175177-13-7 175177-08-1 175177-76-0
187140-27-8 204604-00-8 204604-00-5 231232-47-0 245036-53-7
249030-20-1 249030-20-1 249030-20-1 250203-80-0 250203-81-0
250203-81-0 250203-81-0 250203-81-0 250203-81-0 250203-81-0
250203-84-0 250203-84-0 250203-84-0 250203-84-0 250203-84-0
250203-86-1 250203-86-1 250203-86-1 250203-86-1 250203-86-1
250203-89-4 250203-89-4 250203-89-4 250203-89-4 250203-89-4
250203-93-0 250203-93-0 250203-93-0 250203-93-0 250203-93-0
250203-97-4 250203-97-4 250203-97-4 250203-97-4 250203-97-4
250203-99-6 250203-99-6 250203-99-6 250203-99-6 250203-99-6
250203-01-4 250203-01-4 250203-01-4 250203-01-4 250203-01-4
250203-04-0 250203-04-0 250203-04-0 250203-04-0 250203-04-0
250203-08-0 250203-08-0 250203-08-0 250203-08-0 250203-08-0
250203-11-5 250203-11-5 250203-11-5 250203-11-5 250203-11-5
250203-14-8 250203-14-8 250203-14-8 250203-14-8 250203-14-8
250203-18-0 250203-18-0 250203-18-0 250203-18-0 250203-18-0

PL: BFP (Biological process); BSC (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIEL (Biological study); PPOC (Process); USES (Uses)

(peptide analogs of cell adhesion regions of non-classical cadherins
for use in treatment of cancer)

IT	for use in treatment of cancer)	for use in treatment of cancer)	for use in treatment of cancer)	for use in treatment of cancer)
250742-22-4	250742-23-5	250742-24-6	250742-25-7	250742-26-8
250742-26-8	250742-28-8	250742-29-9	250742-30-0	250742-31-1
250742-32-0	250742-33-1	250742-34-2	250742-35-3	250742-36-4
250742-37-5	250742-38-6	250742-39-7	250742-40-8	250742-41-9
250742-42-0	250742-43-1	250742-44-2	250742-45-3	250742-46-4
250742-47-5	250742-48-6	250742-49-7	250742-50-8	250742-51-9
250742-52-0	250742-53-1	250742-54-2	250742-55-3	250742-56-4
250742-57-5	250742-58-6	250742-59-7	250742-60-8	250742-61-9
250742-62-0	250742-63-1	250742-64-2	250742-65-3	250742-66-4
250742-67-5	250742-68-6	250742-69-7	250742-70-8	250742-71-9
250742-72-0	250742-73-1	250742-74-2	250742-75-3	250742-76-4
250742-77-5	250742-78-6	250742-79-7	250742-80-8	250742-81-9
250742-82-0	250742-83-1	250742-84-2	250742-85-3	250742-86-4
250742-87-5	250742-88-6	250742-89-7	250742-90-8	250742-91-9
250742-92-0	250742-93-1	250742-94-2	250742-95-3	250742-96-4
250742-97-5	250742-98-6	250742-99-7	250742-100-8	250742-101-9
250742-102-0	250742-103-1	250742-104-2	250742-105-3	250742-106-4
250742-107-5	250742-108-6	250742-109-7	250742-110-8	250742-111-9
250742-112-0	250742-113-1	250742-114-2	250742-115-3	250742-116-4
250742-117-5	250742-118-6	250742-119-7	250742-120-8	250742-121-9
250742-122-0	250742-123-1	250742-124-2	250742-125-3	250742-126-4
250742-127-5	250742-128-6	250742-129-7	250742-130-8	250742-131-9
250742-132-0	250742-133-1	250742-134-2	250742-135-3	250742-136-4
250742-137-5	250742-138-6	250742-139-7	250742-140-8	250742-141-9
250742-142-0	250742-143-1	250742-144-2	250742-145-3	250742-146-4
250742-147-5	250742-148-6	250742-149-7	250742-150-8	250742-151-9
250742-152-0	250742-153-1	250742-154-2	250742-155-3	250742-156-4
250742-157-5	250742-158-6	250742-159-7	250742-160-8	250742-161-9
250742-162-0	250742-163-1	250742-164-2	250742-165-3	250742-166-4
250742-167-5	250742-168-6	250742-169-7	250742-170-8	250742-171-9
250742-172-0	250742-173-1	250742-174-2	250742-175-3	250742-176-4
250742-177-5	250742-178-6	250742-179-7	250742-180-8	250742-181-9
250742-182-0	250742-183-1	250742-184-2	250742-185-3	250742-186-4
250742-187-5	250742-188-6	250742-189-7	250742-190-8	250742-191-9
250742-192-0	250742-193-1	250742-194-2	250742-195-3	250742-196-4
250742-197-5	250742-198-6	250742-199-7	250742-200-8	250742-201-9
250742-202-0	250742-203-1	250742-204-2	250742-205-3	250742-206-4
250742-207-5	250742-208-6	250742-209-7	250742-210-8	250742-211-9
250742-212-0	250742-213-1	250742-214-2	250742-215-3	250742-216-4
250742-217-5	250742-218-6	250742-219-7	250742-220-8	250742-221-9
250742-222-0	250742-223-1	250742-224-2	250742-225-3	250742-226-4
250742-227-5	250742-228-6	250742-229-7	250742-230-8	250742-231-9
250742-232-0				

150743-14-7	150743-15-8	150743-15-8	150743-15-9	150743-16-9
150743-17-5	150743-17-0	150743-17-1	150743-17-1	150743-17-1
150743-20-5	150743-18-5	150743-18-6	150743-18-7	150743-18-7
150743-23-8	150743-19-3	150743-19-3	150743-19-9	150743-19-9
150743-25-0	150743-20-1	150743-20-7	150743-20-3	150743-20-4
150743-29-7	150743-21-2	150743-21-4	150743-21-0	150743-21-1
150743-35-2	150743-22-3	150743-22-4	150743-22-5	150743-22-6
150743-40-9	150743-23-0	150743-23-1	150743-23-2	150743-23-3
150743-43-4	150743-24-5	150743-24-6	150743-24-7	150743-24-8
150743-45-1	150743-25-1	150743-25-2	150743-25-4	150743-25-5
150743-45-6	150743-26-3	150743-26-9	150743-26-0	150743-26-3
150743-61-4	150743-27-4	150743-27-5	150743-27-6	150743-27-6
150743-64-7	150743-28-3	150743-28-9	150743-28-0	150743-28-1
150743-69-2	150743-29-5	150743-29-6	150743-29-7	150743-29-7
150743-73-8	150743-29-9	150743-29-9	150743-29-0	150743-29-0
150743-76-1	150743-30-1	150743-29-2	150743-29-2	150743-29-3
150743-78-3	150743-29-4	150743-29-4	150743-29-7	150743-29-7

FL: BPE (Biological process); ECU (Ecological study, unclassified); PRP (Properties); THG (Therapeutic use); BPEL (Biological study); PFOC (Process); USES (Uses)

(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT	150743-80-7	150743-81-5	150743-81-9	150743-81-9	150743-81-9
	150743-83-0	150743-83-0	150743-84-1	150743-84-1	150743-85-2
	150743-86-3	150743-87-4	150743-87-4	150743-88-5	150743-88-5
	150743-89-6	150743-89-6	150743-90-9	150743-90-9	150743-91-0
	150743-91-0	150743-91-1	150743-91-1	150743-91-2	150743-91-2
	150743-94-3	150743-94-4	150743-95-4	150743-95-5	150743-96-5
	150743-97-0	150743-97-6	150743-97-7	150743-98-7	150743-99-8
	150743-99-8	150744-00-4	150744-00-4	150744-01-5	150744-02-6
	150744-03-7	150744-03-7	150744-04-6	150744-04-8	150744-05-9
	150744-05-9	150744-06-0	150744-06-0	150744-07-1	150744-07-1
	150744-08-2	150744-08-2	150744-08-3	150744-09-3	150744-10-6
	150744-10-6	150744-11-7	150744-11-7	150744-11-8	150744-12-3
	150744-13-9	150744-13-9	150744-14-0	150744-14-0	150744-15-1
	150744-15-1	150744-16-2	150744-16-3	150744-17-3	150744-17-3
	150744-19-5	150744-19-5	150744-20-8	150744-20-8	150744-21-9
	150744-21-9	150744-21-0	150744-22-0	150744-23-1	150744-23-1
	150744-24-2	150744-24-2	150744-25-3	150744-26-4	150744-26-4
	150744-27-5	150744-28-6	150744-28-6	150744-29-7	150744-29-7
	150744-30-0	150744-30-0	150744-31-1	150744-31-1	150744-31-2
	150744-32-2	150744-33-3	150744-33-3	150744-34-4	150744-34-4
	150744-35-5	150744-35-5	150744-37-7	150744-37-7	150744-38-8
	150744-38-8	150744-39-9	150744-39-9	150744-40-2	150744-41-3
	150744-42-4	150744-42-5	150744-43-5	150744-44-6	150744-44-6
	150744-45-7	150744-45-7	150744-46-8	150744-46-8	150744-47-9
	150744-47-9	150744-48-0	150744-48-1	150744-49-1	150744-49-1
	150744-50-4	150744-50-4	150744-51-5	150744-51-5	150744-52-6
	150744-52-6	150744-53-7	150744-53-7	150744-54-8	150744-55-9
	150744-55-9	150744-56-0	150744-57-1	150744-58-2	150744-58-2
	150744-59-3	150744-59-3	150744-60-6	150744-60-6	150744-61-7
	150744-61-7	150744-62-8	150744-63-8	150744-64-9	150744-64-9
	150744-64-0	150744-65-1	150744-66-1	150744-66-7	150744-66-7
	150744-67-2	150744-67-2	150744-68-4	150744-69-5	150744-69-5
	150744-70-6	150744-71-9	150744-71-9	150744-72-1	150744-73-0
	150744-73-1	150744-73-1	150744-74-2	150744-74-2	150744-75-3
	150744-75-3	150744-76-4	150744-76-4	150744-77-5	150744-77-5
	150744-78-6	150744-79-6	150744-79-7	150744-79-7	150744-80-0
	150744-80-0	150744-81-1	150744-81-1	150744-82-1	150744-83-2
	150744-83-3	150744-83-3	150744-84-4	150744-84-4	150744-85-5
	150744-86-6	150744-86-6	150744-87-7	150744-88-8	150744-89-9
	150744-89-9	150744-90-2	150744-91-3	150744-91-3	150744-92-4
	150744-92-4	150744-92-5	150744-93-5	150744-94-6	150744-94-6

190745-QA-5 190745-Sub-A 190745-Sub-B 190745-Sub-C
PRP: PRP (biological process); PRP (biological study, unclassified); PRP
(properties); THU (THU-generating drug); PRL (physical study); PRG
(process); USES (uses).
The following are unclassified copperins

IT

19740-87-3 19740-88-4 19740-89-5 19740-90-6
 HL: BFL (Biological process); BFL: Biological study, unclassified; PRP
 (Properties); TH: Therapeutic use; BIC: Biological study; SPOT
 (Process); UCC: Use of a compound in non-classical adhesion

(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT	250746-01-9	250746-02-9	250746-03-9	250746-04-9	250746-05-9
	250746-06-4	250746-07-4	250746-08-4	250746-09-4	250746-10-4
	250747-01-4	250747-02-4	250747-03-4	250747-04-4	250747-05-4
	250747-06-9	250747-07-9	250747-08-9	250747-09-9	250747-10-9
	250747-11-6	250747-12-6	250747-13-6	250747-14-6	250747-15-6
	250747-16-1	250747-17-1	250747-18-1	250747-19-1	250747-20-1
	250747-21-4	250747-22-4	250747-23-4	250747-24-4	250747-25-4
	250747-26-4	250747-27-4	250747-28-4	250747-29-4	250747-30-4
	250747-31-1	250747-32-1	250747-33-1	250747-34-1	250747-35-1
	250747-36-6	250747-37-6	250747-38-6	250747-39-6	250747-40-6
	250747-41-2	250747-42-2	250747-43-2	250747-44-2	250747-45-2
	250747-46-7	250747-47-7	250747-48-7	250747-49-7	250747-50-7
	250747-51-5	250747-52-5	250747-53-5	250747-54-5	250747-55-5
	250747-56-0	250747-57-0	250747-58-0	250747-59-0	250747-60-0
	250747-61-8	250747-62-8	250747-63-8	250747-64-8	250747-65-8
	250747-66-2	250747-67-2	250747-68-2	250747-69-2	250747-70-2
	250747-71-9	250747-72-9	250747-73-9	250747-74-9	250747-75-9
	250747-76-4	250747-77-4	250747-78-4	250747-79-4	250747-80-4
	250747-81-1	250747-82-1	250747-83-1	250747-84-1	250747-85-1
	250747-86-6	250747-87-6	250747-88-6	250747-89-6	250747-90-6
	250747-91-2	250747-92-2	250747-93-2	250747-94-2	250747-95-2
	250747-96-7	250747-97-7	250747-98-7	250747-99-7	250748-00-7
	250748-01-2	250748-02-2	250748-03-2	250748-04-2	250748-05-2
	250748-06-7	250748-07-7	250748-08-7	250748-09-7	250748-10-7
	250748-11-2	250748-12-2	250748-13-2	250748-14-2	250748-15-2
	250748-16-7	250748-17-7	250748-18-7	250748-19-7	250748-20-7
	250748-21-2	250748-22-2	250748-23-2	250748-24-2	250748-25-2
	250748-26-7	250748-27-7	250748-28-7	250748-29-7	250748-30-7
	250748-31-2	250748-32-2	250748-33-2	250748-34-2	250748-35-2
	250748-36-7	250748-37-7	250748-38-7	250748-39-7	250748-40-7
	250748-41-2	250748-42-2	250748-43-2	250748-44-2	250748-45-2
	250748-46-7	250748-47-7	250748-48-7	250748-49-7	250748-50-7
	250748-51-2	250748-52-2	250748-53-2	250748-54-2	250748-55-2
	250748-56-7	250748-57-7	250748-58-7	250748-59-7	250748-60-7
	250748-61-2	250748-62-2	250748-63-2	250748-64-2	250748-65-2
	250748-66-7	250748-67-7	250748-68-7	250748-69-7	250748-70-7
	250748-71-2	250748-72-2	250748-73-2	250748-74-2	250748-75-2
	250748-76-7	250748-77-7	250748-78-7	250748-79-7	250748-80-7
	250748-81-2	250748-82-2	250748-83-2	250748-84-2	250748-85-2
	250748-86-7	250748-87-7	250748-88-7	250748-89-7	250748-90-7
	250748-91-2	250748-92-2	250748-93-2	250748-94-2	250748-95-2
	250748-96-7	250748-97-7	250748-98-7	250748-99-7	250749-00-7
	250749-01-2	250749-02-2	250749-03-2	250749-04-2	250749-05-2
	250749-06-7	250749-07-7	250749-08-7	250749-09-7	250749-10-7
	250749-11-2	250749-12-2	250749-13-2	250749-14-2	250749-15-2
	250749-16-7	250749-17-7	250749-18-7	250749-19-7	250749-20-7
	250749-21-2	250749-22-2	250749-23-2	250749-24-2	250749-25-2
	250749-26-7	250749-27-7	250749-28-7	250749-29-7	250749-30-7
	250749-31-2	250749-32-2	250749-33-2	250749-34-2	250749-35-2
	250749-36-7	250749-37-7	250749-38-7	250749-39-7	250749-40-7
	250749-41-2	250749-42-2	250749-43-2	250749-44-2	250749-45-2
	250749-46-7	250749-47-7	250749-48-7	250749-49-7	250749-50-7
	250749-51-2	250749-52-2	250749-53-2	250749-54-2	250749-55-2
	250749-56-7	250749-57-7	250749-58-7	250749-59-7	250749-60-7
	250749-61-2	250749-62-2	250749-63-2	250749-64-2	250749-65-2
	250749-66-7	250749-67-7	250749-68-7	250749-69-7	250749-70-7
	250749-71-2	250749-72-2	250749-73-2	250749-74-2	250749-75-2
	250749-76-7	250749-77-7	250749-78-7	250749-79-7	250749-80-7
	250749-81-2	250749-82-2	250749-83-2	250749-84-2	250749-85-2
	250749-86-7	250749-87-7	250749-88-7	250749-89-7	250749-90-7
	250749-91-2	250749-92-2	250749-93-2	250749-94-2	250749-95-2
	250749-96-7	250749-97-7	250749-98-7	250749-99-7	250750-00-7

PL: BPP (Biological process); PRP (Biological study, unclassified); PRP (Properties); THG (Therapeutic use); BICL (Biological study); PRP (Process); PRP (Uses).

peptide analysis of beta adrenergic receptors of non-classical amines for use in treatment of cancer.

IT	250749-01-2	250749-02-2	250749-03-2	250749-04-2	250749-05-2
	250749-06-7	250749-07-7	250749-08-7	250749-09-7	250749-10-7
	250749-11-2	250749-12-2	250749-13-2	250749-14-2	250749-15-2
	250749-16-7	250749-17-7	250749-18-7	250749-19-7	250749-20-7
	250749-21-2	250749-22-2	250749-23-2	250749-24-2	250749-25-2
	250749-26-7	250749-27-7	250749-28-7	250749-29-7	250749-30-7
	250749-31-2	250749-32-2	250749-33-2	250749-34-2	250749-35-2
	250749-36-7	250749-37-7	250749-38-7	250749-39-7	250749-40-7
	250749-41-2	250749-42-2	250749-43-2	250749-44-2	250749-45-2
	250749-46-7	250749-47-7	250749-48-7	250749-49-7	250749-50-7
	250749-51-2	250749-52-2	250749-53-2	250749-54-2	250749-55-2
	250749-56-7	250749-57-7	250749-58-7	250749-59-7	250749-60-7
	250749-61-2	250749-62-2	250749-63-2	250749-64-2	250749-65-2
	250749-66-7	250749-67-7	250749-68-7	250749-69-7	250749-70-7
	250749-71-2	250749-72-2	250749-73-2	250749-74-2	250749-75-2
	250749-76-7	250749-77-7	250749-78-7	250749-79-7	250749-80-7
	250749-81-2	250749-82-2	250749-83-2	250749-84-2	250749-85-2
	250749-86-7	250749-87-7	250749-88-7	250749-89-7	250749-90-7
	250749-91-2	250749-92-2	250749-93-2	250749-94-2	250749-95-2
	250749-96-7	250749-97-7	250749-98-7	250749-99-7	250750-00-7

250749-84-1	250750-01-7	250750-03-4	250750-03-9	250750-04-6
250750-06-6	250750-06-7	250750-06-8	250750-06-9	250750-07-1
250750-08-2	250750-08-3	250750-08-4	250750-08-5	250750-08-6
250750-10-0	250750-10-1	250750-10-2	250750-10-3	250750-10-4
250750-12-5	250750-12-6	250750-12-7	250750-12-8	250750-12-9
250750-13-2	250750-13-3	250750-13-4	250750-13-5	250750-13-6
250750-15-7	250750-15-8	250750-15-9	250750-16-0	250750-16-1
250750-17-2	250750-17-3	250750-17-4	250750-17-5	250750-17-6
250750-19-7	250750-19-8	250750-19-9	250750-20-0	250750-20-1
250750-21-4	250750-21-5	250750-21-6	250750-21-7	250750-21-8
250750-23-1	250750-23-2	250750-23-3	250750-23-4	250750-23-5
250750-25-2	250750-25-3	250750-25-4	250750-25-5	250750-25-6
250750-27-7	250750-27-8	250750-27-9	250750-28-0	250750-28-1
250750-29-4	250750-29-5	250750-29-6	250750-29-7	250750-29-8
250750-31-1	250750-31-2	250750-31-3	250750-31-4	250750-31-5
250750-33-2	250750-33-3	250750-33-4	250750-33-5	250750-33-6
250750-35-7	250750-35-8	250750-35-9	250750-36-0	250750-36-1
250750-38-2	250750-38-3	250750-38-4	250750-38-5	250750-38-6
250750-40-7	250750-40-8	250750-40-9	250750-41-0	250750-41-1
250750-43-4	250750-43-5	250750-43-6	250750-43-7	250750-43-8
250750-45-1	250750-45-2	250750-45-3	250750-45-4	250750-45-5
250750-47-2	250750-47-3	250750-47-4	250750-47-5	250750-47-6
250750-49-7	250750-49-8	250750-49-9	250750-50-0	250750-50-1
250750-51-4	250750-51-5	250750-51-6	250750-51-7	250750-51-8
250750-53-1	250750-53-2	250750-53-3	250750-53-4	250750-53-5
250750-55-2	250750-55-3	250750-55-4	250750-55-5	250750-55-6
250750-57-7	250750-57-8	250750-57-9	250750-58-0	250750-58-1
250750-60-4	250750-60-5	250750-60-6	250750-60-7	250750-60-8
250750-62-1	250750-62-2	250750-62-3	250750-62-4	250750-62-5
250750-64-2	250750-64-3	250750-64-4	250750-64-5	250750-64-6
250750-66-7	250750-66-8	250750-66-9	250750-67-0	250750-67-1
250750-69-4	250750-69-5	250750-69-6	250750-69-7	250750-69-8
250750-71-1	250750-71-2	250750-71-3	250750-71-4	250750-71-5
250750-73-2	250750-73-3	250750-73-4	250750-73-5	250750-73-6
250750-75-7	250750-75-8	250750-75-9	250750-76-0	250750-76-1
250750-77-4	250750-77-5	250750-77-6	250750-77-7	250750-77-8
250750-79-1	250750-79-2	250750-79-3	250750-79-4	250750-79-5
250750-81-2	250750-81-3	250750-81-4	250750-81-5	250750-81-6
250750-83-7	250750-83-8	250750-83-9	250750-84-0	250750-84-1
250750-85-4	250750-85-5	250750-85-6	250750-85-7	250750-85-8
250750-87-1	250750-87-2	250750-87-3	250750-87-4	250750-87-5
250750-89-2	250750-89-3	250750-89-4	250750-89-5	250750-89-6
250750-91-7	250750-91-8	250750-91-9	250750-92-0	250750-92-1
250750-93-4	250750-93-5	250750-93-6	250750-93-7	250750-93-8
250750-95-1	250750-95-2	250750-95-3	250750-95-4	250750-95-5
250750-97-2	250750-97-3	250750-97-4	250750-97-5	250750-97-6
250750-99-7	250750-99-8	250750-99-9	250750-100-0	250750-100-1
250750-101-4	250750-101-5	250750-101-6	250750-101-7	250750-101-8
250750-103-1	250750-103-2	250750-103-3	250750-103-4	250750-103-5
250750-105-2	250750-105-3	250750-105-4	250750-105-5	250750-105-6
250750-107-7	250750-107-8	250750-107-9	250750-108-0	250750-108-1
250750-110-4	250750-110-5	250750-110-6	250750-110-7	250750-110-8
250750-112-1	250750-112-2	250750-112-3	250750-112-4	250750-112-5
250750-114-2	250750-114-3	250750-114-4	250750-114-5	250750-114-6
250750-116-7	250750-116-8	250750-116-9	250750-117-0	250750-117-1
250750-118-2	250750-118-3	250750-118-4	250750-118-5	250750-118-6
250750-120-7	250750-120-8	250750-120-9	250750-121-0	250750-121-1
250750-122-4	250750-122-5	250750-122-6	250750-122-7	250750-122-8
250750-124-1	250750-124-2	250750-124-3	250750-124-4	250750-124-5
250750-126-2	250750-126-3	250750-126-4	250750-126-5	250750-126-6
250750-128-7	250750-128-8	250750-128-9	250750-129-0	250750-129-1
250750-130-4	250750-130-5	250750-130-6	250750-130-7	250750-130-8
250750-132-1	250750-132-2	250750-132-3	250750-132-4	250750-132-5
250750-134-2	250750-134-3	250750-134-4	250750-134-5	250750-134-6
250750-136-7	250750-136-8	250750-136-9	250750-137-0	250750-137-1
250750-138-4	250750-138-5	250750-138-6	250750-138-7	250750-138-8
250750-140-1	250750-140-2	250750-140-3	250750-140-4	250750-140-5
250750-142-2	250750-142-3	250750-142-4	250750-142-5	250750-142-6
250750-144-7	250750-144-8	250750-144-9	250750-145-0	250750-145-1
250750-146-4	250750-146-5	250750-146-6	250750-146-7	250750-146-8
250750-148-1	250750-148-2	250750-148-3	250750-148-4	250750-148-5
250750-150-2	250750-150-3	250750-150-4	250750-150-5	250750-150-6
250750-152-7	250750-152-8	250750-152-9	250750-153-0	250750-153-1
250750-154-4	250750-154-5	250750-154-6	250750-154-7	250750-154-8
250750-156-1	250750-156-2	250750-156-3	250750-156-4	250750-156-5
250750-158-2	250750-158-3	250750-158-4	250750-158-5	250750-158-6
250750-160-7	250750-160-8	250750-160-9	250750-161-0	250750-161-1
250750-162-4	250750-162-5	250750-162-6	250750-162-7	250750-162-8
250750-164-1	250750-164-2	250750-164-3	250750-164-4	250750-164-5
250750-166-2	250750-166-3	250750-166-4	250750-166-5	250750-166-6
250750-168-7	250750-168-8	250750-168-9	250750-169-0	250750-169-1
250750-170-4	250750-170-5	250750-170-6	250750-170-7	250750-170-8
250750-172-1	250750-172-2	250750-172-3	250750-172-4	250750-172-5
250750-174-2	250750-174-3	250750-174-4	250750-174-5	250750-174-6
250750-176-7	250750-176-8	250750-176-9	250750-177-0	250750-177-1
250750-178-4	250750-178-5	250750-178-6	250750-178-7	250750-178-8
250750-180-1	250750-180-2	250750-180-3	250750-180-4	250750-180-5
250750-182-2	250750-182-3	250750-182-4	250750-182-5	250750-182-6
250750-184-7	250750-184-8	250750-184-9	250750-185-0	250750-185-1
250750-186-4	250750-186-5	250750-186-6	250750-186-7	250750-186-8
250750-188-1	250750-188-2	250750-188-3	250750-188-4	250750-188-5
250750-190-2	250750-190-3	250750-190-4	250750-190-5	250750-190-6
250750-192-7	250750-192-8	250750-192-9	250750-193-0	250750-193-1
250750-194-4	250750-194-5	250750-194-6	250750-194-7	250750-194-8
250750-196-1	250750-196-2	250750-196-3	250750-196-4	250750-196-5
250750-198-2	250750-198-3	250750-198-4	250750-198-5	250750-198-6
250750-200-7	250750-200-8	250750-200-9	250750-201-0	250750-201-1
250750-202-4	250750-202-5	250750-202-6	250750-202-7	250750-202-8
250750-204-1	250750-204-2	250750-204-3	250750-204-4	250750-204-5
250750-206-2	250750-206-3	250750-206-4	250750-206-5	250750-206-6
250750-208-7	250750-208-8	250750-208-9	250750-209-0	250750-209-1
250750-210-4	250750-210-5	250750-210-6	250750-210-7	250750-210-8
250750-212-1	250750-212-2	250750-212-3	250750-212-4	250750-212-5
250750-214-2	250750-214-3	250750-214-4	250750-214-5	250750-214-6
250750-216-7	250750-216-8	250750-216-9	250750-217-0	250750-217-1
250750-218-4	250750-218-5	250750-218-6	250750-218-7	250750-218-8
250750-220-1	250750-220-2	250750-220-3	250750-220-4	250750-220-5
250750-222-2	250750-222-3	250750-222-4	250750-222-5	250750-222-6
250750-224-7	250750-224-8	250750-224-9	250750-225-0	250750-225-1
250750-226-4	250750-226-5	250750-226-6	250750-226-7	250750-226-8
250750-228-1	250750-228-2	250750-228-3	250750-228-4	250750-228-5
250750-230-2	250750-230-3	250750-230-4	250750-230-5	250750-230-6
250750-232-7	250750-232-8	250750-232-9	250750-233-0	250750-233-1
250750-234-4	250750-234-5	250750-234-6	250750-234-7	250750-234-8
250750-236-1	250750-236-2	250750-236-3	250750-236-4	250750-236-5
250750-238-2	250750-238-3	250750-238-4	250750-238-5	250750-238-6
250750-240-7	250750-240-8	250750-240-9	250750-241-0	250750-241-1
250750-242-4	250750-242-5	250750-242-6	250750-242-7	250750-242-8
250750-244-1	250750-244-2	250750-244-3	250750-244-4	250750-244-5
250750-246-2	250750-246-3	250750-246-4	250750-246-5	250750-246-6
250750-248-7	250750-248-8	250750-248-9	250750-249-0	250750-249-1
250750-250-4	250750-250-5	250750-250-6	250750-250-7	250750-250-8

RL: BFF (Biological process); PSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BICH (Biological study); PROC (Process); USES (Uses)

(peptide analysis of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT	250751-86-1	250751-87-2	250751-88-3	250751-89-4	250751-90-7
	250751-91-8	250751-92-9	250751-93-0	250751-94-1	250751-95-2
	250751-96-3	250751-97-4	250751-98-5	250751-99-6	250751-100-2
	250752-01-3	250752-02-4	250752-03-5	250752-04-6	250752-05-7
	250752-06-8	250752-07-9	250752-08-0	250752-09-1	250752-10-4
	250752-11-5	250752-12-6	250752-13-7	250752-14-8	250752-15-9
	250752-16-0	250752-17-1	250752-18-2	250752-19-3	250752-20-6
	250752-21-7	250752-22-8	250752-23-9	250752-24-0	250752-25-2
	250752-27-3	250752-28-4	250752-29-5	250752-30-8	250752-31-9
	250752-32-0	250752-33-1	250752-34-2	250752-35-3	250752-36-4
	250752-37-5	250752-38-6	250752-39-7	250752-40-0	250752-41-1
	250752-43-4	250752-44-5	250752-45-6	250752-46-6	250752-47-7
	250752-49-8	250752-50-9	250752-51-0	250752-52-2	250752-53-4
	250752-55-5	250752-56-6	250752-57-7	250752-58-8	250752-59-9
	250752-59-0	250752-60-4	250752-61-5	250752-62-6	250752-63-7
	250752-64-8	250752-			

250752-99-9	250753-01-6	250753-02-7	250753-03-8	250753-04-9
250753-05-0	250753-06-1	250753-07-2	250753-08-3	250753-09-4
250753-10-5	250753-11-6	250753-12-7	250753-13-8	250753-14-9
250753-15-0	250753-16-1	250753-17-2	250753-18-3	250753-19-4
250753-20-5	250753-21-6	250753-22-7	250753-23-8	250753-24-9
250753-25-0	250753-26-1	250753-27-2	250753-28-3	250753-29-4
250753-30-5	250753-31-6	250753-32-7	250753-33-8	250753-34-9
250753-35-0	250753-36-1	250753-37-2	250753-38-3	250753-39-4
250753-40-5	250753-41-6	250753-42-7	250753-43-8	250753-44-9
250753-45-0	250753-46-1	250753-47-2	250753-48-3	250753-49-4
250753-50-5	250753-51-6	250753-52-7	250753-53-8	250753-54-9
250753-55-0	250753-56-1	250753-57-2	250753-58-3	250753-59-4
250753-60-5	250753-61-6	250753-62-7	250753-63-8	250753-64-9
250753-65-0	250753-66-1	250753-67-2	250753-68-3	250753-69-4
250753-70-5	250753-71-6	250753-72-7	250753-73-8	250753-74-9
250753-75-0	250753-76-1	250753-77-2	250753-78-3	250753-79-4
250753-80-5	250753-81-6	250753-82-7	250753-83-8	250753-84-9
250753-85-0	250753-86-1	250753-87-2	250753-88-3	250753-89-4
250753-90-5	250753-91-6	250753-92-7	250753-93-8	250753-94-9
250753-95-0	250753-96-1	250753-97-2	250753-98-3	250753-99-4
250754-00-5	250754-01-6	250754-02-7	250754-03-8	250754-04-9
250754-05-0	250754-06-1	250754-07-2	250754-08-3	250754-09-4
250754-10-5	250754-11-6	250754-12-7	250754-13-8	250754-14-9
250754-15-0	250754-16-1	250754-17-2	250754-18-3	250754-19-4
250754-20-5	250754-21-6	250754-22-7	250754-23-8	250754-24-9
250754-25-0	250754-26-1	250754-27-2	250754-28-3	250754-29-4

BL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); PDL (Biological study); PPO (Process); USES (Uses)

(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT

250754-30-1	250754-31-2	250754-32-3	250754-33-4	250754-34-5
250754-35-6	250754-36-7	250754-37-8	250754-38-9	250754-39-0
250754-40-1	250754-41-2	250754-42-3	250754-43-4	250754-44-5
250754-45-6	250754-46-7	250754-47-8	250754-48-9	250754-49-0
250754-50-1	250754-51-2	250754-52-3	250754-53-4	250754-54-5
250754-55-6	250754-56-7	250754-57-8	250754-58-9	250754-59-0
250754-60-1	250754-61-2	250754-62-3	250754-63-4	250754-64-5
250754-65-6	250754-66-7	250754-67-8	250754-68-9	250754-69-0
250754-70-1	250754-71-2	250754-72-3	250754-73-4	250754-74-5
250754-75-6	250754-76-7	250754-77-8	250754-78-9	250754-79-0
250754-80-1	250754-81-2	250754-82-3	250754-83-4	250754-84-5
250754-85-6	250754-86-7	250754-87-8	250754-88-9	250754-89-0
250754-90-1	250754-91-2	250754-92-3	250754-93-4	250754-94-5
250754-95-6	250754-96-7	250754-97-8	250754-98-9	250754-99-0
250755-00-1	250755-01-2	250755-02-3	250755-03-4	250755-04-5
250755-05-6	250755-06-7	250755-07-8	250755-08-9	250755-09-0
250755-10-1	250755-11-2	250755-12-3	250755-13-4	250755-14-5
250755-15-6	250755-16-7	250755-17-8	250755-18-9	250755-19-0
250755-20-1	250755-21-2	250755-22-3	250755-23-4	250755-24-5
250755-25-6	250755-26-7	250755-27-8	250755-28-9	250755-29-0
250755-30-1	250755-31-2	250755-32-3	250755-33-4	250755-34-5
250755-35-6	250755-36-7	250755-37-8	250755-38-9	250755-39-0
250755-40-1	250755-41-2	250755-42-3	250755-43-4	250755-44-5
250755-45-6	250755-46-7	250755-47-8	250755-48-9	250755-49-0
250755-50-1	250755-51-2	250755-52-3	250755-53-4	250755-54-5
250755-55-6	250755-56-7	250755-57-8	250755-58-9	250755-59-0
250755-60-1	250755-61-2	250755-62-3	250755-63-4	250755-64-5
250755-65-6	250755-66-7	250755-67-8	250755-68-9	250755-69-0
250755-70-1	250755-71-2	250755-72-3	250755-73-4	250755-74-5
250755-75-6	250755-76-7	250755-77-8	250755-78-9	250755-79-0
250755-80-1	250755-81-2	250755-82-3	250755-83-4	250755-84-5
250755-85-6	250755-86-7	250755-87-8	250755-88-9	250755-89-0
250755-90-1	250755-91-2	250755-92-3	250755-93-4	250755-94-5
250755-95-6	250755-96-7	250755-97-8	250755-98-9	250755-99-0

150755-09-8	150756-09-4	150756-01-	150756-01-6	150756-03-7
150756-04-8	150756-05-3	150756-06-3	150756-07-1	150756-08-2
150756-09-3	150756-10-0	150756-11-3	150756-12-4	150756-13-3
150756-14-0	150756-16-2	150756-17-3	150756-18-4	150756-19-3
150756-20-3	150756-21-3	150756-22-3	150756-23-1	150756-24-2
150756-25-3	150756-26-4	150756-27-5	150756-28-6	150756-29-7
150756-30-8	150756-31-1	150756-32-2	150756-33-3	150756-34-4
150756-35-5	150756-36-6	150756-37-7	150756-38-8	150756-39-9
150756-40-2	150756-41-3	150756-42-4	150756-43-5	150756-44-6
150756-45-1	150756-46-2	150756-47-3	150756-48-4	150756-49-1
150756-50-4	150756-51-5	150756-52-6	150756-53-7	150756-54-8
150756-55-3	150756-56-4	150756-57-5	150756-58-6	150756-59-3
150756-60-6	150756-61-7	150756-62-8	150756-63-4	150756-64-0
150756-65-1	150756-66-2	150756-67-3	150756-68-4	

PL: BPF (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); PLoL (Biological study); PFOU (Process); USES (Uses)

(peptide analogs of cell adhesion proteins of non-classical cadherins for use in treatment of cancer)

IT	150756-69-5	150756-70-6	150756-71-7	150756-72-0	150756-73-1
	150756-74-2	150756-75-3	150756-76-4	150756-77-1	150756-78-6
	150756-79-7	150756-80-0	150756-81-1	150756-82-2	150756-83-3
	150756-84-4	150756-85-5	150756-86-6	150756-87-7	150756-88-8
	150756-89-9	150756-90-1	150756-91-2	150756-92-3	150756-93-5
	150756-94-6	150756-95-7	150756-96-8	150756-97-9	150756-98-0
	150756-99-1	150757-00-7	150757-01-8	150757-02-9	150757-03-0
	150757-04-1	150757-05-2	150757-06-3	150757-07-4	150757-08-5
	150757-09-6	150757-10-9	150757-11-0	150757-12-1	150757-13-2
	150757-14-3	150757-15-4	150757-16-5	150757-17-6	150757-18-7
	150757-20-1	150757-21-2	150757-22-3	150757-23-4	150757-24-5
	150757-26-9	150757-27-0	150757-28-1	150757-29-2	150757-30-3
	150757-32-6	150757-33-9	150757-34-0	150757-35-1	150757-36-2
	150757-38-5	150757-39-6	150757-40-7	150757-41-8	150757-42-9
	150757-45-1	150757-46-2	150757-47-3	150757-48-4	150757-49-5
	150757-51-7	150757-52-8	150757-53-9	150757-54-0	150757-55-1
	150757-57-2	150757-58-3	150757-59-4	150757-60-5	150757-61-6
	150757-63-0	150757-64-1	150757-65-2	150757-66-3	150757-67-4
	150757-69-8	150757-70-9	150757-71-0	150757-72-1	150757-73-2
	150757-75-6	150757-76-7	150757-77-8	150757-78-9	150757-79-0
	150757-82-3	150757-83-4	150757-84-5	150757-85-6	150757-86-7
	150757-89-1	150757-90-2	150757-91-3	150757-92-4	150757-93-5
	150757-96-9	150757-97-0	150757-98-1	150757-99-2	150758-00-3
	150758-03-7	150758-04-8	150758-05-9	150758-06-0	150758-07-1
	150758-09-5	150758-10-6	150758-11-7	150758-12-8	150758-13-9
	150758-16-2	150758-17-3	150758-18-4	150758-19-5	150758-20-6
	150758-23-0	150758-24-1	150758-25-2	150758-26-3	150758-27-4
	150758-29-8	150758-30-9	150758-31-0	150758-32-1	150758-33-2
	150758-36-6	150758-37-7	150758-38-8	150758-39-9	150758-40-0
	150758-43-4	150758-44-5	150758-45-6	150758-46-7	150758-47-8
	150758-50-2	150758-51-3	150758-52-4	150758-53-5	150758-54-6
	150758-57-0	150758-58-1	150758-59-2	150758-60-3	150758-61-4
	150758-64-8	150758-65-9	150758-66-0	150758-67-1	150758-68-2
	150758-71-6	150758-72-7	150758-73-8	150758-74-9	150758-75-0
	150758-78-4	150758-79-5	150758-80-6	150758-81-7	150758-82-8
	150758-85-2	150758-86-3	150758-87-4	150758-88-5	150758-89-6
	150758-92-0	150758-93-1	150758-94-2	150758-95-3	150758-96-4
	150759-00-8	150759-01-9	150759-02-0	150759-03-1	150759-04-2
	150759-07-5	150759-08-6	150759-09-7	150759-10-8	150759-11-9
	150759-14-7	150759-15-8	150759-16-9	150759-17-0	150759-18-1

(Properties): USES (Uses)
 (positive analogs of well-known relations of the classical algebras
 for use in treatment of Banach)

peptide analysis of cell-mediated regulatory lymphocytal numerals
for use in treatment of cancer

100761-77-2	100761-77-3	100761-77-4	100761-77-5	100761-77-6	100761-77-7	100761-77-8
100761-78-2	100761-78-3	100761-78-4	100761-78-5	100761-78-6	100761-78-7	100761-78-8
100761-79-2	100761-79-3	100761-79-4	100761-79-5	100761-79-6	100761-79-7	100761-79-8
100761-80-2	100761-80-3	100761-80-4	100761-80-5	100761-80-6	100761-80-7	100761-80-8
100761-81-2	100761-81-3	100761-81-4	100761-81-5	100761-81-6	100761-81-7	100761-81-8
100761-82-2	100761-82-3	100761-82-4	100761-82-5	100761-82-6	100761-82-7	100761-82-8
100761-83-2	100761-83-3	100761-83-4	100761-83-5	100761-83-6	100761-83-7	100761-83-8
100761-84-2	100761-84-3	100761-84-4	100761-84-5	100761-84-6	100761-84-7	100761-84-8
100761-85-2	100761-85-3	100761-85-4	100761-85-5	100761-85-6	100761-85-7	100761-85-8
100761-86-2	100761-86-3	100761-86-4	100761-86-5	100761-86-6	100761-86-7	100761-86-8
100761-87-2	100761-87-3	100761-87-4	100761-87-5	100761-87-6	100761-87-7	100761-87-8
100761-88-2	100761-88-3	100761-88-4	100761-88-5	100761-88-6	100761-88-7	100761-88-8
100761-89-2	100761-89-3	100761-89-4	100761-89-5	100761-89-6	100761-89-7	100761-89-8
100761-90-2	100761-90-3	100761-90-4	100761-90-5	100761-90-6	100761-90-7	100761-90-8
100761-91-2	100761-91-3	100761-91-4	100761-91-5	100761-91-6	100761-91-7	100761-91-8
100761-92-2	100761-92-3	100761-92-4	100761-92-5	100761-92-6	100761-92-7	100761-92-8
100761-93-2	100761-93-3	100761-93-4	100761-93-5	100761-93-6	100761-93-7	100761-93-8
100761-94-2	100761-94-3	100761-94-4	100761-94-5	100761-94-6	100761-94-7	100761-94-8
100761-95-2	100761-95-3	100761-95-4	100761-95-5	100761-95-6	100761-95-7	100761-95-8
100761-96-2	100761-96-3	100761-96-4	100761-96-5	100761-96-6	100761-96-7	100761-96-8
100761-97-2	100761-97-3	100761-97-4	100761-97-5	100761-97-6	100761-97-7	100761-97-8
100761-98-2	100761-98-3	100761-98-4	100761-98-5	100761-98-6	100761-98-7	100761-98-8
100761-99-2	100761-99-3	100761-99-4	100761-99-5	100761-99-6	100761-99-7	100761-99-8
100761-00-2	100761-00-3	100761-00-4	100761-00-5	100761-00-6	100761-00-7	100761-00-8

250764-91-1	250764-92-2	250764-93-3	250764-94-4	250764-95-5
250764-96-6	250764-97-7	250764-98-8	250764-99-9	250765-00-0
250765-01-1	250765-02-2	250765-03-3	250765-04-4	250765-05-5
250765-06-6	250765-07-7	250765-08-8	250765-09-9	250765-10-0
250765-11-1	250765-12-2	250765-13-3	250765-14-4	250765-15-5
250765-16-6	250765-17-7	250765-18-8	250765-19-9	250765-20-0
250765-21-1	250765-22-2	250765-23-3	250765-24-4	250765-25-5
250765-26-6	250765-27-7	250765-28-8	250765-29-9	250765-30-0
250765-31-1	250765-32-2	250765-33-3	250765-34-4	250765-35-5
250765-36-6	250765-37-7	250765-38-8	250765-39-9	250765-40-0
250765-41-1	250765-42-2	250765-43-3	250765-44-4	250765-45-5
250765-46-6	250765-47-7	250765-48-8	250765-49-9	250765-50-0
250765-51-1	250765-52-2	250765-53-3	250765-54-4	250765-55-5
250765-56-6	250765-57-7	250765-58-8	250765-59-9	250765-60-0
250765-61-1	250765-62-2	250765-63-3	250765-64-4	250765-65-5
250765-66-6	250765-67-7	250765-68-8	250765-69-9	250765-70-0
250765-71-1	250765-72-2	250765-73-3	250765-74-4	250765-75-5
250765-76-6	250765-77-7	250765-78-8	250765-79-9	250765-80-0
250765-81-1	250765-82-2	250765-83-3	250765-84-4	250765-85-5
250765-86-6	250765-87-7	250765-88-8	250765-89-9	250765-90-0
250765-91-1	250765-92-2	250765-93-3	250765-94-4	250765-95-5
250765-96-6	250765-97-7	250765-98-8	250765-99-9	250766-00-0
250766-01-1	250766-02-2	250766-03-3	250766-04-4	250766-05-5
250766-06-6	250766-07-7	250766-08-8	250766-09-9	250766-10-0
250766-11-1	250766-12-2	250766-13-3	250766-14-4	250766-15-5
250766-16-6	250766-17-7	250766-18-8	250766-19-9	250766-20-0
250766-21-1	250766-22-2	250766-23-3	250766-24-4	250766-25-5
250766-26-6	250766-27-7	250766-28-8	250766-29-9	250766-30-0
250766-31-1	250766-32-2	250766-33-3	250766-34-4	250766-35-5
250766-36-6	250766-37-7	250766-38-8	250766-39-9	250766-40-0
250766-41-1	250766-42-2	250766-43-3	250766-44-4	250766-45-5
250766-46-6	250766-47-7	250766-48-8	250766-49-9	250766-50-0
250766-51-1	250766-52-2	250766-53-3	250766-54-4	250766-55-5
250766-56-6	250766-57-7	250766-58-8	250766-59-9	250766-60-0
250766-61-1	250766-62-2	250766-63-3	250766-64-4	250766-65-5
250766-66-6	250766-67-7	250766-68-8	250766-69-9	250766-70-0
250766-71-1	250766-72-2	250766-73-3	250766-74-4	250766-75-5
250766-76-6	250766-77-7	250766-78-8	250766-79-9	250766-80-0
250766-81-1	250766-82-2	250766-83-3	250766-84-4	250766-85-5
250766-86-6	250766-87-7	250766-88-8	250766-89-9	250766-90-0
250766-91-1	250766-92-2	250766-93-3	250766-94-4	250766-95-5
250766-96-6	250766-97-7	250766-98-8	250766-99-9	250767-00-0
250767-01-1	250767-02-2	250767-03-3	250767-04-4	250767-05-5

PL: BIP (Biological process); BCU: Biological study, unclassified); PRP (Properties); THV (Therapeutic uses); BML (Biological study); BSCC (Process); USBG (Uses)

(peptide analogs of cell adhesion regions of non-classical trophoblasts for use in treatment of cancer)

IT	250767-06-7	250767-07-8	250767-08-9	250767-09-0	250767-10-1
	250767-11-4	250767-12-5	250767-13-6	250767-14-7	250767-15-8
	250767-16-9	250767-17-0	250767-18-1	250767-19-2	250767-20-3
	250767-21-6	250767-22-7	250767-23-8	250767-24-9	250767-25-0
	250767-26-1	250767-27-2	250767-28-3	250767-29-4	250767-30-5
	250767-31-8	250767-32-9	250767-33-0	250767-34-1	250767-35-2
	250767-36-3	250767-37-4	250767-38-5	250767-39-6	250767-40-7
	250767-41-0	250767-42-1	250767-43-2	250767-44-3	250767-45-4
	250767-46-9	250767-47-0	250767-48-1	250767-49-2	250767-50-3
	250767-51-2	250767-52-3	250767-53-4	250767-54-5	250767-55-6
	250767-56-8	250767-57-9	250767-58-0	250767-59-1	250767-60-2
	250767-61-5	250767-62-6	250767-63-7	250767-64-8	250767-65-9
	250767-66-0	250767-67-1	250767-68-2	250767-69-3	250767-70-4
	250767-71-7	250767-72-8	250767-73-9	250767-74-0	250767-75-1
	250767-76-4	250767-77-5	250767-78-6	250767-79-7	250767-80-8
	250767-81-1	250767-82-2	250767-83-3	250767-84-4	250767-85-5
	250767-86-8	250767-87-9	250767-88-0	250767-89-1	250767-90-2
	250767-91-5	250767-92-6	250767-93-7	250767-94-8	250767-95-9
	250768-00-4	250768-01-5	250768-02-6	250768-03-7	250768-04-8
	250768-05-9	250768-06-0	250768-07-1	250768-08-2	250768-09-3
	250768-10-4	250768-11-5	250768-12-6	250768-13-7	250768-14-8
	250768-15-9	250768-16-0	250768-17-1	250768-18-2	250768-19-3
	250768-20-4	250768-21-5	250768-22-6	250768-23-7	250768-24-8
	250768-25-9	250768-26-0	250768-27-1	250768-28-2	250768-29-3
	250768-30-4	250768-31-5	250768-32-6	250768-33-7	250768-34-8
	250768-35-9	250768-36-0	250768-37-1	250768-38-2	250768-39-3
	250768-40-4	250768-41-5	250768-42-6	250768-43-7	250768-44-8
	250768-45-9	250768-46-0	250768-47-1	250768-48-2	250768-49-3
	250768-50-4	250768-51-5	250768-52-6	250768-53-7	250768-54-8
	250768-55-9	250768-56-0	250768-57-1	250768-58-2	250768-59-3
	250768-60-4	250768-61-5	250768-62-6	250768-63-7	250768-64-8
	250768-65-9	250768-66-0	250768-67-1	250768-68-2	250768-69-3
	250768-70-4	250768-71-5	250768-72-6	250768-73-7	250768-74-8
	250768-75-9	250768-76-0	250768-77-1	250768-78-2	250768-79-3
	250768-80-4	250768-81-5	250768-82-6	250768-83-7	250768-84-8
	250768-85-9	250768-86-0	250768-87-1	250768-88-2	250768-89-3
	250768-90-4	250768-91-5	250768-92-6	250768-93-7	250768-94-8
	250768-95-9	250768-96-0	250768-97-1	250768-98-2	250768-99-3

350769-43-1 (Biological process); 350769-44-1 (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIEL (Biological study); PPOC (Process); USES (Uses)

IT	(Process): USE2 (Uses)	(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)	(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)	(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)	(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)
	250769-18-3	250769-48-4	250769-40-7	250769-81-8	250769-81-9
	250769-53-0	250769-74-1	250769-55-2	250769-51-2	250769-17-4
	250769-58-5	250769-59-6	250769-64-9	250769-61-1	250769-61-1
	250769-63-2	250769-66-4	250769-66-1	250769-67-6	250769-68-7
	250769-69-8	250769-70-1	250769-71-1	250769-72-3	250769-72-4
	250769-74-5	250769-75-6	250769-76-7	250769-77-8	250769-78-9
	250769-79-0	250769-80-3	250769-81-4	250769-82-5	250769-83-6
	250769-84-7	250769-85-8	250769-86-9	250769-87-0	250769-88-1
	250769-89-5	250769-91-6	250769-92-7	250769-93-8	250769-94-9
	250769-95-0	250769-96-1	250769-97-2	250769-98-3	250769-99-4
	250770-00-4	250770-01-5	250770-02-6	250770-03-7	250770-04-8
	250770-05-9	250770-06-0	250770-07-1	250770-08-2	250770-09-3
	250770-10-6	250770-11-7	250770-12-8	250770-13-9	250770-14-0
	250770-15-1	250770-16-2	250770-17-3	250770-18-4	250770-19-5
	250770-20-8	250770-21-9	250770-22-0	250770-23-1	250770-24-2
	250770-25-3	250770-26-4	250770-27-5	250770-28-6	250770-29-7
	250770-31-1	250770-32-2	250770-33-3	250770-34-4	250770-35-5
	250770-36-6	250770-37-7	250770-38-8	250770-39-9	250770-40-0
	250770-41-3	250770-42-4	250770-43-5	250770-44-6	250770-45-7
	250770-46-8	250770-47-9	250770-48-0	250770-49-1	250770-50-2
	250770-51-5	250770-52-6	250770-53-7	250770-54-8	250770-55-9
	250770-56-0	250770-57-1	250770-58-2	250770-59-3	250770-60-4
	250770-61-8	250770-62-9	250770-63-0	250770-64-1	250770-65-2
	250770-67-3	250770-68-4	250770-69-5	250770-70-6	250770-71-7
	250770-72-0	250770-73-1	250770-74-2	250770-75-3	250770-76-4
	250770-77-5	250770-78-6	250770-79-7	250770-80-8	250770-81-9
	250770-82-2	250770-83-3	250770-84-4	250770-85-5	250770-86-6
	250770-87-7	250770-88-8	250770-89-9	250770-90-0	250770-91-1
	250770-92-4	250770-93-5	250770-94-6	250770-95-7	250770-96-8
	250770-97-9	250770-98-0	250770-99-1	250771-00-2	250771-01-3
	250771-02-5	250771-03-6	250771-04-7	250771-05-8	250771-06-9
	250771-07-0	250771-08-1	250771-09-2	250771-10-3	250771-11-4
	250771-12-6	250771-13-7	250771-14-8	250771-15-9	250771-16-0
	250771-17-1	250771-18-2	250771-19-3	250771-20-4	250771-21-5
	250771-22-8	250771-23-9	250771-24-0	250771-25-1	250771-26-2
	250771-27-3	250771-28-4	250771-29-5	250771-30-6	250771-31-7
	250771-32-0	250771-33-1	250771-34-2	250771-35-3	250771-36-4
	250771-37-6	250771-38-7	250771-39-8	250771-40-9	250771-41-0
	250771-42-1	250771-43-2	250771-44-3	250771-45-4	250771-46-5
	250771-47-7	250771-48-8	250771-49-9	250771-50-0	250771-51-1
	250771-52-3	250771-53-4	250771-54-5	250771-55-6	250771-56-7
	250771-57-9	250771-58-0	250771-59-1	250771-60-2	250771-61-3
	250771-62-5	250771-63-6	250771-64-7	250771-65-8	250771-66-9
	250771-68-1	250771-69-2	250771-70-3	250771-71-4	250771-72-5
	250771-73-7	25			

150771-34-7	150771-35-7	150771-36-9	150771-37-0	150771-38-1
150771-38-2	150771-39-8	150771-41-6	150771-42-7	150771-43-9
150771-44-3	150771-45-9	150771-46-1	150771-47-2	150771-48-3
150771-49-4	150771-50-7	150771-51-3	150771-52-4	150771-53-0
150771-54-1	150771-55-2	150771-56-7	150771-57-4	150771-58-5
150771-59-6	150771-60-4	150771-61-9	150771-62-1	150771-63-2
150771-64-3	150771-65-4	150771-66-5	150771-67-6	150771-68-7
150771-69-8	150771-71-2	150771-72-2	150771-73-4	150771-74-5
150771-75-6	150771-76-7	150771-77-5	150771-78-3	150771-79-4
150771-80-3	150771-81-4	150771-82-5	150771-83-6	150771-84-7
150771-85-8	150771-86-9	150771-87-0	150771-88-1	

EL: BPS (Biological Process); ENU (Epidemiological Study); unclassified; PRP (Properties); TRU (Therapeutic Use); ENU (Epidemiological Study); PRP (Process); USES (Uses);

(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT

150771-89-1	150771-90-2	150771-91-3	150771-92-4	150771-93-5
150771-94-6	150771-95-7	150771-96-8	150771-97-9	150771-98-0
150771-99-1	150772-00-2	150772-01-3	150772-02-4	150772-03-5
150772-04-6	150772-05-7	150772-06-8	150772-07-9	150772-08-0
150772-09-1	150772-10-2	150772-11-3	150772-12-4	150772-13-5
150772-14-6	150772-15-7	150772-16-8	150772-17-9	150772-18-0
150772-19-1	150772-20-2	150772-21-3	150772-22-4	150772-23-5
150772-24-6	150772-25-7	150772-26-8	150772-27-9	150772-28-0
150772-29-1	150772-30-2	150772-31-3	150772-32-4	150772-33-5
150772-34-6	150772-35-7	150772-36-8	150772-37-9	150772-38-0
150772-39-1	150772-40-2	150772-41-3	150772-42-4	150772-43-5
150772-44-6	150772-45-7	150772-46-8	150772-47-9	150772-48-0
150772-49-1	150772-50-2	150772-51-3	150772-52-4	150772-53-5
150772-54-6	150772-55-7	150772-56-8	150772-57-9	150772-58-0
150772-59-1	150772-60-2	150772-61-3	150772-62-4	150772-63-5
150772-64-6	150772-65-7	150772-66-8	150772-67-9	150772-68-0
150772-69-1	150772-70-2	150772-71-3	150772-72-4	150772-73-5
150772-74-6	150772-75-7	150772-76-8	150772-77-9	150772-78-0
150772-79-1	150772-80-2	150772-81-3	150772-82-4	150772-83-5
150772-84-6	150772-85-7	150772-86-8	150772-87-9	150772-88-0
150772-89-1	150772-90-2	150772-91-3	150772-92-4	150772-93-5
150772-94-6	150772-95-7	150772-96-8	150772-97-9	150772-98-0
150773-00-1	150773-01-2	150773-02-3	150773-03-4	150773-04-5
150773-05-6	150773-06-7	150773-07-8	150773-08-9	150773-09-0
150773-10-1	150773-11-2	150773-12-3	150773-13-4	150773-14-5
150773-15-6	150773-16-7	150773-17-8	150773-18-9	150773-19-0
150773-20-1	150773-21-2	150773-22-3	150773-23-4	150773-24-5
150773-25-6	150773-26-7	150773-27-8	150773-28-9	150773-29-0
150773-30-1	150773-31-2	150773-32-3	150773-33-4	150773-34-5
150773-35-6	150773-36-7	150773-37-8	150773-38-9	150773-39-0
150773-40-1	150773-41-2	150773-42-3	150773-43-4	150773-44-5
150773-45-6	150773-46-7	150773-47-8	150773-48-9	150773-49-0
150773-50-1	150773-51-2	150773-52-3	150773-53-4	150773-54-5
150773-55-6	150773-56-7	150773-57-8	150773-58-9	150773-59-0
150773-60-1	150773-61-2	150773-62-3	150773-63-4	150773-64-5
150773-65-6	150773-66-7	150773-67-8	150773-68-9	150773-69-0
150773-70-1	150773-71-2	150773-72-3	150773-73-4	150773-74-5
150773-75-6	150773-76-7	150773-77-8	150773-78-9	150773-79-0
150773-80-1	150773-81-2	150773-82-3	150773-83-4	150773-84-5
150773-85-6	150773-86-7	150773-87-8	150773-88-9	150773-89-0
150773-90-1	150773-91-2	150773-92-3	150773-93-4	150773-94-5
150773-95-6	150773-96-7	150773-97-8	150773-98-9	150773-99-0
150774-00-1	150774-01-2	150774-02-3	150774-03-4	150774-04-5
150774-05-6	150774-06-7	150774-07-8	150774-08-9	150774-09-0
150774-10-1	150774-11-2	150774-12-3	150774-13-4	150774-14-5
150774-15-6	150774-16-7	150774-17-8	150774-18-9	150774-19-0
150774-20-1	150774-21-2	150774-22-3	150774-23-4	150774-24-5
150774-25-6	150774-26-7	150774-27-8	150774-28-9	150774-29-0
150774-30-1	150774-31-2	150774-32-3	150774-33-4	150774-34-5
150774-35-6	150774-36-7	150774-37-8	150774-38-9	150774-39-0
150774-40-1	150774-41-2	150774-42-3	150774-43-4	150774-44-5
150774-45-6	150774-46-7	150774-47-8	150774-48-9	150774-49-0
150774-50-1	150774-51-2	150774-52-3	150774-53-4	150774-54-5
150774-55-6	150774-56-7	150774-57-8	150774-58-9	150774-59-0
150774-60-1	150774-61-2	150774-62-3	150774-63-4	150774-64-5
150774-65-6	150774-66-7	150774-67-8	150774-68-9	150774-69-0
150774-70-1	150774-71-2	150774-72-3	150774-73-4	150774-74-5
150774-75-6	150774-76-7	150774-77-8	150774-78-9	150774-79-0
150774-80-1	150774-81-2	150774-82-3	150774-83-4	150774-84-5
150774-85-6	150774-86-7	150774-87-8	150774-88-9	150774-89-0
150774-90-1	150774-91-2	150774-92-3	150774-93-4	150774-94-5
150774-95-6	150774-96-7	150774-97-8	150774-98-9	150774-99-0

PL: BPP (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PPOC (Process); USES (Uses)

(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT	250774-81-4	250774-81-7	250774-81-8	250774-81-9	250774-81-0
	250774-82-1	250774-82-4	250774-81-5	250774-82-6	250774-82-7
	250774-84-8	250774-85-6	250774-84-0	250774-87-1	250774-86-2
	250774-93-3	250775-00-2	250775-01-0	250775-02-1	250775-03-2
	250775-04-3	250775-07-4	250775-07-5	250775-07-6	250775-07-7
	250775-07-8	250775-10-1	250775-11-3	250775-12-3	250775-13-4
	250775-14-5	250775-15-6	250775-16-7	250775-17-8	250775-18-9
	250775-19-0	250775-20-1	250775-21-4	250775-22-5	250775-23-6
	250775-24-7	250775-25-8	250775-26-9	250775-27-0	250775-28-1
	250775-29-2	250775-30-3	250775-31-6	250775-32-7	250775-33-8
	250775-34-9	250775-35-0	250775-36-1	250775-37-2	250775-38-3
	250775-39-4	250775-40-7	250775-41-8	250775-42-9	250775-43-0
	250775-44-1	250775-45-2	250775-46-3	250775-47-4	250775-48-5
	250775-49-6	250775-50-9	250775-51-0	250775-52-1	250775-53-2
	250775-54-3	250775-55-4	250775-56-5	250775-57-6	250775-58-7
	250775-59-1	250775-60-2	250775-61-3	250775-62-4	250775-63-5
	250775-65-6	250775-66-7	250775-67-8	250775-68-9	250775-69-0
	250775-70-3	250775-71-4	250775-72-5	250775-73-6	250775-74-7
	250775-75-8	250775-76-9	250775-77-0	250775-78-1	250775-79-2
	250775-81-6	250775-82-7	250775-83-8	250775-84-9	250775-85-0
	250775-86-1	250775-87-2	250775-88-3	250775-89-4	250775-90-5
	250775-92-9	250775-93-0	250775-94-1	250775-95-2	250775-96-3
	250775-97-4	250775-98-5	250776-01-2	250776-02-5	250776-04-6
	250776-05-7	250776-06-2	250776-07-9	250776-08-0	250776-10-4
	250776-11-5	250776-12-6	250776-13-7	250776-14-8	250776-15-9
	250776-16-0	250776-17-1	250776-18-2	250776-19-3	250776-20-6
	250776-21-7	250776-22-8	250776-23-9	250776-24-0	250776-25-1
	250776-26-2	250776-27-3	250776-28-4	250776-29-5	250776-30-8
	250776-31-9	250776-32-0	250776-34-2	250776-36-4	250776-38-6
	250776-40-0	250776-42-2	250776-43-3	250776-44-4	250776-45-5
	250776-46-6	250776-47-7	250776-48-8	250776-49-9	250776-50-2
	251472-94-3	251473-03-6	251473-05-9	251473-07-1	251473-12-3
	251473-16-2	251473-18-4	251473-20-8	251901-78-7	

PL: BPP (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PPOC (Process); USES (Uses)

(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)

IT	249760-78-9	249760-80-3
	PL: APG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)	
	(primer for detection of c5 cadherin mRNA; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)	
IT	249760-91-6	
	PL: APG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)	
	(primer for detection of hypoxanthine phosphoribosyl transferase mRNA; peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)	
IT	250766-73-5	
	PL: BPP (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PPOC (Process); USES (Uses)	
	(peptide analogs of cell adhesion regions of non-classical cadherins for use in treatment of cancer)	

AN 1999:594959 HCAPLUS
 DN 131:21:027
 TI Peptide compositions and formulations for enhancing elasticity and softness of skin and for therapeutic use
 IN Sandberg, Lawrence B.; Ross, Phillip J.; Mitts, Thomas F.
 PA MFS, Ltd, USA
 SO PCT Int. Appl., 58 pp.
 COCEN: P1NND2
 DT Patent
 LA English
 IC ICG AC1K038-10
 ICS AC1K038-06; AC1K038-07; AC1K038-08
 CC 62-4 (Essential Oils and Cosmetics)
 Section cross-reference(s): 02

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945941	A1	19990916	WO 1999-055436	19990312 ---
W: AL, AM, AT, AU, AC, BA, BE, BG, BF, BY, CA, CH, CN, CU, CE, IE, IF, EE, ES, FI, FR, GE, GH, GM, HE, HU, ID, IL, IS, JP, KE, EG, KR, ME, NZ, LC, LE, LF, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NG, NL, PL, PT, PU, PE, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UC, UE, UN, UY, ZW, AM, AN, BY, BG, KZ, MD, EU, TJ, TM				
BW: GR, GN, HE, LS, MW, SD, SL, SC, UE, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GE, HE, IE, IT, LC, MD, NL, PT, SE, SF, SJ, CF, CG, CI, CM, GA, GN, GW, ML, MF, NE, SN, TD, TG				
US 6069125	A	19990530	US 1999-09708	19980312 ---
CA 2323839	AA	19990316	CA 1999-232839	19990312 ---
AU 9930854	A1	19990927	AU 1999-30854	19990312 ---
EP 1064919	A1	20010103	EP 1999-011436	19990312 ---
F: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002506941	T2	20021226	JP 2000-033355	19990312 ---
NO 2000004549	A	20011109	NO 2000-4549	20000312 ---
US 1999-29308	A	19990312 ---		
WO 1999-055436	W	19990312 ---		

AB

The present invention is directed to a compn. which is used to enhance the softness, elasticity, or appearance of tissue. Specifically, the present invention is directed to a compn. formulated from peptides which substantially correspond to those produced from thermolyzing digestion of elastin. This formulation is preferably applied to human skin in a cosmetic or therapeutic formulation. The present compn. specifically includes the known chem. modification of the peptides described herein, specifically carboxy and amino modification including the addn. of amino acids to either end of the peptide fragments.

ST

IT

peptide skin softener elastin thermolysis.
 Cosmetics
 (aerosols; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT

Heart, disease
 (angina pectoris; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT

Artery
 (angioplasty, restenosis after; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT

Lung, disease
 (chronic obstructive; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT

Thrombosis
 (coronary arterial; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT

Artery, disease
 (coronary, restenosis, post-angioplasty; peptide compns. and

- formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Artery, disease
Artery, disease
(coronary; thrombosis; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Artery, disease
(coronary; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Cosmetics
(creams; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Blood vessel
Lung
Skin
(elastin formation in; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Cosmetics
(emulsions; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Cosmetics
(foams; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Drug delivery systems
(injections, s.c.; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Cosmetics
(lotions; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT **Angiogenesis**
(neovascularization; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Drug delivery systems
(ointments; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT **Angiogenesis**
Antianginal agents
Antiartherosclerotics
Anticoagulants
Antihypertensives
Arteriosclerosis
Cosmetics
Hypertension
Protein sequences
(peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Peptides, biological studies
PL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); EUU (Biological use, unclassified); PFP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Elastins
PL: BSU (Biological study, unclassified); PFP (Properties); BIOL (Biological study)
(peptide fragments of; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Cosmetics
(powders; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)
- IT Cosmetics
(sprays; peptide compns. and formulations for enhancing elasticity and

softness of skin and for therapeutic use

IT Drug delivery systems
(topical; peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT 9973-75-3, Thermolysin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

IT 236-50-0 1187-50-4 58272-50-7 61434-54-6 66835-73-2
68293-03-8 29132-25-1 103184-76-5 16341-00-6 211750-16-2
243647-47-4 243647-50-9 243647-54-3 243647-56-5 243647-58-7
243647-61-2 243647-63-4 243647-65-6 243647-67-3
243647-68-9 243647-70-3 243647-72-5 243647-73-6 243647-75-3
243647-77-0 243647-79-1 243647-82-7 243647-84-9 243647-87-2
243647-90-7 243647-92-3 243647-94-1 243647-97-4 243647-98-5
243647-99-6 243648-00-1 243648-01-3 243648-03-5 243648-04-6
243648-05-7 243648-06-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); PFP (Properties); THU (Therapeutic use); BIOL (Biological study); PPOC (Process); USES (Uses)
(peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Charten; Pharmacochem Libr 1987, V10, P245
- (2) Hunninghake, G; Science 1981, V112, P923 HCAPLUS
- (3) Lograno, M; Int J Biochem Cell Biol 1998, V30, P497 HCAPLUS

IT 1187-50-4 68293-03-8 243647-63-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PEP (Physical, engineering or chemical process); PFP (Properties); THU (Therapeutic use); BIOL (Biological study); PPOC (Process); USES (Uses)
(peptide compns. and formulations for enhancing elasticity and softness of skin and for therapeutic use)

EN 1187-50-4 HCAPLUS

CN Glycine, L-leucylglycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



EN 68293-03-8 HCAPLUS


CN Glycine, L-isoleucylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 243647-62-4 HCAPLUS
 CN L-Alanine, L-leucylglycyl- (PCI, (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2002 ACS
 AN 1999:454259 HCAPLUS
 DN 131:97621
 TI Compounds and methods for modulating occludin-related tissue permeability
 IN Blaschuk, Orest W.; Spur, Barbara J.
 PA Adherex Technologies, Can.
 SD PCT Int. Appl., 132 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM 007K014-47
 ICS 007K014-705; 007K016-16; 007K016-26; A61K039-17; A61K039-395;
 G01N033-68
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9905106	A1	19990715	WO 1998-CA1208	19981230 ---
W: AL, AM, AT, AU, BA, BE, BG, BR, BY, CA, CH, CN, CO, CZ, DE, DK, EE, ES, FI, GB, GR, GE, GH, GM, HE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LF, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, PG, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, EG, KZ, MD, RU, TG, TM				
RW: GH, GM, HE, LS, MW, SD, SE, UG, ZW, AT, BE, CH, CY, IE, UK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BE, EG, CF, CG, CI, CM, GA, GN, GW, ML, MF, NE, SN, TD, TG				
US 6248804	B1	19910619	US 1997-1811	19971231 ---
AU 9918666	A1	19990726	AU 1997-18665	19981230 ---
EP 1041265	A1	19990721	EP 1997-963311	19981230 ---
F: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000090973	T2	20020326	JP 1999-517461	19981230 ---
US 0319177	B1	20011030	US 1999-510616	20000122 ---
PRAI US 1997-1511	A	19971231 ---		
WO 1998-CA1208	W	19981230 ---		

AB Methods for using modulating agents to enhance or inhibit occludin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. Within certain embodiments, the modulating agents may be used to increase vasopermeability. The modulating agents comprise at least one occludin cell adhesion recognition sequence or an antibody or fragment thereof that specifically binds the occludin cell adhesion recognition sequence. Modulating agents may addnl. comprise one or more cell adhesion recognition sequences recognized by other adhesion mols. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

ST peptide modulator occludin related tissue permeability; cell adhesion occludin mediated peptide modulator; antibody occludin adhesion

- recognition tissue permeability
- IT Cadherins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PPOC (Process)
 (E-; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Cytometry
 (FACS (fluorescence-activated cell sorting); compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Cell adhesion molecules
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PPOC (Process)
 (N-CAM; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Bioreactors
 Membranes, nonbiological
 Microparticles
 Ultrathin films
 (adhesion-modulating agent conjugates with solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Artery
 (aorta, endothelium; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Antitumor agents
 (bladder carcinoma; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Cadherins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PPOC (Process)
 (cadherin 5; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Bladder
 Bladder
 (carcinoma, inhibitors; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Antitumor agents
 (carcinoma; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Drugs
 (cell adhesion-modulating agent conjugates with drugs; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Polymers, biological studies
 RL: BSU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (cell adhesion-modulating agent conjugates with polymeric matrix solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Plastics, biological studies
 RL: BSU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
 (cell adhesion-modulating agent conjugates with solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Drug targeting
 (cell adhesion-modulating agent conjugates with targeting agents; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Kerplasm
 (cells, culture; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Nervous system

- (central, drug delivery to; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Proteins, specific or class
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (claudins; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT **Angiogenesis inhibitors**
 Animal tissue culture
 Antidiarrheals
 Antitumor agents
 Apoptosis
 Cell adhesion
 Drug delivery systems
 Drug screening
 Epithelium
 Immunomodulators
 Protein sequences
 Transplant and Transplantation
 Wound healing promoters
 (compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Cadherins
 Fibronectins
 Integrins
 Laminins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); EPOC (Process)
 (compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Peptides, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclic; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Glycoproteins, specific or class
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); EPOC (Process)
 (desmocollins; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Glycoproteins, specific or class
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); EPOC (Process)
 (desmogleins; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Skin
 (drug delivery through; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT **Blood vessel**
 (endothelium; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Proteins, specific or class
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); EPOC (Process)
 (extracellular matrix-asscd.; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Animal tissue
 (implant; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Ovary, neoplasm
 Ovary, neoplasm
 (inhibitors; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)

- IT Antitumor agents
(leukemia; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Antitumor agents
(melanoma; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Kidney
(normal rat kidney cells; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Proteins, specific or class
RL: RFE (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); EFOC (Process)
(occludins; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Drug delivery systems
(oral; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Antitumor agents
Antitumor agents
(ovary; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT **Blood vessel**
(permeability; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Biological transport
(permeation, vascular; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Laboratory ware
(plastic dishes, cell adhesion-modulating agent conjugates with solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Pipes and Tubes
(plastic, cell adhesion-modulating agent conjugates with solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Transplant and Transplantation
Transplant and Transplantation
(skin; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Medical goods
(sutures, adhesion-modulating agent conjugates with solid support; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Cell junction
(tight junction, epithelial cell; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(to cell adhesion recognition sequence; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Drug delivery systems
(transdermal; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT Skin
Skin
(transplant; compds. and methods for modulating occludin-related cell adhesion and tissue permeability)
- IT 60961-76-4 99896-85-2 132151-24-7
143113-41-1 157535-09-6 175177-02-3
175177-14-7 175177-70-5 204644-26-8 222169-83-7 222169-83-7D,
derivs. 231282-25-8D, derivs. 231282-26-1 231282-26-1D, derivs.

231282-27-2 231282-27-2D, derivs. 231282-28-3 231282-28-3D, derivs.
 231282-29-4 231282-29-4D, derivs. 231282-30-7 231282-30-7D, derivs.
 231282-31-8 231282-31-8D, derivs. 231282-32-9 231282-32-9D, derivs.
 231282-34-1 231282-34-1D, derivs. 231282-35-2 231282-35-2D, derivs.
 231282-36-3 231282-36-3D, derivs. 231282-37-4 231282-37-4D, derivs.
 231282-38-6 231282-38-6D, derivs. 231282-40-9 231282-40-9D, derivs.
 231282-41-0 231282-41-0D, derivs. 231282-43-2 231282-44-3
 231282-45-4 231282-46-5 231282-47-6 231282-48-7 231282-49-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); PRP (Properties); THU (Therapeutic use);
 BIOL (Biological study); USES (Uses)
 (comps. and methods for modulating occludin-related cell adhesion and
 tissue permeability)

IT 231282-25-0
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (comps. and methods for modulating occludin-related cell adhesion and
 tissue permeability)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

- RE
 (1) Eisai Co Ltd; EP 081142 A 1998 HCAPLUS
 (2) Furuse, M; Journal of Cell Biology 1997, V138(6), P1777 HCAPLUS
 (3) Jaeger, E; Mol Biol Cell (Suppl) 1997, V8, P205A
 (4) Figue, C; Journal of Virology 1996, V70(8), P4919 HCAPLUS
 (5) Fraeies Pharm Inc; WO 980167 A 1998 HCAPLUS
 (6) Van Itallie, C; WO 9703605 A 1997 HCAPLUS
 (7) Wong; The Journal of Cell Biology 1997, V136(2), P329 HCAPLUS

IT 60961-76-4 99896-85-2 132151-24-7
 143113-41-1 157535-09-6 175177-02-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); PRP (Properties); THU (Therapeutic use);
 BIOL (Biological study); USES (Uses)
 (comps. and methods for modulating occludin-related cell adhesion and
 tissue permeability)


FN 60961-76-4 HCAPLUS
 CN L-Tyrosine, L-.alpha.-glutamyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




FN 99896-85-2 HCAPLUS
 CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 132151-24-7 HCAPLUS
 CN L-Glutamine, L-.alpha.-glutamyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 143113-41-1 HCAPLUS
 CN L-Valine, L-histidyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 157535-09-6 HCAPLUS
 CN L-Lysine, L-asparaginyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 175177-02-3 HCAPLUS
 CN L-Lysine, L-.alpha.-aspartyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2002 ACS
 AN 1999:033936 HCAPLUS
 EN 130:060373
 TI Compounds and methods for regulating cell adhesion
 IN Blaschuck, Orest W.; Gour, Barbara J.
 PA Adherex Inc., Can.
 SO PCT Int. Appl., 14: pt.
 CODE: PIMM2

DT Patent

LA English

IC ICM 067K014-795

ICS 067K016-29; A61K047-48; 067K027-06

IC 15-3 (Immunochemistry)

Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	FILE	DATE	APPLICATION NO.	DATE
WO 9910791	A2	19990403	WO 1998-CA902	19980929 ---
WO 9910791	A3	19990520		
W:	AL, AN, AT, AU, AC, BA, BE, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, GM, HR, HU, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LR, LU, LV, MG, MK, MU, MW, MX, NO, NZ, PL, PT, RO, RU, SI, SE, SG, SK, SL, TR, TT, UA, US, VE, VN, YU, ZW, AM, AZ, BY, EG, KZ, MD, RU, TG, TM, TW, GB, GM, KE, LS, MW, ST, SE, SG, SW, AT, BE, CH, CY, IE, IT, ES, FI, FR, GE, GR, IE, IT, LU, MC, NL, PT, SE, SF, EC, CP, CS, CL, CM, GA, GU, GW, ML, MK, NE, SN, TD, TG			
US 6,037,783	B1	20010320	US 1997-939853	19970419 ---
AU 9832483	A1	19990413	AC 1998-92443	19980929 ---
PRAI US 1997-939853	A	19970929 ---		
WO 1998-CA902	W	19980929 ---		

AB Methods for using modulating agents to enhance or inhibit cadherin-mediated cell adhesion in a variety of in vivo and in vitro contexts are provided. In particular, the modulating agents may be used in the therapy of multiple sclerosis and other demyelinating diseases. The modulating agents comprise at least one cadherin cell adhesion recognition sequence (HCR) or an antibody or fragment thereof that specifically binds to a cadherin cell adhesion recognition sequence. Modulating agents may adm. comprise one or more cell adhesion recognition sequences recognized by other adhesion mols. Such modulating agents may, but need not, be linked to a targeting agent, drug and/or support material.

ST antibody cadherin cell adhesion; multiple sclerosis; demyelinating disease; cadherin antibody cell adhesion; tumor healing cadherin antibody cell adhesion.

IT Cadherins
 FL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 TE: antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating

- diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Cell adhesion molecules
 RL: BIF (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 'N'-AM, sequence recognition; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis and tumor)
- IT Cell migration
 (Schwann cells; antibodies or fragments for identifying agent capable of modulating cadherin-mediated cell adhesion)
- IT Astrocyte
 (antibodies or fragments for identifying agent capable of modulating cadherin-mediated cell adhesion)
- IT **Angiogenesis inhibitors**
 Animal tissue
 Apoptosis
 Carcinoma
 Circulation
 Disease, animal
 Drugs
 Epithelium
 Fluorescent substances
 Immunomodulators
 Inflammation
 Injury
 Leukemia
 Mammal (Mammalia)
 Melanoma
 Microfilament
 Multiple sclerosis
 Neoplasm
 Oligodendrocyte
 Ovary, neoplasm
 Protein sequences
 Schwann cell
 Skin
 Surgery
 Test kits
 Transplant and Transplantation
 Wound healing
 (antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Cadherins
 RL: BIF (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Antibodies
 PL: BSU (Biological study, unclassified); PRF (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Animal cell
 cadherin-expressing; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, and tumor)


- IT Drug delivery systems
(carriers; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Nervous system
(central; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Nerve, disease
(demyelination, neuritis; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Nerve, disease
(demyelination; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis and tumor)
- IT Blood vessel
(endothelium; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Drug delivery systems
Prosthetic materials and Prosthetics
(implants; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Spinal cord
(injury; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Rat
(kidney cells; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis and tumor)
- IT Cell adhesion
(modulator; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Bladder
(epithelium; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Nerve
(neuron; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Axon
(outgrowth enhancer; antibodies or fragments for regulating cadherin-mediated cell adhesion, for skin and CNS drug delivery, and for treating demyelinating diseases, multiple sclerosis and tumor)
- IT Blood vessel
(permeability, enhancer; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

- IT Biological transport
(permeation, vascular, enhancer; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Pregnancy
(prevention; antibodies or fragments for regulating cadherin-mediated cell adhesion and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Oligodendrocyte
(progenitor; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT Kidney
(rats; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis and tumor)
- IT Drug delivery systems
(skin patch; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases and multiple sclerosis)
- IT Synapse
(stability inhibition; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis and tumor)
- IT Laminins
RL: AFU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(surface coated with; antibodies or fragments for identifying agent capable of modulating cadherin-mediated cell adhesion)
- IT Drug delivery systems
(transdermal; antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT 99896-85-2 110590-04-2 117058-06-7, F-A1 117650-00-3
143304-79-4 164300-50-9 175294-44-7 175294-48-8 175294-46-9
182788-96-7 222169-79-1 222169-80-4
222169-81-5 222169-82-6 222169-83-7 222169-84-8
222169-85-9 222169-86-0 222169-87-1 222169-88-2 222169-89-3
222169-90-6 222169-91-8, 143-143-000000 (human)
RL: BSU (Biological study, unclassified); PPS (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT 143113-41-1
RL: BSU (Biological study, unclassified); THU (Therapeutic use);
BIOL (Biological study); USES (Uses)
(antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)
- IT 05104-18-1, Polylysine 3800-00-9, Polylysine
RL: AFU (Analytical role, unclassified); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(surface coated with; antibodies or fragments for identifying agent capable of modulating cadherin-mediated cell adhesion)
- IT 99896-85-2 117058-06-7, F-A1 222169-79-1
222169-80-4 222169-81-5

RL: PSU (Biological study, unclassified); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antibodies or fragments for regulating cadherin-mediated cell
 adhesion, CNS or skin drug delivery and treating demyelinating
 diseases, multiple sclerosis, tumor, wound healing, spinal cord injury,
 surgery injury, and inflammation)


RN 99896-85-2 HCAPLUS
 CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 117053-06-7 HCAPLUS
 CN L-Leucine, L-arginyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 222169-79-1 HCAPLUS
 CN L-Threonine, L-tyrosyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 222169-80-4 HCAPLUS
 CN L-Serine, L-tyrosyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 222169-91-5 HCAPLUS
 CN L-Threonine, L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 143113-41-1


RL: PS3 (Biological study, unclassified); THU (Therapeutic use);
 BTCL (Biological study); USES (Uses)

(antibodies or fragments for regulating cadherin-mediated cell adhesion, CNS or skin drug delivery and treating demyelinating diseases, multiple sclerosis, tumor, wound healing, spinal cord injury, surgery injury, and inflammation)

RN 143113-41-1 HCAPLUS

CN L-Valine, L-histidyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:119732 HCAPLUS

DI 190:195781

TI CXCR chemokines as regulators of **angiogenesis**

IP Strlester, Robert M.; Polverini, Peter J.; Kunkel, Steven L.

PA The Regent of the University of Michigan, USA

SO U.S., 145 pp.

DOIEN: UCKXAM

DT Patent

LA English

IC ICM A61K038-19

NCL 434085100

CC 15-5 (Immunochimistry)

Section cross-reference(s): 1, 3

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5471723	A	19990216	US 1995-468819	19950606 <--

AB Disclosed are various discoveries concerning the **angiogenic** and angiostatic properties of the CXCR chemokines, including the finding that the ELR motif controls the ability of these mols. to induce **angiogenesis**. Aspects of the invention include, for example, the identification of .gamma.-interferon-inducible protein IP-10, MIG (chemokine induced by .gamma.-interferon) and certain IL-8 analogs as angiostatic agents, and their use in inhibiting **angiogenesis** in

various systems. Thus, maltose-binding protein-Factor Xet-TVR-IL-8, maltose-binding protein-Factor Xa-DLQ-IL-8, and glutathione-S-transferase protein-thrombin cleavage site-ELR-MIG were prepd. by mol. cloning, and were tested for inhibiting **angiogenesis**-related events assocd. with tumor.

ST CXC chemokine **angiogenesis** antagonist IL8 MIG; tumor

angiogenesis inhibitor IP10 IL8 MIG

IT Chemokines

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(C-X-C; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Chemokines

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(C-X-C; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Gene, animal

RL: PSU (Biological study, unclassified); BIOL (Biological study)

(CXC chemokine; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT **Angiogenesis inhibitors**

Chemotaxis

DNA sequences

Lung, neoplasm

Molecular cloning

Neoplasm

Protein motifs

Protein sequences

Transformation, neoplastic

Wound

Wound healing

(ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Interleukin 8

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Fusion proteins (chimeric proteins)

RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Monokines

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MIG or monokine induced by gamma.-interferon; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Carcinoma

(adenocarcinoma; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT **Angiogenic factors**

Angiogenic factors

Growth inhibitors, animal

Growth innikitors, animal

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

PREP (Properties); THU (Therapeutic use); BICL (Biological study); PREP

(Preparation); USES (Uses)

(**angiogenic** growth-inhibiting factors; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Epithelium

Neutrophil

(chemotaxis; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Blood vessel

(**endothelium**, chemotaxis; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Animal

(human; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Cytokines

FL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

PREP (Properties); THU (Therapeutic use); BICL (Biological study); PREP

(Preparation); USES (Uses)

(interferon-inducible IP-10; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Skin

(keratinocyte, proliferation; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Chemotaxis

(neutrophil; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Drug delivery systems

(parenterals; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Transplant and Transplantation

(skin; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Lung, neoplasm

(small-cell carcinoma; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Carcinoma

(squamous cell; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT Skin

(transplant; ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT 37270-04-1, Platelet factor 4

RL: BSU (Biological study, unclassified); BICL (Biological study)

(ELR, TVR, DLQ or KGR motif-contg. CXC chemokines such as IP-10, MIG

and certain IL-8 analogs as angiostatic agents for treating cancer and other **angiogenesis**-assocd. conditions)

IT 85570-39-8 172684-39-8 178493-56-6 220715-47-9
 RL: BSU (Biological study, unclassified); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USFS (Uses)
 (ELF, TVF, DLQ or KGF motif-contg. CXK chemokines such as IP-10, MIG
 and certain IL-8 analogs as angiostatic agents for treating cancer and
 other **angiogenesis**-assocd. conditions)

IT 220793-78-2 220793-80-4 220793-81-6
 RL: PRP (Properties)
 (amino acid sequence; ELF, TVF, DLQ or KGF motif-contg. CXK chemokines
 such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for
 treating cancer and other **angiogenesis**-assocd. conditions)

IT 220793-79-3 220793-81-7 220793-83-9
 RL: PRP (Properties)
 (nucleotide sequence; ELF, TVF, DLQ or KGF motif-contg. CXK chemokines
 such as IP-10, MIG and certain IL-8 analogs as angiostatic agents for
 treating cancer and other **angiogenesis**-assocd. conditions)

RE.CNT 2 THERE ARE LISTED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Fellins; US 5459133 1995 HCAPLUS

(2) Fellins; US 5729133 1998 HCAPLUS

IT 172684-39-8


RL: BSU (Biological study, unclassified); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USFS (Uses)

(ELF, TVF, DLQ or KGF motif-contg. CXK chemokines such as IP-10, MIG
 and certain IL-8 analogs as angiostatic agents for treating cancer and
 other **angiogenesis**-assocd. conditions)

RN 172684-39-8 HCAPLUS

CN L-Arginine, L-lysylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:104500 HCAPLUS

DN 199:168189

TI Cyclic GS-1 peptidomimetics, compositions, and methods of treatment of
 immunoinflammatory conditions

IN Arrhenius, Thomas S.; Tempczyk, Anna; Elices, Mariano J.; Sheng, Zhong-Li

FA Cytel Corporation, USA

SO U.S., 51 pp., Cont.-in-part of U.S. Ser. No. 483,077.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K038-06

ICS A61K038-11; C07K037-00; C07K007-10

NCL 514011000

CC 1-7 (Pharmacology)

Section cross-reference(s): 03

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5809448	A	1999-09-09	US 1991-510109	19950825 <--
	US 5811391	A	1999-09-22	US 1991-483077	19950607 <--

- PRAI US 1994-296241 19940827 ---
 US 1995-483077 19950607 ---
- OS MAPPAT 130:163185
- AB Cyclic peptides are disclosed that inhibit the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compns. contg. a cyclic peptide of the invention, as well as processes for treating immunoinflammatory conditions using a binding-inhibitory cyclic peptide, are also disclosed.
- ST cyclic peptide VLA4 binding inhibition; fibronectin CS1 binding inhibition cyclic peptide; endothelium leukocyte binding inhibition cyclic peptide; immune inflammatory condition cyclic peptide
- IT Fibronectins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); EPOT (Process)
 (CS-1 peptide; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)
- IT Animal cell line
 (JURKAT; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)
- IT Cell adhesion molecules
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); EPOT (Process)
 (VCAM-1, sol.; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)
- IT Anti-inflammatory agents
 Antirheumatic agents
 Drug delivery systems
 Leukocyte
 Peptidomimetics
 Structure-activity relationship
 (cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)
- IT Peptides, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclic; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)
- IT Immunity
 (disorder; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)
- IT Blood vessel
 (endothelium; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)
- IT Drug delivery systems
 (prodrugs; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)
- IT Integrins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); EPOT (Process)
 (.alpha.4.beta.1; cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, compns., and methods of treatment of immunoinflammatory conditions)

IT 164740-10-7 184292-92-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, comps., and methods of treatment of immunoinflammatory conditions)

IT 38763-90-5P 77292-72-9P 120445-45-9P 177081-18-2P 177081-24-2P 177081-28-6P
 177081-19-9P 177081-21-1P 177081-21-9P 177081-24-2P 177081-28-6P
 177081-29-7P 177081-28-2P 177081-31-1P 177081-32-2P 177081-34-4P
 177081-35-1P 177081-37-7P 177081-38-2P 177081-39-9P 177081-40-6P
 177081-41-4P 177081-41-4P 177081-41-4P 177081-43-6P 177081-44-6P
 177081-45-7P 177081-46-4P 177081-47-8P 177081-48-0P
 177081-49-1P 177081-51-4P 177081-51-5P 177081-52-6P
 177081-53-7P 177081-54-8P 177081-55-4P 177081-56-0P 177081-57-1P
 177081-58-2P 177081-59-4P 177081-60-4P 177081-61-7P 177081-62-8P
 177081-64-8P 177081-65-1P 177081-66-1P 177081-67-4P 177081-68-5P
 213326-76-1P 213326-77-3P 213326-78-5P 213326-80-3P 213326-81-9P
 213326-82-1P 213326-83-4P 213326-84-4P 213326-87-5P 220445-54-5P
 220445-58-9P 220445-59-0P 220445-60-2P 220445-61-4P 220445-62-8P
 220445-63-6P 220445-64-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, comps., and methods of treatment of immunoinflammatory conditions)

IT 107979-77-8
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
 (cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, comps., and methods of treatment of immunoinflammatory conditions)

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon.; WO 900995 1992 HCAFLUS
- (2) Anon.; WO 941595 1994 HCAFLUS
- (3) Cardarelli, F; J Biol Chem 1994, V269, F18668 HCAFLUS
- (4) Hansen; US 5109833 1992 HCAFLUS
- (5) Hart, S; J Biol Chem 1994, V269, F18466 HCAFLUS
- (6) Kivimunen, E; J Cell Biol 1994, V124, P377 HCAFLUS
- (7) Komoriya, A; J Biol Chem 1991, V266, F15875 HCAFLUS
- (8) Mousa, S; Cardiology 1991, V81, P374 HCAFLUS
- (9) Newlin, D; J Biol Chem 1994, V269, F18451 HCAFLUS
- (10) Pfaff, M; J Biol Chem 1994, V269, F18237 HCAFLUS
- (11) Sekti; US 5601004 1997 HCAFLUS
- (12) Wayne, E; J Cell Biology 1990, V110, P480
- (13) Yanofsky; US 5604335 1997 HCAFLUS


IT 38763-90-5P 77292-72-9P 177081-48-0P
 177081-49-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (cyclic peptides inhibiting binding of VLA4 receptor and fibronectin CS-1 peptide, comps., and methods of treatment of immunoinflammatory conditions)

RN 38763-90-5 HCAFLUS


CN L-Phenylalaninamide, L-leucyl-L-.alpha.-aspartyl- (LICI) (CA INDEX NAME)

Absolute stereochemistry.




RN 77292-72-9 HCAPLUS
 CN L-Valinamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 177081-48-0 HCAPLUS
 CN L-Valinamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177081-49-1 HCAPLUS
 CN L-Phenylalaninamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 1993:785612 HCAPLUS

EN 130:22918

TI Method and devices for altering the differentiation of anchorage-dependent cells on an electrically-conducting polymer

IN Wong, Joyce Y.; Ingber, Donald E.; Langer, Robert S.

IA Massachusetts Institute of Technology, USA; Children's Medical Center Corporation

SO U.S., 17 pp.

CODEN: USKXAM

BT Patent

LA English

IC ICM C12N013-G0

NCL 435173800

CC 9-11 (Biochemical Methods)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	FIND	DATE	APPLICATION NO.	DATE
PI	US 5842741	A	19981201	US 1994-085402	19940801 <--
AB	Described is a method and cell culture system for altering the proliferation, differentiation, or function of anchorage-dependent cells which includes assocg. the cells with a surface formed of an elec.-conducting polymer and applying an effective amt. of a voltage to change the oxidn. state of the polymer without damaging the cells. Substrates are prepd. which are formed of or coated with an elec.-conducting biocompatible polymer which are used in vitro for cell culture or in vivo to aid in healing, etc. Examples demonstrate the effect of culturing two different types of cells (bovine aortic endothelial cells and Balb/c3T3 mouse fibroblasts) on fibronectin-coated polypyrrole conducting polymer substrates and the effect of applied voltage and the modifications possible through variation of attachment mol. d. on the conducting polymer substrate.				
ST	cell differentiation culture elec conducting polymer; medical device elec conducting polymer				
IT	Cell (anchorage-dependent; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)				
IT	Artery Artery (acuta, endothelium, cells of, of bovine; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)				
IT	Agglutinins and Lectins Albumins, biological studies Carbohydrates, biological studies Entactin Fibrinogens Fibronectins Gelatin, biological studies				

- Glycosaminoglycans, biological studies
 Growth factors, animal
 Laminins
 Peptides, biological studies
 Proteoglycans, biological studies
 Thrombospondins
 Vitronectin
 RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); PPOC (Process); USES (Uses)
 (as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Polyacetylenes, biological studies
 Polyanilines
 Polythiophenylenes
 RL: BBU (Biological use, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as elec.-conducting polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Sialoglycoproteins
 RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); PPOC (Process); USES (Uses)
 (asialoglycoproteins, as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Polymers, biological studies
 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (biodegradable, elec.-conducting polymer coated onto device of; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Polymers, biological studies
 RL: BBU (Biological use, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (elec.-conducting; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Medical goods
 Medical goods
 (films, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Screws
 (for bone, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Drug delivery systems
 Prosthetic materials and Prosthetics
 (implants, polymer coated onto structure for; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Lipoproteins
 RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); PPOC (Process); USES (Uses)
 (low-d., as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Films
 Films
 (medical, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Animal cell
 Cell differentiation
 Fibroblast

- Plant cell
Wound healing
(method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Fasteners
(nails, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Bone
(polymer coated onto screws for; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Animal tissue culture
Plant tissue culture
(polymer coated onto structure for; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Apparatus
Medical goods
Pipes and Tubes
Plates
(polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Receptors
RL: BPF (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(polymer-immobilized attachment mols. specific for, on cell surface; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Bone, disease
Nerve
(repair or regeneration of; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Medical goods
(sheets, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Medical goods
(stents, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Medical goods
(sutures, polymer coated onto; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT Cell adhesion
(treatment of diseases from; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT 9002-04-4, Thrombin 9045-44-4, Heparin, biological studies 25104-18-1, Poly-L-lysine
RL: BPF (Biological process); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT 20604-81-08, Polypyrrolone
RL: BUU (Biological use, unclassified); DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(as elec.-conducting polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT 25007-54-7, Polyacetylene 25293-64-4, Polythiophene 25638-49-2, Polyphenylenevinylene
RL: BUU (Biological use, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as elec.-conducting polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)
- IT 99896-85-2 11590-64-1 128720-18-1

RL: BPP (Biological process ; BSH (Biological study, unclassified); DEV (Device component use ; IRP (Properties); THU (Therapeutic use);
 BIOL (Biological study); PPO (Process); USES (Uses)
 (peptides contg., as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

IT 9004-83-0 1990-11-A, Indium tin oxide
 RL: DEV (Device component use); NUR (Other use, unclassified); PEP (Physical, engineering or chemical process); IROC (Process); USES (Uses)
 (polymer; as thin films; chem. synthesis on; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Aklonis; US 514177 1991 HCAPLUS
- (2) Alberts, B; Molecular Biology of the Cell 2nd ed 1989, P727
- (3) Alt; US 5143089 1991
- (4) Andreatta, A; Synth Met 1988, V58(2), F1017
- (5) Anon; WO 8701795 1987
- (6) Anon; WO 8803745 1988
- (7) Anon; WO 8902876 1989 HCAPLUS
- (8) Anon; WO 8904849 1989 HCAPLUS
- (9) Anon; DE 4016976 A1 1990 HCAPLUS
- (10) Anon; EP 0471998 A2 1991 HCAPLUS
- (11) Anon; WO 9011644 1991 HCAPLUS
- (12) Ames, C; Synthetic Metals 1987, V20, P365 HCAPLUS
- (13) Atkins; US 4888254 1988 HCAPLUS
- (14) Bauer, P; Science 1988, V161, P1600 HCAPLUS
- (15) Ben Ce'Ev, A; Cell 1989, V58, P361 HCAPLUS
- (16) Ben Ce'Ev, A; Proc Natl Acad Sci USA 1988, V85, P1161 HCAPLUS
- (17) Bissell, D; J Clin Invest 1987, V79, P891 HCAPLUS
- (18) Bissell, D; Grand J Gastroenterol 1988, V23, P1
- (19) Bjorkland; US 4511450 1985 HCAPLUS
- (20) Bourdillon, C; Journal of the American Chemical Society 1989, V102(12), P4231 HCAPLUS
- (21) Bull, F; J Electrochem Soc 1981, V128(3), F1009 HCAPLUS
- (22) Bull, F; J Electrochem Soc 1981, V128(7), F1036 HCAPLUS
- (23) Burgmayer, J; Handbook of Conducting Polymers V1, P507
- (24) Byers; US 4208468 1988
- (25) Cao, Y; Synth Met 1991, V48, P91 HCAPLUS
- (26) Cao, Y; Synthetic Metals 1992, V11, P143 HCAPLUS
- (27) Carnig; US 5174076 1992
- (28) Cohen, S; The Journal of Biological Chemistry 1982, V257(3), P1523
- (29) Couchman, J; The Journal of Cell Biology 1981, V93, P402 HCAPLUS
- (30) Cunningham; US 5116464 1991 HCAPLUS
- (31) Decker, G; Thin Solid Films 1992, V110/111(1-2), P831
- (32) Denk, H; Sem Liver Disease 1986, V6(3), P139 MEDLINE
- (33) Diaz, A; J C S Chem Comm 1979, P631 HCAPLUS
- (34) Eisenhammer; US 4861622 1991 HCAPLUS
- (35) Giannessi; US 38/1961 1975
- (36) Garrett; US 4687806 1987 HCAPLUS
- (37) Macurek; US 4491003 1983 HCAPLUS
- (38) Methia; US 5196118 1991
- (39) Pierschbacher; US 5116464 1991 HCAPLUS
- (40) Pibi; US 5116464 1991 HCAPLUS
- (41) Roberts; US 4644457 1987 HCAPLUS
- (42) Spector; US 4164184 1978 HCAPLUS

IT 99896-85-2

RL: BPP (Biological process); BSH (Biological study, unclassified); DEV (Device component use ; IRP (Properties); THU (Therapeutic use);
 BIOL (Biological study); PPO (Process); USES (Uses)
 (peptides contg., as attachment mols. on polymer; method for altering differentiation of anchorage-dependent cells on elec.-conducting polymers)

polymers)
 RN 99936-45-2 HCAPLUS
 CN L-Aspartic acid, L-arginylglycyl- (ACI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 1998:024019 HCAPLUS

DN 129:290239

TI Tissue implant comprising collagen and a hydrated alginate gel matrix

IN Lee, David Alan; Eader, Daniel Lawrence; Stephens, Myra Deborah

PA University College London, UK; Queen Mary & Westfield College

SO PET Int. Appl., 49 pp.

COOEN: PLEND2

DT Patent

LA English

IC ICM A61L027-00

CC 63-7 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	FIND	DATE	APPLICATION NO.	DATE
PI	WG 9840111	A1	19980917	WG 1998-SB673	19980306 ---
	W:	AL, AM, AT, AU, AC, BA, BF, BG, BE, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GE, GR, HM, HU, IL, IN, IS, JP, KE, KG, KR, KZ, LA, LB, LC, LF, LG, LT, LU, LV, MD, MG, MK, MN, MW, MX, MY, NG, NI, NO, PL, PT, PU, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AC, BY, BG, BE, MD, BU, TJ, TM			
	FW:	GR, GM, PE, LS, MW, SD, SO, OG, ZW, AT, BE, CH, DE, DK, ES, FI, FF, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9865066	A1	19980919	AU 1998-65066	19980306 ---
	EP 1819109	A1	19980719	EP 1998-91094	19980306 ---
	F:	BE, CH, DE, ES, FF, GB, IT, LI, NL			
	JP 2001514551	T2	20010911	JP 1998-519340	19980306 ---
	US 6366169	B1	20011023	US 1998-118169	19981109 ---
PRAI	GE 1997-4749	A	19970307 ---		
	WG 1998-SB673	W	19980306 ---		

AB A biomech. implant is described which comprises at least two matrix components, the first matrix component being composed of collagen with a porous macrostructure with the ability to withstand tensile or shear forces, the second matrix component being a hydrated alginate gel which substantially fills the porous macrostructure of the first component and exerts a swelling pressure, the implant addnl. comprising a population of cells comprising chondrocytes, fibrochondrocytes, fibroblasts or osteoblasts, or precursors thereof. Collagens gels with chondrocytes were placed in wells of a tissue culture plate and a 3% alginate in Earle's buffered salt soln. contg. 4x10⁶ cells/mL in DMEM and 10% fetal calf serum was gently layered on top of the collagen gel or sponge. The tissue culture plate was centrifuged at 100 g for 5 min to incorporate the alginate and cell suspension within the collagen gel or sponge. Crosslinking of the alginate was affected by bathing the construct in a soln. of 100 mM CaCl₂ in DMEM/10% fetal calf serum. The tangents modulus and equil. modulus of the gel was 55, and 32 Pa, resp.

ST tissue implant collagen alginate matrix

- IT Transplant and Transplantation
(autotransplant; tissue implant comprising collagen and hydrated alginate gel matrix)
- IT Polymers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bio-degradable; tissue implant comprising collagen and hydrated alginate gel matrix)
- IT Prosthetic materials and Prosthetics
(implants; tissue implant comprising collagen and hydrated alginate gel matrix)
- IT Spinal column
(intervertebral disk; tissue implant comprising collagen and hydrated alginate gel matrix)
- IT Foams
Plates
(medical goods; tissue implant comprising collagen and hydrated alginate gel matrix)
- IT Joint, anatomical
(meniscus; tissue implant comprising collagen and hydrated alginate gel matrix)
- IT Porosity
(microporosity; tissue implant comprising collagen and hydrated alginate gel matrix)
- IT Medical goods
(sponges; tissue implant comprising collagen and hydrated alginate gel matrix)
- IT Cartilage
Chondrocyte
Crosslinking agents
Fibroblast
Osteoblast
Particle size
(tissue implant comprising collagen and hydrated alginate gel matrix)
- IT Collagens, biological studies
Fibers
Fibronectins
Gelatins, biological studies
Glycosaminoglycans, biological studies
Polyanhydrides
Polyoxyalkylenes, biological studies
Proteoglycans, biological studies
Vitronectin
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tissue implant comprising collagen and hydrated alginate gel matrix)
- IT **Angiogenic factors**
Chemotactic factors
Cytokines
Enzymes, biological studies
Growth factors, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tissue implant comprising collagen and hydrated alginate gel matrix)
- IT 1306-96-5, Hydroxyapatite 9001-07-1, Carrageenan 9004-61-3, Hyaluronan 9005-31-7, Alginate acid 9012-36-6, Agarose 24980-41-4, Polycaprolactone 21248-42-4, Polycaprolactone 25322-68-3, Polyethyleneoxide 36563-90-3, Polyhydroxybutyrate 26124-68-5, PolyL-glycolic acid 26161-42-2 26744-04-7 26811-96-1, PolyL-lactic acid 99896-85-2
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tissue implant comprising collagen and hydrated alginate gel matrix)
- IT 99896-85-2

RL: DEV (Device component use); THU (Therapeutic use); BICL
(Biological study); USES (Uses)
(tissue implant comprising collagen and hydrated alginate gel matrix)

RN 99906-85-1 HCAPLUS

CN L-Aspartic acid; L-arginylethyl- (PCI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 14 OF 11 HCAPLUS COPYRIGHT 2002 ACS

AN 1998:133534 HCAPLUS

DN 128:162877

TI Cationic liposome:DNA complex vehicles encoding anti-angiogenic peptides for use in gene therapy

IN Mixson, Archibald James

PA Mixson, Archibald James, USA

SO Eur. Pat. Appl., 47 pp.

CODEN: EFXMLW

DT Patent

LA English

IC ICM C12N015-12

ICS C12N015-14; A61K048-00

CC 1-6 (Immunology)

Section cross-references: 2

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	EP 819758	A1	19980121	EP 1997-112154	19970716 <--
FI	EP 819758	A1	19980204		
	P: AT, BE, CH, DE, DK, ES, FF, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6080728	A	20000627	US 1997-385526	19971205 <--
	JP 11187886	A2	19990713	JP 1998-201996	19980716 <--
FRAI	US 1996-080845	A	19960716 <--		
	EP 1997-112154	A	19970716 <--		
	US 1997-385526	A	19971205 <--		

AB Cationic vehicles:DNA complexes comprising DNA encoding an anti-angiogenic peptide or DNA encoding a tumor suppressor protein and DNA encoding an anti-angiogenic peptide, as well as their use in gene therapy, are disclosed. The liposomal components may comprise 1,2-dioleoyl-sn-glycerol-3-ethylphosphocholine, 1,2-dimyristoyl-sn-glycerol-3-ethylphosphocholine, and 2,3-dioleoyloxypropyl-N,N,N-trimethylammonium chloride), optionally in combination with polyethylene glycol and a targeted ligand such as Arg-Gly-Asp, ferritin, or antibodies targeted toward HER1. DNA is prep. encoding anti-angiogenic peptide fragments of thrombospondin 1, fibronectin, laminin, platelet factor 4, angiostatin, and prolactin, as well as concatemers of these fragments. Tumor suppressor protein genes include p53, p21, or Rb. Thus, liposome:DNA vectors encoding p53 in combination with a thrombospondin I fragment reduced tumors more effectively than p53 alone. The cationic polymer allows superior transfection of endothelial cells; Superfect is a better transfection agent than cationic liposomes for many different cell lines.

ST cationic liposome DNA vector gene therapy; antiangiogenic peptide liposome vector gene therapy; tumor inhibitor

- antiangiogenic peptide DNA liposome**
- IT Thrombospondins
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (I; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT Gene, animal
 FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 RE1; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT Transcription factors
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (RE; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT Gene, animal
 FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 TP63; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT Peptides, biological studies
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-**angiogenic**; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT **Angiogenesis inhibitors**
 Antitumor agents
 Gene therapy
 Liposomes
 Transformation, genetic
 (cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT Antibodies
 Ferritins
 Fibronectins
 Laminins
 Polyoxyalkylenes, biological studies
 p53 (protein)
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT Synthetic gene
 FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT DNA sequences
 (for synthetic genes encoding anti-**angiogenic** peptides in cationic liposome:DNA complex vehicles for use in gene therapy)
- IT Protein sequences
 (of anti-**angiogenic** peptides in cationic liposome:DNA complex vehicles for use in gene therapy)
- IT Proteins, specific or class
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 p21; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT Gene, animal
 FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

- (p21; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT Gen.: animal
 FL: THU (Therapeutic use); BIOC (Biological study); USES (Uses)
 (tumor suppressor; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT 102937-31-3, Thrombospondin 1 (human fragment) 102937-32-4
 102937-40-4, Angiostatin (human fragment) 102937-41-5, Angiostatin (human fragment concatamer) 102937-44-8, Prolactin (human fragment) 102937-46-9, Prolactin (human fragment concatamer) 102939-05-6
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); USES (Uses)
 (amino acid sequence; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT 4004-05-1, Bisdodecylphosphatidylethanolamine 9002-62-4, Prolactin, biological studies 9002-98-6, Polyethylamine 10104-18-1, Polylysine 10312-68-2 10002-48-6, Polyhistidine 20854-81-9, Polynitidine 17270-24-3, Blood platelet factor 4 13009-36-5, Polylysine 51110-01-1, Angiostatin 9004-05-6, Angiostatin 99896-85-2 104162-48-3, DOTMA 183183-12-7 186491-13-5 190916-04-5, APL Polysat57 103009-02-4
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); USES (Uses)
 (cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT 101645-50-5
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); USES (Uses)
 (fibronectin fragment concatamer; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT 102936-70-7
 FL: THU (Therapeutic use); BIOC (Biological study); USES (Uses)
 (fibronectin fragment-specifying; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT 102645-55-4
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); USES (Uses)
 (fibronectin fragment; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT 102645-52-1
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); USES (Uses)
 (laminin fragment concatamer; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT 102645-51-0
 FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOC (Biological study); USES (Uses)
 (laminin fragment; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT 102936-68-2
 FL: THU (Therapeutic use); BIOC (Biological study); USES (Uses)
 (laminin peptide fragment-specifying; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)
- IT 102937-47-1 102937-48-2

(nucleotide sequence; cationic liposome:DNA complex vehicles encoding anti-**angiogenic** peptides for use in gene therapy)

FL: THU (Therapeutic use); FBL (Biological study); USES (Uses)

IT 100-645-53-2

(Uses)
(platelet factor 4 fragment; cationic liposome:RNA complex vehicles
encoding anti-angiogenic peptides for use in gene therapy)

103008-99-5
FL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BLOS (Biological study); USES (Uses)

IT 202936-69-4

PL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(somatostatin fragment-specifying; cationic liposome:DNA complex
vehicles encoding anti-angiogenic peptides for use in gene
therapy)

002645-54-2
EL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIEL (Biological study); USES (Uses)

(Uses)
(somatostatin fragment; cationic liposome:DNA complex vehicles encoding anti-angiogenic peptides for use in gene therapy)


99896-85-2
 RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

```
study); USES USES;
(cationic liposome:RNA complex vehicles encoding anti-
angiogenic peptides for use in gene therapy)
```

RI 39896-35-2 HCAPLUS

RN	39E96-85-1	HAPLOS
CN	L-Aspartic acid, L-arginylglycyl-	(SC1) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 15 OF 21 BCAPLUS COPYRIGHT 2002 ACS

AN 1497:54353- HCAPLJS

DN 127:164690

TI Inhibitors of MADCAM-1-mediated interactions and methods of use therefor

IN Schwender, Charles F.; Shroff, Hitesh N.

IN Schwender, Charles F.; Shroff, Hitesh N.
 EA Leukosite, Inc., USA; Schwender, Charles F.; Shroff, Hitesh N.

SO ECT Int. Appl., 167 pp.

CUDEN: PIRKDE

DT Patent

LA English
 IC ICM 007K014-705
 ICS 007K015-06; A61K038-05; A61K038-08
 CC 13-2 (Immunochemistry)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 97/03511	A2	19970717	WO 1997-US291	19970103 <--
	W:				
	AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, DE, DK, EE, ES, FI, GR, GE, HU, IL, IS, JP, KE, KG, KP, KR, LC, LK, LA, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RS, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UK, US, VN, AM, AC, BY, EG, RU, MD, EU, TU, TM				
	PW:				
	KE, LB, MW, SD, UC, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BT, CF, CG, CI, CM, GA, GN, ML, HE, HE, CN, TD, TG				
	US 6067224	A	19990314	US 1996-591740	19960104 <--
	CA 2241168	AA	19970717	CA 1997-2241168	19970103 <--
	AC 0701415	A1	19970801	AU 1997-22415	19970103 <--
	AT 711613	B2	19970717		
	EP 871670	A2	19970717	EP 1997-991664	19970103 <--
	F:				
	AT, BA, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT, IE, FI				
	JP 2000508103	T2	20000314	JP 1997-527161	19970103 <--
	US 6034556	B1	19990314	US 1996-113473	19960703 <--
	US 2001103111	A1	20010801	US 2001-554214	20010916 <--

PRAI US 1996-591740 A2 19960717 <--
 WO 1997-US291 W 19970717 <--
 US 1996-113473 A1 19960703 <--

OS MARPAT 127:134698

AB The present invention provides novel compds. comprising peptide sequences which mimic the conserved amino acid motif LDTSL of MAdCAM-1 and which have groups bonded to the N- and C-termini. Also provided are methods of inhibiting the interaction of a cell bearing a ligand of MAdCAM-1, such as human alpha.4.beta.7, with MAdCAM-1 or a portion thereof (e.g., the extracellular domain), comprising contacting the cell with a compd. of the present invention. The MAdCAM-1 inhibitors are useful for treating disease assocd. with leukocyte infiltration of tissue, such as inflammatory bowel disease, with fewer side effects in other tissues where adhesion is mediated by alpha.4.beta.1 integrin, for example. The inhibitors can also be used for induction of antibodies selectively bind epitopes of MAdCAM-1 and useful for quantitating MAdCAM-1 on cell surface.

ST MAdCAM1 peptide leukocyte infiltration inhibition; inflammatory bowel disease MAdCAM1 inhibitor

IT Integrins

RL: BPR (Biological process); BST (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(LFA-1 (lymphocyte P-er)- patch high endothelial venule adhesion mol. 1); peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration

IT Proteins, specific or class

RL: BPR (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USEP (Uses)

(antibodies, MAdCAM-1 or mucosal addressing cell adhesion mol.-1; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)

IT Blood vessel

(endothelium, cells; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)


IT Leukocyte

(infiltration; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)

IT Intestine, disease

- (inflammatory; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)
- IT Diabetes mellitus
(insulin-dependent; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)
- IT Cell migration
(leukocyte infiltration; peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)
- IT Protein sequences
(peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)
- IT 193217-37-2 193217-99-2 193218-01-6 193218-03-6 193218-05-2
193218-07-4 193218-09-6 193218-11-0 193218-13-2 193218-15-4
193218-17-6 193218-19-8 193218-23-4 193218-25-6 193218-27-8
193218-28-9 193218-30-3 193218-31-4 193218-32-8 193218-33-6
193218-34-7 193218-35-5 193218-36-9 193218-37-8 193218-38-1
193218-39-2 193218-40-5 193218-41-0 193218-42-7 193218-43-8
193218-44-9 193218-45-9 193218-46-1 193218-47-3 193218-48-5
193218-49-4 193218-50-7 193218-51-2 193218-52-9 193218-53-0
193218-54-1 193218-55-1 193218-56-2 193218-57-4 193218-58-5
193218-59-6 193218-60-9 193218-61-0 193218-62-1 193218-64-3
193218-65-4 193218-66-5 193218-68-7 193218-69-2 193218-70-1
193218-71-2 193218-72-3 193218-73-4 193218-74-5 193218-75-6
193218-76-7 193218-77-2 193218-78-9 193218-80-2 193218-81-4
193218-82-5 193218-83-6 193218-84-7 193218-85-8
193218-86-9 193218-87-0 193218-88-1 193218-89-1 193218-90-5
193218-91-6 193218-92-7 193218-93-8 193218-94-9 193218-95-0
193218-96-1 193218-97-2 193218-98-3 193218-99-4 193219-00-0
193219-01-1 193219-02-2 193219-03-3 193219-04-4 193219-05-6
193219-06-8 193219-09-2 193219-11-1 193219-14-6
193219-16-8 193219-18-0 193219-20-4
- FL: PAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)
- IT 193218-84-7 193218-85-8 193219-14-6
193219-16-8 193219-20-4
- FL: PAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide inhibitors of MAdCAM-1-mediated interactions for treating disease assocd. with leukocyte infiltration)
- RN 193218-54-7 HCAPLUS
- CN L-Threonine, N-benzyloxycarbonyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193218-95-8 HCAPLUS

CN L-Threonine, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193219-14-6 HCAPLUS

CN L-Threoninamide, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-
cyclopropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193219-16-6 HCAPLUS

CN L-Threoninamide, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-
cyclooctyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193219-20-4 HCAPLUS

CN L-Threoninamide, N-(2-benzofuranylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-
(2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 16 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 1997:319616 HCAPLUS

DN 126:27241

TI Molecules that home to a selected organ or tissue in vivo, and methods of identifying them

IN Ruoslahti, Erkki; Pasqualini, Renata

PA La Jolla Cancer Research Foundation, USA

SO ECT Int. Appl., 76 pp.

CODEN: PIXKD2

DT **Patent**

LA English

IC ICM G01N033-567

ICS G01N033-S1; C07K001-04; A01K047-48

CC 1-1 (Pharmacology)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8710597	A1	19870310	WO 1996-US14600	19960310 <--
	W: AU, CA, JP				
	FW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 4622449	A	19870410	US 1995-026710	19950911 <--
	CA 2204838	AA	19870310	CA 1996-0204535	19960310 <--
	AU 666039	A1	19870401	AU 1996-69739	19960310 <--
	AU 680723	B1	19880701		
	EP 373441	A1	19871010	EP 1996-050195	19960310 <--
	EP 373441	B1	20001801		
	F: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 19810674	T1	19881010	JP 1996-012087	19960310 <--
	EP 876611	A1	19881111	EP 1996-050824	19960310 <--
	F: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	EP 887175	A1	20000311	EP 1999-050432	19960310 <--
	F: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 145141	E	20000815	AT 1996-250195	19960310 <--
	AU 666039	A1	19870410	AU 1993-63740	19960430 <--
	AU 713666	B1	20011110		
PRAI	US 1996-026708	A	19960911 <--		
	US 1996-026710	A	19960911 <--		
	EP 1996-050195	A3	19960910 <--		
	WO 1996-US14600	W	19960910 <--		

AB The present invention provides an in vivo method for identifying mols. that home to a selected organ or tissue. In addn., the invention provides peptides that home to a selected organ or tissue. For example, the invention provides peptides that selectively home to an organ, e.g. brain or kidney, or to a tissue, e.g. a tumor tissue. The invention further provides methods of using an organ homing mol. e.g. to target an agent such as a drug to a selected organ or to identify the target mol.

expressed by the selected organ. The invention also provides methods of targeting an organ or tissue contg. **angiogenic** vasculature by contacting the organ or tissue with a mol. that specifically binds an .alpha.v-contg. integrin. Methods are demonstrated for prepg. a phage library and screening the library using in vivo panning to identify phage-expressing peptides that home to a selected organ or tissue; peptide sequences are included. The brain-homing peptide CLSSRLDAC directs red blood cells to the brain. Also described is use of in vivo panning to identify peptides homing to a breast tumor or a melanoma.

ST tissue organ targeting mol identification; drug targeting tissue organ homing mol; peptide organ tissue tumor homing; brain kidney tumor homing mol; **angiogenic** vasculature tissue targeting integrin ligand

IT **Blood vessel**

(**angiogenic**; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Erythrocyte

(brain-homing peptide directs red blood cells to brain)

IT Mammary gland

(carcinoma; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Medical goods

(chambered microdevices, targeting mol. complexes; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Animal tissue

Brain

Drug targeting

Immobilization, biochemical

Kidney

Melanoma

Neoplasm

Nucleic acid library

Organ, animal

Phage display library

Protein sequences

Reticuloendothelial system

(mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Peptides, biological studies

PGD peptides

PL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Mammary gland

(neoplasm; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Proliferation inhibition

(proliferation inhibitors, targeting mol. complexes; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Liver

Spleen

(reticuloendothelial system; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Cytotoxic agents

(targeting mol. complexes; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Antibodies

PL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.alpha.v-contg. integrin-binding; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Integrins

PL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process.)

4. alpha.v; moles, homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT Integrins

EB: BPR (Biological process); BFT (Biological study, unclassified); BIGH (Biological study); BPGC (Process)

alpha.v.beta.3; mols. homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT 200401-66-0

File: BBS (Biological process); BSI (Biological study, unclassified); BIOD (Biological study); PROC (Process)

cells, homing to selected organ or tissue in vivo, and methods of identification and targeting.

IT 16-173-57-5 176254-11-8 176254-12-9 176254-13-0 176254-14-1

176254-15-2 176254-16-3 176254-17-4 176254-18-5 176254-19-6

176254-10-9 183013-57-2 183012-53-3 183023-59-4 183025-60-2

$$1841235-63=1$$

15 90 13-64-3 15 90 13-65-3 15 90 13-66-3 15 90 13-67-3 15 90 13-68-3
15 90 13-69-3 15 90 13-70-3 15 90 13-71-3 15 90 13-72-3 15 90 13-73-3

15 961.5-66-3 15 961.5-67-4 15 961.5-68-5 15 961.5-69-6 15 961.5-70-7
15 961.5-71-8 15 961.5-72-9 15 961.5-73-0 15 961.5-74-1 15 961.5-75-2

1139011-71-0 1139012-72-1 1139013-73-2 1139014-74-3 1139015-75-4
1139016-76-5 1139017-77-6 1139018-78-7 1139019-79-8 1139020-80-9

1E 301.1-76-5 1E 301.1-77-6 1E 301.2-73-7 1E 301.3-79-8 1E 301.5-80-1
1E 301.3-87-1 1E 301.3-88-3 1E 301.3-88-4 1E 301.5-88-5 1E 301.5-88-6

1830.3-81-2 1830.3-82-3 1830.3-83-4
1830.3-86-7 1830.3-87-8 1830.3-88-9

FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

models, homing to selected organ or tissue in vivo, and methods of identification and targeting)

IT 99896-85-2

FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

peptide contg. sequence of; mols. homing to selected organ or tissue
in vivo; and methods of identification and targeting)

IT 99896-85-2


FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptide contg. sequence of; nols. homing to selected organ or tissue
in vivo; and methods of identification and targeting)

PN 94-34-20-5 HCAPLUN

CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 17 OF 21 HCAPLUS COPYRIGHT 2012 ACS

AN 1497:141047 HCAPLIS

DOI: 10.1002/anie.200701761

T1 Anti-metastatic and anti-angiogenic thrombin derivatives

IN Fur-Shavit, Rachel

FA Hadasit Medical Research Services and Development Co. Ltd., Israel;

Ear-Shavit, Rachel

SO INT Int. Appl., 45 pp.

CODEN: PIRMD2

Patent

LA English.

IC IMM A61K039-10

IC: A01N037-13; GJ1N033-574; C07K016-00; C12P021-08

CC 1-6 (Pharmacology)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
PI WO 8700077      A1 1987-0103      WO 1996-1112      19960612 <--
    W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
      ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LE, LR, LS,
      LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RG, RU, SD,
      SE, SG
      RW: KE, LS, MW, SD, SF, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
      IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA
    IL 114140      A1 2006-0601      IL 1996-114140      19960614 <--
    CA 1996-224560      AA 1997-0103      CA 1996-2224560      19960612 <--
    AU 6060146      A1 1997-0111      AU 1996-60146      19960612 <--
    EP 6060146      A1 1996-0429      EP 1996-01764      19960612 <--
      E: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, PT
    US 6116124      A 2001-0114      US 1996-031388      19980127 <--
PRAI IL 1996-114140      A 19960614 <--
    WO 1996-1112      W 19960612 <--
AB A novel pharmaceutical compn. for the treatment of cancer, either by
inhibition of the tumor metastatic tendency or alternatively by inhibiting
formation of new blood vessels (angiogenesis) and thus depriving
the tumor of its blood source, consists of a fragment of the thrombin
B-chain comprising the sequence Arg-Gly-Asp in an exposed orientation, or
modified thrombin in which the naturally cryptic Arg-Gly-Asp (RGD)
sequence has been modified so that it is in an exposed orientation. Thus,
RGD-contg. thrombin fragments inhibited lung colonization in mice by
metastatic murine melanoma cells with a potency approx. 20-fold greater
than that of prior art RGD-contg. fragments of other proteins such as
fibronectin; the fragments bound strongly to these cells in vitro. Such
fragments also inhibited microvessel sprouting and induced apoptosis in an
exptl. model of angiogenesis in rat aorta rings in vitro.
ST thrombin peptide metastasis angiogenesis inhibitor; antitumor
thrombin peptide
IT Angiogenesis inhibitors
    Antiarthritides
    (anti-metastatic and anti-angiogenic thrombin derivs.)
IT Adhesion, biological
    (by metastatic cells, detn. of; anti-metastatic and anti-
angiogenic thrombin derivs.)
IT Eye, disease
    (diabetic retinopathy; anti-metastatic and anti-angiogenic
    thrombin derivs.)
IT Neoplasm
    (metastasis, adhesion by cells of, detn. of; anti-metastatic and anti-
angiogenic thrombin derivs.)
IT Antitumor agents
    Melanoma
    (metastasis; anti-metastatic and anti-angiogenic thrombin
    derivs.)
IT Lung, neoplasm
    (metastatic melanoma cell colonization of; anti-metastatic and anti-
angiogenic thrombin derivs.)
IT Antineoplas
    EL: AEG (Analytical reagent use); ANST (Analytical study); USES (Uses)
    (thrombin RGD domain; anti-metastatic and anti-angiogenic
    thrombin derivs.)
IT 9002-94-43, Thrombin, derivs. and fragments 186689-86-1 186689-87-2
    EL: BAC (Biological activity or effector, except adverse); BSU (Biological
    study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
    (Uses)
    (Anti-metastatic and anti-angiogenic thrombin derivs.)
IT 99896-85-2
    EL: BAC (Biological activity or effector, except adverse); BSU (Biological
    study, unclassified); THU (Therapeutic use); BIOL (Biological
    study); USES (Uses)

```

(thrombin derivs. and fragments contg.; anti-metastatic and anti-
angiogenic thrombin derivs.)

IT 99896-85-2


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); UJEE (Uses)

(thrombin derivs. and fragments contg.; anti-metastatic and anti-
angiogenic thrombin derivs.)

RN 99896-85-2 HCAPLUS

CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L73 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 1996:326413 HCAPLUS

DN 136:1396

TI Cyclic peptide analogs that mimic the CS-1 domain of fibronectin for inhibition of interaction of fibronectin and the VLA-4 receptor

IN Arrhenius, Thomas S.; Elises, Marian J.; Tempczyk, Anna; Zheng, Zhong-Li

PA Cytel Corporation, USA

SO PCT Int. Appl., 117 pp.

CODEN: SIXXDE

DT **Patent**

LA English

IC ICM C07K005-11

ICS C07K014-78; C07K007-16

CC 1-7 (Pharmacology)

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9606108	A1	19960629	WO 1995-US10811	19950315 <--
WO 9606108	A3	19960629		
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN			
RW:	FE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, RF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5811341	A	19990602	US 1995-483077	19950607 <--
AU 9534953	A1	19960614	AU 1995-34953	19950825 <--
EP 777681	A2	19960611	EP 1995-931546	19950825 <--
E:	AT, BE, CH, DE, DK, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
PFAI US 1994-376241		19940625 <--		
US 1995-4-3077		19951107 <--		
WO 1995-US11311		19950623 <--		
OS M&SPAT 1.5:1376				
AB	A class of cyclic peptides (Markush structures given) that inhibit the binding of the VLA-4 receptor of inflammatory leukocytes to the CS-1 domain of fibronectin on endothelial cells that are involved in immunoinflammatory disease states are described. Pharmaceutical comps. contg. a contemplated cyclic peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory cyclic peptide are also disclosed.			

ST CS1 fibronectin peptidomimetic inflammation inhibitor
 IT Inflammation inhibitors
 (cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT Leukocyte
 (inflammatory, inhibition of binding to endothelium of; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT Fibronectins
 RL: BPS (Biological process); BSU Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (inhibition of VLA-4 binding to; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT Asthma
 (non-bronchodilator treatment of; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT Multiple sclerosis
 (treatment of exptl. models of; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT Inflammation inhibitors
 (anti-rheumatics, cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT Encephalomyelitis
 (autoimmune, demyelinating, exptl., treatment of; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT Peptides, Biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); ERP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (cyclic-, mimetics; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT Blood vessel
 (endothelium, inhibition of inflammatory leukocyte binding to; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT Transplant and Transplantation
 (graft-vs.-host reaction, inhibitors of; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT Integrins
 RL: BPS (Biological process); BSU Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (alpha.4.beta.1, inhibition of fibronectin binding to; cyclic peptide analogs that mimic CS-1 domain of fibronectin for inhibition of interaction of fibronectin and VLA-4 receptor)
 IT 13483-09-5DP, N- and C-terminal extension and cyclic analogs
 38763-90-5P 77292-72-9P 177180-87-4DP, N- and C-terminal extension and cyclic analogs 177130-88-5DP, N- and C-terminal extension and cyclic analogs 177080-89-6DP, N- and C-terminal extension and cyclic analogs 177080-90-9DP, N- and C-terminal extension and cyclic analogs 177080-91-3DP, N- and C-terminal extension and cyclic analogs 177080-92-1DP, N- and C-terminal extension and cyclic analogs 177080-93-1DP, N- and C-terminal extension and cyclic analogs 177080-94-3EP, N- and C-terminal extension and cyclic analogs 177080-95-4DP, N- and C-terminal extension and cyclic analogs 177080-96-5DP, N- and C-terminal extension and cyclic analogs

177080-37-6DP, N- and C-terminal extension and cyclic analogs
 177080-38-7DP, N- and C-terminal extension and cyclic analogs
 177080-39-8DP, N- and C-terminal extension and cyclic analogs
 177081-00-4DP, N- and C-terminal extension and cyclic analogs
 177081-01-5DP, N- and C-terminal extension and cyclic analogs
 177081-02-6DP, N- and C-terminal extension and cyclic analogs
 177081-03-7DP, N- and C-terminal extension and cyclic analogs
 177081-04-8DP, N- and C-terminal extension and cyclic analogs
 177081-05-9DP, N- and C-terminal extension and cyclic analogs
 177081-06-0DP, N- and C-terminal extension and cyclic analogs
 177081-07-1DP, N- and C-terminal extension and cyclic analogs
 177081-08-2DP, N- and C-terminal extension and cyclic analogs
 177081-09-3DP, N- and C-terminal extension and cyclic analogs
 177081-10-4DP, N- and C-terminal extension and cyclic analogs
 177081-11-5P 177081-12-6P 177081-13-7P 177081-14-8P 177081-15-1DP,
 N- and C-terminal extension and cyclic analogs 177081-16-2P
 177081-17-3DP, N- and C-terminal extension and cyclic analogs
 177081-18-4P 177081-19-5P 177081-20-6P 177081-21-7P 177081-22-8P
 177081-23-9P 177081-24-0P 177081-25-1DP, N- and C-terminal extension
 and cyclic analogs 177081-26-2DP, N- and C-terminal extension and cyclic
 analogs 177081-27-3DP, N- and C-terminal extension and cyclic analogs
 177081-28-4P 177081-29-5P 177081-30-6P 177081-31-7P 177081-32-8P
 177081-33-9P 177081-34-0P 177081-35-1P 177081-36-2P 177081-37-3P
 177081-38-4P 177081-39-5P 177081-40-6P 177081-41-7P 177081-42-8P
 177081-43-9P 177081-44-0P 177081-45-1P 177081-46-2P 177081-47-3P
 177081-48-4P 177081-49-5P 177081-50-6P 177081-51-7P
 177081-52-8P 177081-53-9P 177081-54-0P 177081-55-1P 177081-56-2P
 177081-57-3P 177081-58-4P 177081-59-5P 177081-60-6P 177081-61-7P
 177081-62-8P 177081-63-9P 177081-64-0P 177081-65-1P 177081-66-2P
 177081-67-3P 177081-68-4P 177081-69-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); PEP (Properties); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(cyclic peptide analogs that mimic CS-1 domain of fibronectin for
 inhibition of interaction of fibronectin and VLA-4 receptor)

IT 38763-90-5P 77292-72-9P 177081-48-0P

177081-49-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); PEP (Properties); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP


(Preparation); USES (Uses)

(cyclic peptide analogs that mimic CS-1 domain of fibronectin for
 inhibition of interaction of fibronectin and VLA-4 receptor)

RN 38763-90-5 HCAPLUS

CN L-Phenylalaninamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77292-72-9 HCAPLUS

CN L-Valinamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 177081-43-3 HCAPLUS

CN L-Valinamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 177081-43-1 HCAPLUS

CN L-Phenylalaninamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



LN3 ANSWER 19 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 1495:958291 HCAPLUS

DN 124:787

TI Integrin antagonists for inhibition of angiogenesis

IN Brooks, Peter; Cheresh, David A.

PA Scripps Research Inst., USA

SO PCT Int. Appl., 134 pp.

CODEN: FIXXD2

DT Patent

LA English

IC ICM A61K039-395
 ICS C 7H016-10; C07K016-18; C07K016-22; C07K016-30
 CC 1-3 (Pharmacology)
 Section cross-reference(s): 15

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9503035	A1	19950303	WO 1995-035035	19950309 <--
	W: AM, AI, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, FR, GE, GR, HU, JP, KR, KZ, LB, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ				
	EW: BF, BW, SD, SZ, TG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CN, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5754240	A	19990519	US 1994-210715	19940519 <--
	US 5766541	A	19990610	US 1994-366665	19941130 <--
	AU 6510902	A1	19951009	AU 1995-19982	19950609 <--
	AU 703648	B2	19990901		
	EP 094054	A1	19970111	EP 1996-918644	19960609 <--
	E: AI, BE, CH, DE, DK, EE, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10500308	T2	19961114	JP 1995-824675	19960309 <--
	RU 2161712	C2	20010218	RU 1996-120204	19960309 <--
	NO 360384	A	19961118	NO 1996-3194	19960917 <--
	FI 6601641	A	19961918	FI 1996-3698	19960918 <--
PRAI	US 1994-310715	A	19940314 <--		
	US 1994-366665	A	199412 <--		
	WO 1995-035035	W	19950303 <--		

AB **Angiogenesis** is inhibited in tissues, esp. in inflamed tissues, tumor tissues, and metastases, by application of integrin .alpha.v.beta.3 antagonists to the tissue. The antagonist may be a monoclonal antibody to .alpha.v.beta.3 or a polypeptide contg. the sequence Arg-Gly-Asp. This method may be applied for treatment of inflammation, arthritis, diabetic retinopathy, hemangiomas, and tumors. Thus, basic FGF-induced **angiogenesis** in the chick chorioallantoic membrane was inhibited by the cyclic peptide cyclo(L-Arg-Gly-L-Asp-D-Phe-L-Val); a similar effect was seen when this peptide was injected into melanoma-induced blood vessels.

ST **angiogenesis** inhibitor integrin antagonist peptide; antitumor monoclonal antibody integrin

IT Fibrinogens

RL: EAC (Biological activity or effector, except adverse); ECU (Biological study, unclassified); EOL (Biological study)

(binding to integrin .alpha.v.beta.3; integrin antagonists for inhibition of **angiogenesis**)

IT **Blood vessel**

(formation of; integrin antagonists for inhibition of **angiogenesis**)

IT Apoptosis

(in neovasculature; integrin antagonists for inhibition of **angiogenesis**)

IT Inflammation inhibitors

Neoplasm inhibitors

(integrin antagonists for inhibition of **angiogenesis**)

IT Granulation tissue

(integrin .alpha.v.beta.3 of blood vessels of; integrin antagonists for inhibition of **angiogenesis**)

IT Neoplasm

(integrin .alpha.v.beta.3 of; integrin antagonists for inhibition of **angiogenesis**)

IT Skin

(integrins and laminins of; integrin antagonists for inhibition of **angiogenesis**)

- IT Chorioallantois
(integrins of; integrin antagonists for inhibition of
angiogenesis)
- IT Basement membrane
(laminins of, of skin epithelium; integrin antagonists for inhibition
of **angiogenesis**)
- IT Laminins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
BIOL (Biological study); OCCU (Occurrence)
(of blood vessels and skin epithelium basement membrane; integrin
antagonists for inhibition of **angiogenesis**)
- IT Diabetes mellitus
(retinopathy in; integrin antagonists for inhibition of
angiogenesis)
- IT Inflammation inhibitors
(antiarthritics, integrin antagonists for inhibition of
angiogenesis)
- IT Artery, disease
(coronary, restenosis, integrin antagonists for inhibition of
angiogenesis)
- IT Blood vessel, neoplasm
(hemangioma, integrin antagonists for inhibition of
angiogenesis)
- IT Neoplasm inhibitors
(metastasis, integrin antagonists for inhibition of
angiogenesis)
- IT Antibodies
RL: EAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(monoclonal, to integrin .alpha.v.beta.3; integrin antagonists for
inhibition of **angiogenesis**)
- IT Eye, disease
(retinopathy, in diabetes mellitus; integrin antagonists for inhibition
of **angiogenesis**)
- IT Lymphokines and Cytokines
RL: EAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(tumor necrosis factor-.alpha., integrin .alpha.v.beta.3 expression in
chorioallantois in response to; integrin antagonists for inhibition of
angiogenesis)
- IT Animal growth regulators
RL: EAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(vitronectins, binding to integrin .alpha.v.beta.3; integrin
antagonists for inhibition of **angiogenesis**)
- IT Integrins
FL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological
study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC
(Process)
(.alpha.v.beta.3, integrin antagonists for inhibition of
angiogenesis)
- IT Integrins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
BIOL (Biological study); OCCU (Occurrence)
(.beta.1, of skin and granulation tissue; integrin antagonists for
inhibition of **angiogenesis**)
- IT 99896-85-2D, peptides contg. 133563-10-0 137811-15-5
137813-30-6 137824-01-0 137894-03-2 153127-31-1 153127-32-3
153127-33-4 170930-40-2 170930-41-3 170930-42-4 170930-43-5
170930-44-6 171035-53-1 171035-54-4 171035-55-5 171035-56-6
171035-57-7 171035-58-8 171035-59-9
RL: EAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Integrin antagonists for inhibition of angiogenesis)

IT 106996-94-9, Basic FGF

EL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(Integrin α 5 β 1 expression in chorioallantois in response to; Integrin antagonists for inhibition of angiogenesis)

IT 99896-85-2D, peptides contg.


EL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Integrin antagonists for inhibition of angiogenesis)

RN 99896-85-2 HCAPLUT

CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



LT3 ANSWER 1 OF 11 HCAPLUT COPYRIGHT 2002 ACS

AN 1995:789404 HCAPLUTS

DN 123:333284

TI Novel integrin-binding peptides and their analytical and therapeutic uses in the control of cellular adhesion

IN Kioslahti, Erkki; Koivunen, Erkki

PA La Jolla Cancer Research Foundation, USA

SO PCT Int. Appl., 83 pp.

CODEN: PEXNDJ

DT Patent

LA English

IC 10M C07K014-75

ICS C07K014-13; C07K014-703; A61K038-39; A61K027-00

CC C-3 (General Biochemistry)

Section cross-reference(s): 1

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9414114	A1	19930601	WO 1994-US13542	19941122 <--
	W: AM, AR, BR, BG, BE, BY, CA, CN, CL, FI, GE, HU, JP, KE, KG, KP, KR, KC, IE, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, VE, VN				
	EW: EE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BG, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5961478	A	19931109	US 1994-286861	19940804 <--
	AU 6812596	A1	19930613	AU 1995-12596	19941122 <--
	AC 682561	B2	19931109		
	EP 733600	A1	19930911	EP 1995-903595	19941122 <--
	EP 733600	B1	2010530		
	R: BE, CH, DE, DK, FR, GB, IT, LI, NL, SE				
	JP 08131441	T2	19970916	JP 1994-515220	19941122 <--
PRAI	US 1993-158001	A	19931124 <--		
	US 1994-156861	A	19940804 <--		
	WO 1994-US13542	W	19941122 <--		
OS	MAEPAT 123:333284				

- AB Novel integrin-binding peptides that bind to α .v- or α .5-contg. integrins and can exhibit high binding affinity. They contain one of the following sequence motifs: RKLEEKZWK (esp. RRETAWA); PGDGX in which X is an amino acid with a hydrophobic, arom. side chain; the double cyclic CKLCRGDEKLC; and RLE. The peptides generally exhibit their highest binding affinity when they assume a conformationally stabilized configuration, e.g. by cyclization through disulfide bonds. These peptides may be used as affinity labels for purifn. and anal. of integrins, e.g. in the testing of the efficacy of integrin-binding pharmaceuticals such as antithrombotics. These peptides may also be useful as substrates for attachment of integrin-bearing cells to surfaces such as prosthetic devices or in preventing the unwanted binding of cells to a target, such as the binding of osteoclasts to bone in the treatment of osteoporosis; the inhibition of **angiogenesis**, and as tumor inhibitors. Integrin-binding peptides were obtained by affinity purifn. of a phage display library contg. random sequences in the display cassette by panning with integrins. Peptides specific for several different classes of integrin were obtained.
- ST integrin binding peptide cellular adhesion control
- IT Transplant and Transplantation
(controlling cellular adhesion to; integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)
- IT Fibronectins
EL: BFF (Biological process); BCU (Biological study, unclassified); BIOL (Biological study); FPOC (Process)
(integrin binding of; inhibition of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)
- IT Bone
(integrin binding peptides for prevention of binding of osteoclasts to; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)
- IT Osteoclast
(integrin binding peptides for prevention of binding to bone of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)
- IT Peptides, biological studies
EL: AFG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(integrin-binding; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)
- IT **Blood vessel**
(integrin-binding peptides for inhibition of formation of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)
- IT Wound healing promoters
(patch grafts contg. integrin-binding peptides for use as; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)
- IT Collagens, biological studies
Glycosaminoglycans, biological studies
Proteoglycans, biological studies
EL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prosthetic matrices contg., controlling cellular adhesion to; integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)
- IT Antibodies
EL: AFG (Analytical role, unclassified); ANST (Analytical study)
(to cytoplasmic tails of integrins; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)
- IT Integrins

PL: BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(.alpha.v- or .alpha.3-subunit-contg.; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Adhesion

(bio-, control of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Prosthetic materials and Prosthetics

(implants, controlling cellular adhesion to, integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Prosthetic materials and Prosthetics

(implants, **vascular**, controlling cellular adhesion to, integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Neoplasm inhibitors

(metastasis, integrin-binding peptides as; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Muscle

(smooth, integrin-binding peptides for inhibition of migration of cells of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Skin

(transplant, controlling cellular adhesion to, integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Prosthetic materials and Prosthetics

(**vascular**, controlling cellular adhesion to, integrin-binding peptides for; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Integrins

PL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.alpha.IIb.beta.3, novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Integrins

PL: BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(.alpha.v.beta.3, novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT Integrins

PL: BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(.alpha.3.beta.1, novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 168179-04-2 168179-05-3 168179-06-4 168179-07-5 168179-08-6

168179-09-7 168179-10-8 168179-11-1 168179-12-2 168179-13-3

168179-14-4 168179-15-5 168179-16-6 168179-17-7 168179-18-8

168179-19-9 168179-20-0 168179-21-1 168179-22-4 168179-23-5

168179-24-6 168179-25-7 168179-26-8 168179-27-9 168179-28-0

168179-29-1 168179-30-4 168179-31-5 168179-32-6 168179-33-7

168179-34-8 168179-35-9 168179-36-0 168179-37-1 168179-38-2

PL: PAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(binding to .alpha.IIb.beta.3 integrin of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 168178-56-1 168178-57-2 168178-58-3 168178-59-4 168178-60-7

168178-61-9	168178-62-9	168178-63-0	168178-64-1	168178-65-2
168178-66-3	168178-67-4	168178-68-5	168178-69-6	168178-70-9
168178-71-0	168178-72-1	168178-73-2	168178-74-3	168178-75-4
168178-76-5	168178-77-6	168178-78-7	168178-79-8	168178-80-1
168178-81-2	168178-82-3	168178-83-4	168178-84-5	168178-85-6
168178-86-7	168178-87-8	168178-88-9	168178-89-0	168178-90-3
168178-91-4	168178-92-5	168178-93-6	168178-94-7	168178-95-8
168178-96-9	168178-97-0	168178-98-1	168178-99-2	168178-00-3
168179-01-9	168179-02-0	168179-03-1		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(binding to .alpha.v.beta.1 integrin of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT	168179-39-3	168179-40-4	168179-41-5	168179-42-6	168179-43-9
	168179-44-0	168179-45-1	168179-46-2	168179-47-3	168179-48-4
	168179-49-5	168179-50-6	168179-51-7	168179-52-8	168179-53-1
	168179-54-2	168179-55-3	168179-56-4	168179-57-5D, internal disulfide bond-contg.	168179-58-6D, internal disulfide bond-contg.
	168179-59-7D, internal disulfide bond-contg.	168179-60-0D, internal disulfide bond-contg.	168179-61-1	168179-62-2	168179-63-3
	168179-64-4	168179-65-5	168179-66-6	168179-67-7	168179-68-8
	168179-69-1	168179-70-2	168179-71-3	168179-72-4	168179-73-5
	168179-74-6	168179-75-7	168179-76-8	168179-77-9	168179-78-0
	168179-79-1	168179-80-4	168179-81-5	168179-82-6	168179-83-7
	168179-84-8	168179-85-9	168179-86-0	168179-87-1	168179-88-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(binding to .alpha.v.beta.5 integrin of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT	168179-49-5				
----	-------------	--	--	--	--

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(binding to .alpha.v.beta.1 integrin of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT	168177-46-4	168177-47-5	168177-48-6	168177-49-7	168177-50-1
	168177-51-1	168177-52-2	168177-53-3	168177-54-4	168177-55-5
	168177-56-6	168177-57-7	168177-58-8	168177-59-9	168177-60-3
	168178-01-0	168178-02-1	168178-03-2	168178-04-3	168178-05-0
	168178-06-1	168178-07-2	168178-08-3	168178-09-4	168178-10-7
	168178-11-8	168178-12-9	168178-13-0	168178-14-1	168178-15-2
	168178-16-3	168178-17-4	168178-18-5	168178-19-6	168178-20-9
	168178-21-0	168178-22-1	168178-23-2	168178-24-3	168178-25-4
	168178-26-5	168178-27-6	168178-28-7	168178-29-8	168178-30-1
	168178-31-2	168178-32-3	168178-33-4	168178-34-5	168178-35-6
	168178-36-7	168178-37-8	168178-38-9	168178-39-0	168178-40-3
	168178-41-4	168178-42-5	168178-43-6	168178-44-7	168178-45-9
	168178-46-0	168178-47-1	168178-48-2	168178-49-3	168178-50-6
	168178-51-7	168178-52-8	168178-53-9	168178-54-0	168178-55-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(binding to .alpha.v.beta.1 integrin of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT	99896-88-5P				
----	-------------	--	--	--	--

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(control peptide, lack of integrin binding by; novel integrin-binding

peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 91037-75-1 **99896-85-2D**, N- and C-terminal extension analogs
 111119-23-9 129136-70-5D, N- and C-terminal extension analogs
 135701-31-7 149635-23-0D, analogs 149635-34-7 152880-66-5
 162901-03-0 167820-90-4D, analogs 167820-97-5D, analogs
 167820-98-6D, analogs 167820-99-7D, analogs 167821-01-4D, analogs
 167821-02-5D, analogs 168179-90-6D, N- and C-terminal extension analogs
 168179-91-0 168179-94-0 168179-95-1 168179-96-2
 168179-97-3 168179-98-4 168179-99-5 168180-00-5D, analogs
 168180-01-6D, analogs

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PFP (Properties); THU (Therapeutic use);

BIOL (Biological study); USES (Uses)

(integrin binding properties of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT 168179-99-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PFP (Properties); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

IT **99896-85-2D**, N- and C-terminal extension analogs

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PFP (Properties); THU (Therapeutic use);


BIOL (Biological study); USES (Uses)

(integrin binding properties of; novel integrin-binding peptides and their anal. and therapeutic uses in control of cellular adhesion)

RN 91037-75-1 HCAPLUS

CH L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



LM3 ANSWER 21 OF 21 HCAPLUS COPYRIGHT 2002 ACS

AN 1005:578768 HCAPLUS

BN 100:332688

TI Local polymeric gel cellular therapy

IN Slepian, Marvin; Massia, Stephen P.

PA USA

SO PCT Int. Appl., 80 pp.

COSEN: SIXXD2

DT **Patent**

LA English

IC ICM A61D027-00

ICS A61D031-00; A61D025-00

CC 61-6 (Pharmaceuticals)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9509659	A1	19950410	WO 1994-US11304	19941006 <--
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5375815	A	19961119	US 1993-132745	19931006 <--
	AU 9479671	A1	19950501	AU 1994-79671	19941006 <--

AU 703003 E2 19990211
 EP 72346 A1 1996031 EP 1994-930006 19941006 ---
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
 JP 09506911 T2 19970617 JP 1994-511004 19941006 ---
 PRAI US 1994-132745 A 19931106 --
 US 1994-138331 A 19940906 --
 US 1988-338998 B1 19881214 ---
 US 1990-193102 B1 19901001 ---
 US 1992-057780 A1 19920615 ---
 US 1993-087157 B1 19921117 ---
 US 1994-118878 B1 19931112 --
 WO 1994-051104 W 19941006 ---
 AB A synthetic barrier made of biocompatible polymeric materials is applied in vivo to a tissue or cellular surface such as the interior surface of a blood vessel, tissue lumen or other hollow space. The material may also be applied to tissue-contacting surfaces of implantable medical devices. The polymeric materials are characterized by a fluid state which allows application to, and preferably adhesion to, tissue lumen surfaces, which can be increased or altered to a fluid state in situ; controlled permeability and degradability; and, in the preferred embodiments, incorporation of bioactive materials (e.g. peptides) for release in vivo, either to the tissue lumen surface or to the interior of the lumen, which alter cell-to-cell interactions. The materials may be used to prevent proliferation or migration of smooth muscle or endothelial cells and thereby prevent intimal thickening, restenosis, adhesions, etc. Tenascin is a mediator of smooth muscle cell migration through interaction with specific integrin components of the cells; the polymeric material may be used to inhibit this interaction. Thus, application of a thermoreversible, biodegradable, erodible polyether gel film to the injured intimal surface of rat aorta reduced the thrombogenicity of the intimal surface and the eventual development of neointimal hyperplasia.
 ST polymer gel film tissue barrier; blood vessel film barrier polymer; cell migration proliferation polymer gel
 IT Chemotaxis
 (agents; local polymeric gel cellular therapy)
 IT Chelating agents
 (for calcium; local polymeric gel cellular therapy)
 IT Laminins
 BL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fragments; local polymeric gel cellular therapy)
 IT Polymers, biological studies
 BL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (gel films; local polymeric gel cellular therapy)
 IT Cell proliferation
 (inhibitors; local polymeric gel cellular therapy)
 IT Animal cell
 (interactions and migration and proliferation; local polymeric gel cellular therapy)
 IT Adhesion, anatomical
 Animal tissue
 Anticoagulants and Antithrombotics
 Cation exchangers
 Inflammation inhibitors
 Organ
 Prosthetic materials and Prosthetics
 Surgery
 Transplant and Transplantation
 (local polymeric gel cellular therapy)
 IT Animal growth regulators
 Peptides, biological studies
 Polyethers, biological studies

RL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (local polymeric gel cellular therapy)

IT Lipids, processes
 FL: REM (Removal or disposal); PROC (Process)
 (local polymeric gel cellular therapy)

IT Proteins, biological studies
 FL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (of extracellular matrix; local polymeric gel cellular therapy)

IT Integrins
 FL: PPE (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (of smooth muscle cells; local polymeric gel cellular therapy)

IT Biodegradable materials
 Pharmaceutical dosage forms
 (polymer gel films; local polymeric gel cellular therapy)

IT Films
 (polymer gel; local polymeric gel cellular therapy)

IT Extracellular matrix
 (proteins of; local polymeric gel cellular therapy)

IT Heart, disease
 (angina pectoris, local polymeric gel cellular therapy)

IT **Animal growth regulators**
 FL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (angiogenic factors, antagonists; local polymeric gel cellular therapy)

IT Antiarteriosclerotics
 (antiatherosclerotics, local polymeric gel cellular therapy)

IT Animal growth regulators
 FL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (blood platelet-derived growth factors, local polymeric gel cellular therapy)

IT Medical goods
 (catheters, local polymeric gel cellular therapy)

IT Peptides, biological studies
 FL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclo-, local polymeric gel cellular therapy)

IT **Blood vessel**
 (endothelium, local polymeric gel cellular therapy)

IT Gels
 (hydro-, polymeric, films; local polymeric gel cellular therapy)

IT Prosthetic materials and Prosthetics
 (implants, local polymeric gel cellular therapy)

IT Heart, disease
 (infarction, local polymeric gel cellular therapy)

IT **Artery, disease**
 (injury, local polymeric gel cellular therapy)

IT Lymphokines and Cytokines
 FL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (macrophage chemotactic factor, local polymeric gel cellular therapy)

IT Biological transport
 (secretion, inhibitors; local polymeric gel cellular therapy)

IT Muscle
(smooth, local polymeric gel cellular therapy)

IT Medical goods
(stents, local polymeric gel cellular therapy)

IT Glyc proteins, specific or class
FL: RPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(tenascins, local polymeric gel cellular therapy)

IT Integrins
FL: RPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.alpha.v.beta.3, of smooth muscle cells; local polymeric gel cellular therapy)

IT 7440-73-1, Calcium, processes
FL: REM (Removal or disposal); PROC (Process)
(chelators; local polymeric gel cellular therapy)

IT 117563-96-9
FL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogel film; local polymeric gel cellular therapy)

IT 9008-43-0, Heparin, biological studies 62229-50-9, EGF 71812-41-4, Tumor-**angiogenesis** factor 106696-93-9, Basic fibroblast growth factor 106392-12-1, Pluronic F127 110590-61-9 126716-29-7
FL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(local polymeric gel cellular therapy)


IT 99896-85-2 110190-64-2 122192-97-6 181167-89-0
FL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptides and proteins contg.; local polymeric gel cellular therapy)

IT 99896-85-2
FL: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptides and proteins contg.; local polymeric gel cellular therapy)

RN 99896-85-1 HCAPLUS

CN L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil req

FILE 'REGISTRY' ENTERED AT 10:19:33 ON 16 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2012 American Chemical Society (ACS)

Property values tagged with IT are from the EIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 OCT 2002 HIGHEST RN 461638-40-4

DICTIONARY FILE UPDATES: 15 OCT 2002 HIGHEST RN 461638-40-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> divide can tot 171

L71 ANSWER 1 OF 25 REGISTRY COPYRIGHT 2002 ACS

PN 302578-05-8 REGISTRY

CN L-Valine, L-seryl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 16: PN: W00003236 PAGE: 17 claimed sequence


PC STEREOSEARCH

MF C13 H21 N3 O7

SE CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:303223

L71 ANSWER 2 OF 25 REGISTRY COPYRIGHT 2002 ACS

PN 255052-65-4 REGISTRY

CN L-Proline, L-isoleucyl-L-asparaginyl- (9CI) (CA INDEX NAME)


PC STEREOSEARCH

MF C15 H26 N4 O5

SE CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:106963

L71 ANSWER 3 OF 25 REGISTRY COPYRIGHT 2002 ACS
 PN 243647-63-4 REGISTRY
 CN L-Alanine, L-leucylglycyl- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 4: PN: W00028996 SEQID: 13 unclaimed sequence
 FS STEREOSEARCH
 MF C11 H21 N3 O4
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATEFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:11141


REFERENCE 2: 133:22140

REFERENCE 3: 131:219027

L71 ANSWER 4 OF 25 REGISTRY COPYRIGHT 2002 ACS
 PN 222169-81-5 REGISTRY
 CN L-Threonine, L-phenylalanyl-L-alanyl- (9CI) (CA INDEX NAME)
 OTHER NAMES:

CN 12: PN: W00171956 PAGE: 92 claimed sequence
 ES STEREOSEARCH
 MF C16 H13 N3 O5
 SR CA
 LC STN Files: CA, CAPLUS, USPATEFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


- 1 REFERENCES IN FILE CA (1962 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:300243

REFERENCE 2: 133:266373

L71 ANSWER 5 OF 25 REGISTRY COPYRIGHT 2002 ACS
 PN 222169-80-4 REGISTRY
 CN L-Serine, L-tyrosyl-L-alanyl- (PCI) (CA INDEX NAME)
 OTHER NAMES:
 CN 13: PN: W00171956 PAGE: 92 claimed sequence
 ES STEREOSEARCH
 MF C16 H13 N3 O6
 SR CA
 LC STN Files: CA, CAPLUS, USPATEFULL

Absolute stereochemistry.



EO

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

- 1 REFERENCES IN FILE CA (1962 TO DATE)
- 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 133:300243

REFERENCE 2: 133:266373

L71 ANSWER 6 OF 25 REGISTRY COPYRIGHT 2002 ACS
 PN 222169-79-1 REGISTRY

CN L-Threonine, L-tyrosyl-L-alanyl- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 11: PN: W00172955 PAGE: 92 claimed sequence
 FS STEREOSEARCH
 MF C16 H23 N3 O6
 SR CA
 LC STM Files: CA, CAPLUS, USPATEFULL

Absolute stereochemistry.



HO

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:303343

REFERENCE 2: 130:266373

L71 ANSWER 7 OF 25 REGISTRY COPYRIGHT 2002 ACS

PN 193219-20-4 REGISTRY

CN L-Threoninamide, N-(2-benzofuranylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-(2,3-dihydro-1H-imidazo-1-yl)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C32 H43 N4 O8

SR CA

LC STM Files: CA, CAPLUS, USPATEFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 127:134640

L71 ANSWER 8 OF 25 REGISTRY COPYRIGHT 2002 ACS


PN 193219-16-8 REGISTRY

CN L-Threoninamide, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-cyclooctyl- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C32 H45 N5 O7
 SR CA
 LC STN Files: CA, CAPLUS, USPATEFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 127:134690

L71 ANSWER 9 OF 25 REGISTRY COPYRIGHT 2002 ACS
 RN 193219-14-6 REGISTRY
 CN L-Threoninamide, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl-N-cyclopropyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C32 H45 N5 O7
 SR CA
 LC STN Files: CA, CAPLUS, USPATEFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 127:134690

L71 ANSWER 10 OF 25 REGISTRY COPYRIGHT 2002 ACS
 RN 193218-85-8 REGISTRY
 CN L-Threonine, N-(3-isoquinolinylcarbonyl)-L-leucyl-L-.alpha.-aspartyl- (+CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C24 H30 N4 O8

SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:177422

REFERENCE 2: 127:134690

L71 ANSWER 11 OF 25 REGISTRY COPYRIGHT 2002 ACS

RN 193218-84-7 REGISTRY

CN L-Threonine, N-benzoyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)


PS STEREOSEARCH

MF C21 H29 N3 O8

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 127:134690

L71 ANSWER 12 OF 25 REGISTRY COPYRIGHT 2002 ACS
 RN 177081-49-1 REGISTRY
 CN L-Phenylalaninamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA
 INDEX NAME)
 FS STEREOSEARCH
 MF C21 H30 N4 O6
 SR CA
 LC STN Files: CA, CAPLUS, USPATEFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1962 TO DATE)
 7 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:103312
 REFERENCE 2: 131:139496
 REFERENCE 3: 130:161130
 REFERENCE 4: 129:291438
 REFERENCE 5: 129:245438
 REFERENCE 6: 129:95722
 REFERENCE 7: 128:1376

L71 ANSWER 13 OF 25 REGISTRY COPYRIGHT 2002 ACS
 RN 177081-48-0 REGISTRY
 CN L-Valinamide, N-acetyl-L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C17 H30 N4 O6
 SR CA
 LC STN Files: CA, CAPLUS, USPATEFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1962 TO DATE)
7 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 1-2:108302
REFERENCE 2: 1-1:139486
REFERENCE 3: 1-0:163160
REFERENCE 4: 1-9:296411
REFERENCE 5: 1-9:243493
REFERENCE 6: 1-9:95701
REFERENCE 7: 1-5:1376

171 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2002 ACS

RI 175177-02-3 REGISTRY

CI L-Lysine, L-.alpha.-aspartyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CI L-Lysine, N2-(N-L-.alpha.-aspartyl-L-.alpha.-aspartyl)-


ES STEREOSEARCH

MF C14 H24 N4 O6

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATEFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1962 TO DATE)
6 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE	1:	130:98441
REFERENCE	2:	104:307089
REFERENCE	3:	102:187704
REFERENCE	4:	101:97601
REFERENCE	5:	100:160628
REFERENCE	6:	104:350196

```

L71  ANSWER 15 OF 15  REGISTRY  COPYRIGHT 2002 ACS
FN   172684-39-8  REGISTRY
CN   L-Arginine, L-lysylglycyl- (9CI)  (CA INDEX NAME)
OTHE CA INDEX NAMES:
CN   L-Arginine, NE-(N-L-lysylglycyl)-
ES   STEREOSEARCH
MF   C14 H29 N7 O4
SE   CA
LC   STN Files:  CA, CASPLUS, USPATEFULL

```

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

REFERENCES IN FILE CA (1962 TO DATE)
REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 130:195763
REFERENCE 2: 124:106631

```

L11 ANSWER 16 OF 15  REGISTRY  COPYRIGHT 2002 ACS
FN  157535-09-6  REGISTRY
CN  L-Lysine, L-asparaginyl-L-glutaminyl- (9CI)  (CA INDEX NAME)
CTHEF CA INDEX NAMES:
CN  L-Lysine, N2-(N1-L-asparaginyl-L-glutaminyl)-
CTHEF NAMES:
CN  4: FN: W00172956 PAGE: 92 claimed sequence
FN  STEREOSEARCH
MF  C15 H28 N6 O6
SE  CA
LC  STN Files:  CA, CAPLUS, TOXCENTER, USPATEFULL

```

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1962 TO DATE)
5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:88441
REFERENCE 2: 136:360243
REFERENCE 3: 132:18714
REFERENCE 4: 131:97631
REFERENCE 5: 121:149077

LV1 ANSWER 17 OF 25 REGISTRY COPYRIGHT 2002 ACS
EN 143113-41-1 REGISTRY
CN L-Valine, L-histidyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN L-Valine, N-(N-L-histidyl-L-alanyl)-
ES STEREOSEARCH
MF C14 H23 N5 O4
SR CA
IC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


15 REFERENCES IN FILE CA (1962 TO DATE)
15 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:88441
REFERENCE 2: 137:73269
REFERENCE 3: 136:161398

REFERENCE 4: 136:48463
 REFERENCE 5: 137:14798
 REFERENCE 6: 138:261163
 REFERENCE 7: 138:90384
 REFERENCE 8: 138:286523
 REFERENCE 9: 138:103895
 REFERENCE 10: 138:97621

L71 ANSWER 18 OF 15 REGISTRY COPYRIGHT 2002 ACS
 FN 132151-24-7 REGISTRY
 CN L-Glutamine, L-.alpha.-glutamyl-L-alanyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN L-Glutamine, N2-(N-L-.alpha.-glutamyl-L-alanyl)-
 OTHER NAMES:
 CN 1159: FN: W00068601 TABLE: 17 claimed sequence
 ES STEREOSEARCH
 MF C13 H22 N4 O7
 SE CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


5 REFERENCES IN FILE CA (1962 TO DATE)
 5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:226199
 REFERENCE 2: 137:88441
 REFERENCE 3: 138:18784
 REFERENCE 4: 138:97621
 REFERENCE 5: 114:116372

L71 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2002 ACS
 FN 117058-06-7 REGISTRY
 CN L-Leucine, L-arginyl-L-alanyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN L-Leucine, N-(N-L-arginyl-L-alanyl)-
 OTHER NAMES:
 CN 9: PN: W00172456 PAGE: 92 claimed sequence

PS STEREOSEARCH
 MF C15 H16 N6 O4
 CI COM
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:330243

REFERENCE 2: 130:366373

REFERENCE 3: 110:171424

L71 ANSWER 20 OF 25 REGISTRY COPYRIGHT 2002 ACS

PN 99896-85-2 REGISTRY

CI L-Aspartic acid, L-arginylglycyl- (9CI) (CA INDEX NAME)

OTHEP CA INDEX NAMES:

CI L-Aspartic acid, N-(N-L-arginylglycyl)-

OTHEP NAMES:

CI 13: PN: W00147189 SEQID: 1 claimed protein

CI 1: PN: W00147189 SEQID: 1 claimed protein

CI 1: PN: W00147189 PAGE: 31 claimed protein

CI 1: PN: W00147189 PAGE: 199 claimed protein

CI 1: PN: W00147189 PAGE: 13 claimed sequence

CI 4: PN: W00147189 PAGE: 19 claimed sequence

CI 503: PN: W00183525 TABLE: 9 claimed sequence

CI 31: PN: W00183525 SEQID: 81 claimed protein

CI Arginylglycylaspartic acid

PS STEREOSEARCH

MF C12 H16 N6 O6

CI COM

SR CA

LC STN Files: BEILSTEIN*, BIOSIS, BIOC TECHNO, CA, CANCERLIT, CAPLUS,
 CASREACT, CHEMCATS, CS-CHEM, EMBASE, MEDLINE, MSDS-OHS, TOXCENTER,
 USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

634 REFERENCES IN FILE CA (1962 TO DATE)
 117 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 634 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:237626
 REFERENCE 2: 137:186136
 REFERENCE 3: 137:181341
 REFERENCE 4: 137:175009
 REFERENCE 5: 137:174738
 REFERENCE 6: 137:16672
 REFERENCE 7: 137:150814
 REFERENCE 8: 137:148645
 REFERENCE 9: 137:140659
 REFERENCE 10: 137:133625

171 ANSWER 21 OF 25 REGISTRY COPYRIGHT 2002 ACS

FN 77292-72-9 REGISTRY

CN L-Valinamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

OTHER NAMES:


CN 27: PN: W00004941 PAGE: 32 claimed sequence

FS STEREOSEARCH

MF C15 H28 N4 O5

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1962 TO DATE)
 9 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:142003
 REFERENCE 2: 133:108302
 REFERENCE 3: 131:139496
 REFERENCE 4: 133:103300
 REFERENCE 5: 133:290438
 REFERENCE 6: 133:165488
 REFERENCE 7: 133:35713
 REFERENCE 8: 133:1376
 REFERENCE 9: 94:171464

L71 ANSWER 22 OF 25 REGISTRY COPYRIGHT 2002 ACS

FN 68293-03-8 REGISTRY

CN Glycine, L-isoleucylglycyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glycine, N-(D-L-isoleucylglycyl)-

OTHER NAMES:

CN 34: PN: W0101996 SEQID: 3 unclaimed sequence

CN L-Isoleucylglycylglycine


ES STEREOSEARCH

MF C16 H19 N3 O4

CI COM

LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1962 TO DATE)
 12 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:11191
 REFERENCE 2: 134:11113
 REFERENCE 3: 133:22140
 REFERENCE 4: 131:219027
 REFERENCE 5: 123:990
 REFERENCE 6: 113:15462

REFERENCE 7: 113:168289

REFERENCE 8: 111:1:9-55

REFERENCE 9: 100:7541

REFERENCE 10: 101:229408

L71 ANSWER 23 OF 25 REGISTRY COPYRIGHT 2002 ACS

RN 60961-76-4 REGISTRY

CN L-Tyrosine, L-.alpha.-glutamyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Tyrosine, N-(N-L-.alpha.-glutamyl-L-.alpha.-glutamyl)-


FS STEREOSEARCH

MF C19 H25 N3 O5

CI COM

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:88441

REFERENCE 2: 131:1:774

REFERENCE 3: 131:90621

REFERENCE 4: 114:121070

REFERENCE 5: 111:227787

L71 ANSWER 24 OF 25 REGISTRY COPYRIGHT 2002 ACS

RN 38763-90-5 REGISTRY

CN L-Phenylalaninamide, L-leucyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN L-Leucyl-L-aspartyl-L-phenylalaninamide


FS STEREOSEARCH

MF C19 H28 N4 O5

CI COM

LC STN Files: BEILSTEIN*, CA, CAPLUS, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1962 TO DATE)
13 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:108302
REFERENCE 2: 131:179496
REFERENCE 3: 130:103180
REFERENCE 4: 128:280488
REFERENCE 5: 128:248444
REFERENCE 6: 128:67211
REFERENCE 7: 125:1876
REFERENCE 8: 123:56559
REFERENCE 9: 118:50304
REFERENCE 10: 111:187011

L71 ANSWER 25 OF 25 REGISTRY COPYRIGHT 2002 ACS

BN 1187-50-4 REGISTRY

CN Glycine, L-leucylglycyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Glycine, N-(L-leucylglycyl)- (7CI, 8CI)

CN Glycine, N-(D-leucylglycyl)- (6CI)

OTHER NAMES:

CN 37: PN: W010.8906 SEQID: 6 unclaimed sequence

CN L-Leucylglycylglycine

CN Leu-Gly-Gly

CN Leucylglycylglycine

PS STEREOSEARCH

MF C16 H19 N3 O4

CI COM


LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, GMELIN*, MEDLINE, POCENTER, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**

(*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

246 REFERENCES IN FILE CA (1962 TO DATE)
 10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 246 REFERENCES IN FILE CAPLOS (1962 TO DATE)
 45 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:200095
 REFERENCE 2: 136:200098
 REFERENCE 3: 136:200099
 REFERENCE 4: 136:200101
 REFERENCE 5: 136:200103
 REFERENCE 6: 136:200104
 REFERENCE 7: 136:200105
 REFERENCE 8: 136:200106
 REFERENCE 9: 136:200107
 REFERENCE 10: 136:200108

end his

(FILE 'HOME' ENTERED AT 09:53:31 ON 16 OCT 2002)
 SET COST OFF

FILE 'REGISTRY' ENTERED AT 09:53:48 ON 16 OCT 2002

L1 STR
 L2 20 S L1 CSS
 L3 SCR 2043 OF 2127
 L4 7 S L1 NOT L3 CSS
 L5 STR L1
 L6 6 S L5 CSS
 L7 STR L5
 L8 SCR 2043 OF 2127 OR 2050 OR 2049 OR 2048 OR 2053 OR 2052 OR 205
 L9 3 S L7 NOT L8 CSS
 L10 SCR 2043 OF 2126 OR 1929
 L11 1 S L7 NOT (L8 OR L10) CSS SAM
 L12 SCR 2043
 L13 4 S L7 NOT (L8 OR L10 OR L12) CSS SAM
 L14 SCR 2043
 L15 6 S L7 NOT (L8 OR L10 OR L12 OR L14) CSS SAM
 L16 7 S L13 NOT L16
 L17 SCR 2043 OF 2127 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 OR 204
 L18 7 S L7 NOT L17 CSS
 L19 SCR 2043 OF 2127 OR 2049 OR 2048 OR 2053 OR 2052 OR 2051 OR 204

L20 4 S L7 NOT L19 CSS
L21 SCR 2049 OR 2050 OR 2049 OR 2049 OR 2053 OR 2052 OR 2051 OR 204
L22 7 S L7 NOT L21 CSS
L23 STE L7
L24 13 S L2 NOT L21 CSS
L25 284 S L2 NOT L21 CSS FUL
SAV L2 GAB10 4A/A
L26 STE L2
L27 S L2 CSS JAM SUB=L25
L28 16 S L2 CSS FUL SUB=L25
SAV L2 GAB10 4A/A
L29 13 S L2 NOT SQL FA
L30 1831 S L2 NOT L28
L31 1674 S L2 NOT SQL FA

FILE 'RCAPLUS' ENTERED AT 10:30:07 ON 16 OCT 2002

L32 6 S L29
E SCIALONE N AU
L33 17 S E4,E5
E MOUSA S/AU
L34 17 S E4,E5,E12-E13
E SHREY S/AU
L35 17 S E4-E5
L36 54249 S (REPORT OR DU)PONT OR NEMOUR?)/PA,CS
L37 1 S L35 AND L35-L36
SEL RN

FILE 'REGISTRY' ENTERED AT 10:32:47 ON 16 OCT 2002

L38 1 S E1-E11
L39 17 S L35 AND L35
L40 11 S L35 NOT L35
L41 10 S L40 NOT PMS/CI
L42 1 S L41 NOT SQL FA
L43 17 S L35,L42
L44 1 S L35 NOT L43
SAV L4 GAB1004B/A

FILE 'RCAPLUS' ENTERED AT 10:35:08 ON 16 OCT 2002

L45 6 S L43
L46 1 S L45 AND L45-L46
L47 6 S L45,L46

FILE 'USPATELL, WHEAT' ENTERED AT 10:35:26 ON 16 OCT 2002

L48 6 S L43

FILE 'REGISTRY' ENTERED AT 10:36:01 ON 16 OCT 2002

FILE 'RCAPLUS' ENTERED AT 10:37:06 ON 16 OCT 2002

L49 5144 S L41
L50 1045 S L44 AND (PRD<=20010216 OR PRD<=20010216 OR AD<=20010216)
L51 51 S L50 AND PANGIOGEN?
E ANGIOGENESIS/CT
E E7+ALL
L52 7139 S E4+NT
E E10+ALL
L53 2695 S E4+NT
E E7+ALL
L54 1514 S E4,E4,E2+NT
E E7+ALL
L55 1755 S E4,E1+NT
E ANGIOGENESIS/CT
E E3+ALL
E E12+ALL

L56 127085 S E5,E4+NT
 E ANGIOGENESIS/CT
 E E7+ALL
 L57 2695 S E4+NT
 L58 43 S L50 AND L52-L55,L57
 L59 138 S L50 AND L55
 L60 2279 S L50 (L) ANGIOGEN?
 L61 38951 S L50 (L) ENDOTHEL?
 L62 47 S L50 AND L60,L61
 L63 122 S L51,L58,L61
 L64 121 S L63 NOT L45
 L65 40 S L61 AND P/DT
 L66 41 S L65 AND US/PC
 L67 414 S L31 (L) (PAC OR THU)/RL
 L68 45 S L67 AND L64
 L69 12 S L68 AND L66
 SEL HIT FN

FILE 'REGISTRY' ENTERED AT 10:45:54 ON 16 OCT 2002

L70 15 S E1-E26
 L71 15 S L70 NOT NCSC2/ES

FILE 'HCAPLUS' ENTERED AT 10:51:54 ON 16 OCT 2002

L72 924 S L71
 L73 21 S L72 AND L69

FILE 'REGISTRY' ENTERED AT 10:59:33 ON 16 OCT 2002